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Abstract 
Introduction: Chronic inflammation with aging is associated with sarcopenia and osteoporosis. 
Bovine colostrum is the first milk secreted by cows following parturition and contains bioactive 
substances, while ibuprofen is a non-steroidal anti-inflammatory drug. Both target the 
inflammatory pathway regulated by cyclooxygenase and have potential to increase muscle and 
bone mass when combined with resistance training. Objectives: To determine efficacy of novel 
anti-inflammatory nutritional (bovine colostrum) and pharmaceutical (ibuprofen) 
supplementation during resistance training on muscle and bone properties and strength in older 
adults. Methods: Older adults (≥50y) were randomly assigned to receive 38g/d of colostrum or 
whey protein during a resistance training program for 8 weeks; postmenopausal women (≥60y) 
were randomly assigned to receive ibuprofen (400 mg) or placebo post-exercise while 
performing a resistance training program or stretching program (3d/wk) for 9 months. Both 
studies utilized dual energy x-ray absorptiometry (DXA) for body composition and predicted 1-
repetition maximum for strength. The bovine colostrum study further assessed muscle thickness 
of the biceps and quadriceps, plasma insulin-like growth factor-1, and inflammation and bone 
resorption markers; the ibuprofen study further assessed bone and muscle properties and 
estimates of bone strength (peripheral quantitative computed tomography), and dynamic balance. 
Results: Bovine colostrum supplementation during resistance training increased leg press 
strength (21%) and reduced bone resorption (-29%) versus whey protein. Both colostrum and 
whey protein groups improved chest press strength, muscle thickness, and lean tissue mass. 
Ibuprofen alone appeared beneficial for preventing loss of areal bone density at Ward’s region 
(3%) and bone properties at the distal radius (0.5%) and radial shaft (1.1%), while exercise alone 
appeared beneficial for bone properties at the distal radius (0.6%). However, the interaction of 
resistance training and ibuprofen negated the benefits at the distal radius (-1.5%). Neither 
ibuprofen nor resistance training was effective for increasing lean tissue mass, although 
resistance training improved body fat percentage (-2.0%), increased upper and lower body 
strength (23%, 110%), and preserved muscle density of the calf (-3.1%). Conclusion: While 
bovine colostrum could be taken within close proximity to exercise, ibuprofen should not be as it 
may interfere with the effects of exercise when the two interventions are combined. 
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1.0. Introduction 
By 2031 it is estimated up to 25% percent of the Canadian population will be 65 years and older; 
this is the most rapidly growing and dominant demographic age group (Ramage-Morin, Shields, 
& Martel, 2010). With advancing age there is a deterioration in most physiological systems, 
hence age-related chronic diseases are becoming more numerous because of  this growing 
demographic (i.e. >65 years) (American College of Sports Medicine [ACSM], 2009; Milan & 
Vézina, 2011). Inflammation is considered the main pathophysiological contributor to this 
deterioration and may lead to the majority of age-related diseases. The term ‘inflammaging’ has 
been considered for describing this phenomenon (Corsonello et al., 2010; Franceschi, 2007). 
Specific inflammation-related diseases of interest for this thesis are sarcopenia and osteoporosis. 
A significant loss of muscle and bone mass leading to reduced function and higher risk of 
fracture during the natural aging process is known as sarcopenia and osteoporosis, respectively, 
and occurs particularly in load-bearing regions of the body (International Working Group on 
Sarcopenia [IWGS], 2011). Such processes, among others, are associated with frailty, functional 
impairment, and higher rates of mortality resulting in decreased capacity to perform activities of 
daily living, ultimately impacting on quality of life (Bolton et al., 2012; Corsonello et al., 2010; 
de Kam, Smulders, Weerdesteyn, & Smits-Engelsman, 2009; Degens, 2010; Franceschi, 2007; 
Garriguet, 2011; IWGS, 2011; Ramage-Morin et al., 2010). The increase in the senior population 
suffering from these diseases and the consequential need for health care becomes somewhat of a 
burden due to the ever increasing imbalance between the beneficiaries (i.e. rapidly growing 
population of seniors with health conditions and diseases) and contributors (i.e. those who work 
for the health system) of the health care support system resulting in a serious social and 
economic health problem (Ramage-Morin et al., 2010). The burden from sarcopenic muscle loss 
in the United States for 2000 was estimated to be $18.5 billion while the burden from 
osteoporotic fractures in Canada for 2010 was calculated to be $2.3 billion (Janssen, Shephard, 
Katzmarzyk, & Roubenoff, 2004; Tarride et al., 2012). 
Successful aging, a concept referring to the minimization of the harmful effects of aging 
and maintenance of ‘good health’, would enhance overall quality of life for seniors and lessen 
the burden on health care resources (Ramage-Morin et al., 2010). ‘Good health’ encompasses 
functional abilities, independence, and positive self-perceived general and mental health 
(Ramage-Morin et al., 2010). To achieve successful aging, one must recognize the “overlap 
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between syndromes of disuse and aging” and focus attention on modifiable physiological 
changes rather than immutable ones (Singh, 2004). Many prevention strategies have been 
studied, but physical activity and/or exercise have been strongly linked to successful aging 
(Concannon, Grierson, & Harrast, 2012; Corsonello et al., 2010; Ramage-Morin et al., 2010; 
Singh, 2004). Other strategies for prevention include nutritional and pharmacological 
supplementation (Corsonello et al., 2010; Ramage-Morin et al., 2010).  
The focus of this thesis is to investigate bovine colostrum and ibuprofen supplementation 
during resistance training as novel interventions to prevent muscle and bone loss via unique anti-
inflammatory properties of each supplement. These supplements specifically show promise in 
the literature and are relatively inexpensive and easily accessible to the general public. The 
novelty lies within the unknown interactions between supplement and exercise, specifically in 
the aging population. Further, while bovine colostrum and ibuprofen are similar in the sense that 
they target a common inflammatory pathway, the cyclooxygenase (COX) pathway, they are 
unique as they target the COX pathway via different mechanisms. Figure 1.0 demonstrates the 
role these supplements play in preventing the loss of muscle and bone mass in relation to 
inflammation produced through the cyclooxygenase 1 (COX-1) and 2 (COX-2) pathway. Bovine 
colostrum has potential to neutralize inflammation through the anti-inflammatory properties of 
immunoglobulins (Ig). Bovine colostrum may further counteract the harmful effects of 
inflammation via growth stimulating properties of insulin-like growth factor 1 (IGF-1) (Figure 
1.0). In contrast, ibuprofen has potential to neutralize inflammation by inhibiting COX enzymes, 
therefore reducing the amount of pro-inflammatory prostanoids and cytokines produced (Figure 
1.0). The following literature review aims to further explore the processes depicted in Figure 1.0 
and will focus on: i) regulation of inflammation via the immune system at the cellular level, ii) 
effects at the cellular level of inflammation on muscle and bone, iii) definition of sarcopenia and 
osteoporosis and the clinical importance, iv) determination of muscle strength and regulation of 
bone strength, v) estimation of muscle and bone strength at the tissue level, and vi) novel 
modification strategies to slow sarcopenia and bone fragility.   
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Figure 1.0. Pathways by which muscle protein breakdown and bone resorption may be 
influenced by inflammation and potential mechanism by which anti-inflammatory agents, bovine 
colostrum and ibuprofen, provide a preventative effect.  
Dashed arrow = inhibits; Solid arrow = activates.  
Abbreviations: COX-1, cyclooxygenase-1; COX-2, cyclooxygenase-2; PGE2, prostaglandin E2-
α; NFκB, nuclear-factor kappa B; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; IGF-1, 
insulin-like growth factor-1. 
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2.0. Literature Review 
2.1. Role of Inflammation and Aging 
 2.1.1. What is inflammation? Nine tentative hallmarks of aging in mammalians have 
been enumerated: genomic instability, telomere attrition, epigenetic alterations, loss of 
proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem 
cell exhaustion, and altered intercellular communication (Lopez-Otin, Blasco, Partridge, Serrano, 
& Kroemer, 2013). Thus, aging is a complex issue, of which this thesis focuses on inflammation, 
a small aspect of altered intercellular communication (Lopez-Otin et al., 2013). Inflammation is 
of pertinent interest because it contributes to most age-related chronic diseases and their 
coexistence and represents the most common link between said diseases and disability and the 
related burden to the health care system (Corsonello et al., 2010). Specifically, inflammation at 
the cellular and metabolic level of muscle and bone manifest as sarcopenia and osteoporosis, 
measurable at the tissue level via loss of muscle mass and strength and bone fragility. While 
inflammation is the focus, inflammation occurs via second and third phase of the immune 
response (Eales, 2003); thus, a brief review of the immune response and the inflammatory 
response is necessary for a complete understanding.  
The immune response occurs via three stages: i) non-induced innate, non-specific (0-4 
hours), ii) induced innate, broadly specific, and iii) induced adaptive, highly specific (Mak & 
Saunders, 2006). Interaction between innate and adaptive response provides host defense and 
healing of tissues damaged by microorganisms (Parkin & Cohen, 2001). Leukocytes (i.e. white 
blood cells) are cells of the immune system responsible for inflammation and include myeloid 
and lymphoid cells; myeloid cells include monocytes (macrophages) and granulocytes 
(neutrophils, basophils, eosinophils), while lymphoid cells include natural killer cells, T-cells (T-
helper, T-suppressor, T-cytotoxic), and B-cells (Chaplin, 2010). Leukocytes are attracted to the 
injured site via chemoattraction to destroy the invading microorganism (Parkin & Cohen, 2001). 
All leukocytes have an important and unique role in the inflammatory response, however this 
overview will focus on those pertinent to further discussion within this thesis. 
Macrophages facilitate destruction of microorganisms via phagocytosis, but will also 
release cytokines, specifically interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), to 
attract T-cells to help with the process (Eales, 2003). T-cells are named because they must 
migrate to the thymus gland to differentiate, with the main purpose to control the adaptive 
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immune response via subsets of the T-cell (Parkin & Cohen, 2001). While macrophages are the 
main source of pro-inflammatory cytokines, specifically IL-6 and TNF-α, T-cells and natural 
killer cells will also release cytokines (Parkin & Cohen, 2001). Nuclear factor kappa-B (NFκB) 
is another cytokine of interest, and is responsible for upregulation of IL-6 and TNF-α (Lopez-
Otin et al., 2013; Mak & Saunders, 2006). These specific cytokines (IL-6, TNF-α, and NFκB) are 
among numerous other pro-inflammatory cytokines that act as soluble mediators of the immune 
system; anti-inflammatory cytokines are limited, but include IL-10 and transforming growth 
factor-β (TGF-β) (Mak & Saunders, 2006).  
Besides cytokines, other mediators of interest for the purpose of this thesis include 
immunoglobulins (Ig), acute phase proteins, and eicosanoids. Briefly, Igs are glycoproteins that 
produce antibodies in response to antigens (i.e. microorganisms), and acute phase proteins, 
specifically C-reactive protein (CRP), bind microbes and activate other mediators (Eales, 2003; 
Mak & Saunders, 2006). Eicosanoids are lipid based molecules produced by oxidation of fatty 
acids (omega-3 and 6) and resulting production of arachidonic acid (AA), which is further 
metabolized by enzymes including cyclooxygenase (COX), lipoxygenase (LOX), and 
phospholipase. ‘Classic eicosanoids’ include prostaglandins (PGE), thromboxanes (TX), and 
leukotrienes (LTB); PGE2 and LTB4 are pro-inflammatory while PGE3 and LTB5 are anti-
inflammatory (Eales, 2003).  
Finally, this brief review of the immune system and inflammatory response would not be 
complete without mention of oxidative stress. Macrophages and neutrophils also release reactive 
oxygen species (ROS) which are toxic to microorganisms via their ability to ‘steal’ electrons 
(Chaplin, 2010). Further, oxidation of fatty acids by either COX or LOX also releases ROS, of 
which the initial products in eicosanoid generation are themselves highly reactive peroxides 
(Eales, 2003). Thus, while the focus of this thesis is inflammation, it must be noted that oxidative 
stress (as a result of increasing levels of ROS) and chronic inflammation occur with aging, 
usually concurrently. 
Inflammatory responses are beneficial and necessary in younger individuals, but with 
longer life expectancy these responses become overstimulated and inefficient (Franceschi, 2007). 
The alterations in intercellular communication with age has been coined ‘inflammaging’ and is 
most commonly linked to cellular damage from accumulation of lifelong exposures to 
microorganisms (Corsonello et al., 2010; Degens, 2010; Franceschi, 2007; Lopez-Otin et al., 
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2013). Beyond lifelong exposures to microorganisms, other causes include “the failure of an ever 
more dysfunctional immune system to effectively clear pathogens and dysfunctional host cells, 
the propensity of senescent cells to secrete pro-inflammatory cytokines…., the enhanced 
activation of the NFkβ transcription factor or the occurrence of a defective autophagy response” 
(Lopez-Otin et al., 2013; Salminen, Kaarniranta, & Kauppinen, 2012). Over-activation of pro-
inflammatory pathways, such as NFkB, results from these alterations and leads to increased 
production of cytokines (IL, TNFα) and eicosanoids (PGE2) and reduced levels of gonadotropin 
releasing hormone (GnRH) (Green, Galluzzi, & Kroemer, 2011; Lopez-Otin et al., 2013; 
Salminen et al., 2012; Zhang et al., 2013). IL-6 tends to be the focus of studies on aging and 
inflammation and has been denoted as a ‘cytokine for gerontologists’, while TNFα promotes 
protein catabolism and inhibits myogenic differentiation (Nicklas & Brinkley, 2009; Ogawa, 
Sanada, Machida, & Okutsu, 2010). IL-6 inhibits TNF gene expression and TNF-α stimulates 
production of IL-6, thus the two are interconnected (Schaap et al., 2009).  
 2.1.2. How is muscle altered by inflammation? Older muscle is more sensitive to a 
modest degree of damage leading to a changed/delayed response in regeneration of damaged 
muscle (Degens, 2010; Thalacker-Mercer, Dell’Italia, Cui, Cross, & Bamman, 2010). The 
changed/delayed response is linked to: i) differentially expressed skeletal muscle transcriptome 
genes associated with stress and inflammation, and ii) impaired recruitment of satellite cells for 
proliferation and differentiation after damage (Degens, 2010; Thalacker-Mercer et al., 2010). 
‘Chronic low-grade systematic inflammation’ is indicated as the main contributing factor to the 
attenuated hypertrophic response of old muscle to resistance training and plays an important role 
in the development of disability (Corsonello et al., 2010; Degens, 2010; Visser et al., 2002).   
The alteration of the immune system may be accelerated due to increased adipose tissue 
and less effective anti-oxidant systems that occur with aging and affect inflammatory cytokines, 
specifically TNFα and IL-6, which stimulate the response of macrophages to the site of 
inflammation (Degens, 2010). Pro-inflammatory cytokines are detrimental to skeletal muscle, 
likely causing muscle atrophy via loss of myofibers and disruption of contractile function 
(Nicklas & Brinkley, 2009). Controversy exists regarding the inflammatory role of IL-6, while 
TNFα’s role is definite, specifically stimulating protein loss  which dimishes muscle strength 
(Schaap et al., 2009). Higher levels of inflammatory markers IL-6, TNF-α, and CRP are also 
associated with a greater loss in muscle area of the lower body, while only TNF-α has been 
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associated with decreases in strength of the upper and lower body (Schaap, et al., 2009).The 
response of skeletal muscle to inflammation is as follows: COX-1 and COX-2 stimulates 
production of PGE2 which stimulates NFKB which stimulates production of TNFα and 
interleukin-6 (IL-6) (Greig, Atherton, & Rennie, 2009). TNFα and IL-6 then stimulate cell 
signaling pathways which lead to protein catabolism in muscle (Greig et al., 2009). Further, the 
alteration in TNFα and IL-6 diminish the efficacy of insulin-like growth factor-1 (IGF-1), an 
anabolic hormone responsible for muscle hypertrophy and regeneration (Degens, 2010). 
Increased levels of TNFα and IL-6 and decreased levels of IGF-1 are associated with lower 
muscle mass and strength in older adults (Greig et al., 2009; Schaap et al., 2009; Visser et al., 
2002). Serological markers of inflammation include TNFα and IL-6, as well as CRP, and may 
predict frailty and mortality in older individuals (Corsonello et al., 2010; Schaap et al., 2009).  
Oxidative stress is part of the ‘mitochondrial free radical theory of aging’ due to the age-
related increase in the production of ROS (known to be harmful to many tissues, including 
muscle) primarily within the  mitochondria during oxidative phosphorylation (Johnston, De 
Lisio, & Parise, 2008).  Despite a compensatory upregulation of anti-oxidant enzymes in 
response to increases of ROS, the  rate of oxidant production with age outweighs antioxidant 
defense systems, resulting in cellular damage, which suggests an inability of the aging system to 
cope (Johnston et al., 2008). Thus, sarcopenia can be attributed to both chronic inflammation and 
oxidative stress. 
 2.1.3. How are bone metabolic pathways altered by inflammation? One metabolic 
pathway that influences bone homeostasis is that regualted by COX enzyme and follows a 
similar pathway as that which affects muscle. Prostaglandins (i.e. PGE1 and PGE2) are 
synthesized by the substrate AA via the COX pathway and are involved in the bone remodeling 
cycle, but their effects on bone health are contradictory. PGE2 specifically can decrease bone 
formation or resorption to the same extent and therefore could be considered a safeguard that 
regulates bone metabolism by balancing bone resorption and formation (Carbone et al., 2003; 
Gregory, Kelly, Reid, & Forwood, 2006; Kohrt et al., 2010; Pountos, Georgouli, Calori, & 
Giannoudis, 2012). However, the main function of TNFα and IL-6 is to stimulate osteoclast 
development and bone resorption; therefore, the stimulatory effect of PGE2 on NFKB and 
consequently TNFα and IL-6 would be harmful to bone health (Ershler, Harman, & Kellert, 
1997; Greig et al., 2009; Manolagas, 1995; Steeve, Marc, Sandrine, Dominique & Yannick, 
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2004). This stimulatory effect of IL-6 specifically becomes more potent with age as a result of 
andropause and menopause (Ershler et al., 1997). If bone follows a similar pathway as muscle, 
where PGE2 is linked to production of TNFα and IL-6, it could be justified that during 
inflammatory responses with aging PGE stimulates bone resorption via TNFα and IL-6 rather 
than acting as a safeguard. Further, as previously stated, the alteration in TNFα and IL-6 
diminish the efficacy of insulin-like growth factor-1 (IGF-1), an anabolic hormone that works 
with transforming growth factor-β (TGF- β) as a powerful stimulus to osteoblast precursor 
proliferation (Degens, 2010; Mundy et al., 1995). Biochemical markers of bone metabolism 
include urinary cross-linked telopeptides of type I collagen (Ntx) and serum cross-linked 
telopeptides of type I collagen (CTX-MMP) for bone resorption and bone-specific alkaline 
phosphatase (BAP) and amino-terminal propeptide of type I procollagen (PINP) for bone 
formation (Konstantinidis et al., 2012). Prostaglandin production is regulated by either of the 
COX isoforms (COX-1 and COX-2), of which COX-1 is the regulatory enzyme and COX-2 the 
inducible enzyme (Carbone et al., 2003; Gregory et al., 2006). Of the two isoforms, both act on 
AA to synthesize prostaglandins, but COX-2 may have a more important role in bone 
metabolism as it mediates prostaglandin production in osteoblasts (Carbone et al., 2003). 
2.2. Sarcopenia 
2.2.1. What is sarcopenia? Sarcopenia has been defined as the age-associated loss of 
skeletal muscle mass and function (European Working Group on Sarcopenia in Older People 
[EWGSOP], 2010; IWGS, 2011). The EWGSOP (2010) recommended that sarcopenia be 
diagnosed based on two criteria: (i) the presence of low muscle mass, and (ii) low muscle 
function (strength or performance). Further, three conceptual stages have been suggested: (i) 
‘pre-sarcopenia’ low muscle mass, (ii) ‘sarcopenia’ low muscle mass plus low muscle strength or 
performance, and (iii) ‘severe sarcopenia’ low muscle mass plus low muscle strength and 
performance. ‘Presarcopenia’ would be identified by accurate measures of muscle mass in 
reference to standard populations (EWGSOP, 2010). There are no conclusive ‘cut-off points’ but 
propositions involve the ‘gold standard’ dual energy x-ray absorptiometry (DXA) to measure 
skeletal muscle mass index (SMI), defined as appendicular skeletal muscle mass (ASM) divided 
by height in meters squared (SMI = ASM/height2 = kg/m2) (Baumgartner et al., 1998; EWGSOP, 
2010; Newman et al., 2003). Reference groups were defined as ‘2 SD below mean of young 
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adults (Rosetta Study)’ or ‘Based on sex-specific lowest 20% (Health ABC Study)’ 
(Baumgartner et al., 1998; EWGSOP, 2010; Newman et al., 2003). 
Sarcopenia is a result of many complex physiological and environmental factors (IWGS, 
2011; Roubenoff, 2003). In general, physiologically the predicament is not only the increased 
catabolic signal (i.e. break-down of muscle tissue) driven by inflammation but also the decreased 
anabolic signal (i.e. build-up of muscle tissue) from the decline and diminished efficacy of 
growth hormones (GH) (Concannon et al., 2012; Roubenoff, 2003; Visser et al., 2002). 
Specifically, loss of muscle mass with age is attributed to increases in catabolic cytokine levels, 
oxidative stress, and cellular apoptosis, as well as decreases in anabolic hormone production, 
muscle fiber number and size (type IIx [fast twitch] denervation), neuromuscular function (less 
synchronization of motor units), satellite cell activity and content, muscle protein kinetics, and 
mitochondrial function (Concannon et al., 2012; Candow, Chilibeck, Abeysekara, & Zello, 
2011). Alterations in physical activity and dietary patterns further contribute to the dimishment 
of muscle mass with age (Candow et al., 2011; 2012). Preventing muscle atrophy, rather than 
muscle hypoplasia, is the primary focus for successful aging as muscle atrophy is more ‘labile 
and reversible’ than muscle hypoplasia (Roubenoff, 2003).  
 2.2.2. Why is sarcopenia important? Despite the inability of sarcopenia to explain all 
loss of muscle strength with age, these two factors are tightly coupled and should be considered 
together. It is quite the predicament; muscle mass and strength is lost beginning at the age of 40 
and to an accelerated rate after the age of 65, due to decreased levels of physical activity volume 
and intensity, and muscle mass and strength become less responsive to any physical activity that 
is done, specifically resistance training (ACSM, 2009; Candow et al. 2008; 2011; Candow & 
Chilibeck, 2005; Chrusch et al. 2001; Concannon et al., 2012; Degens, 2010; Roubenoff, 2003). 
This loss in muscle mass is a known predictor of disability and mortality risk and is associated 
with decreased strength, power, and endurance, which consequently reduces functional ability 
and lessens independence (ACSM, 2009; Candow et al., 2011; Candow & Chilibeck, 2005; 
Degens, 2010; EWGSOP, 2010; IWGS, 2011). The lower body loses muscle mass faster, likely 
because reductions in physical activity affect the lower body more (e.g. walking, stair-climbing; 
lower body dependent) leading to weakness and further avoidance of said activity (e.g. taking the  
elevator instead of stairs), consequently leading to the need for compensation from upper body 
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(i.e. use arms to help get up from chair) which helps to maintain upper body strength while lower 
body strength is diminishing (ACSM, 2009; Candow & Chilibeck, 2005).  
 2.2.3. How is muscle strength determined? Muscle strength encompasses muscle mass 
(i.e. quantity) and muscle performance (i.e. quality) (ACSM, 2009; Newman et al., 2006). Thus, 
muscle strength is not dependent solely on muscle mass, as strength is lost to a greater degree 
than muscle mass; a 10% decrease in muscle mass with age results in a 20% decrease in strength 
(Candow et al., 2011; Candow & Chilibeck, 2005; EWGSOP, 2010). Johannesdottir et al. (2012) 
confirm muscle strength declines moreso than muscle area, implying that muscle quality is also 
lost with age. Decreased muscle strength is attributed to decreased motor unit recruitment, 
atrophy of type IIx muscle fibers, alterations in muscle architecture and tendon stiffness, and 
increased activation of antagonist muscle groups (ACSM, 2009; Candow & Chilibeck, 2005). 
Decreased muscle strength, independent of muscle mass, can be a strong predictor of mortality 
(Newman et al., 2006). Of the three different classifications for muscle-weakening diseases (i.e. 
primary, secondary, nutrition-related), age-related sarcopenia is a primary disease encompassing 
a relevant issue in the aging literature. 
 2.2.4. How is muscle mass & strength measured? The parameters of sarcopenia 
include the measurable variables of muscle mass, strength, and performance (EWGSOP, 2011). 
Muscle mass can be measured several ways within research and clinical settings, including: i) 
DXA, ii) computed tomography (CT), iii) magnetic resonance imaging (MRI), iv) bioimpedance 
analysis (BIA),  v) anthropometry (EWGSOP), and (vi) muscle ultrasound.  Discussed in further 
detail within this literature review is the rationale of measuring muscle thickness via muscle 
ultrasound, and muscle mass and cross-sectional area and bone mass and strength via DXA and 
peripheral quantitative computed tomography (pQCT).  
 Strength can be measured via a variety of methods, including isometric (e.g. handgrip 
strength) and isokinetic (e.g. knee flexion/extension), but maximum effort 1-repetition maximum 
(1-RM) protocols can generally depict greater increases in strength (ACSM, 2009; EWGSOP, 
2011).  An alternative to 1-RM is a predicted 1-RM, which may be safer and less daunting to 
older individuals. Baechle and Earle (2000) provide an equation allowing prediction of 1-RM of 
any exercise based on the number of repetitions completed (maximum 10 repetitions) and load 
used. Predicted 1-RM has been shown to be strongly correlated to actual 1-RM for upper and 
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lower extremity exercises in older women, although it underestimated actual 1-RM (1-10 kg) 
(Knutzen, Brilla, & Caine, 1999). 
 Previously it was thought that there was a link between muscle and bone: inactivity → 
sarcopenia → muscle weakness → increased inactivity → osteopenia → osteoporosis → fracture 
(Singh, 2004). More recently it has been suggested that muscle mass loss may act independently 
of bone loss (Johannesdottir et al., 2012). Regardless, increasing or maintaining bone strength in 
older adults is useful for reducing fracture risk, but muscle strength also protects against 
fractures (specifically of the lower limbs) (Johannesdottir, et al., 2012). Strategies to prevent 
fractures should therefore focus not only on increasing bone strength but also reduction of fall 
incidence via increased muscle strength (de Kam et al., 2009). The emphasis lies upon increasing 
bone and muscle strength in conjunction with bone and muscle mass, rather than simply bone 
and muscle mass. 
2.3. Bone Fragility 
 2.3.1. What is osteoporosis and bone strength? The World Health Organization 
(WHO) has defined osteoporosis  as “bone density 2.5 standard deviation units below the young 
adult mean” and osteopenia, the precursor to osteoporosis, as “bone mineral density 1.0 standard 
deviation unit below the young adult mean” (WHO, 1994).  Thus, osteoporosis is diagnosed 
based on a t-score of ≤ -2.5 and osteopenia is diagnosed based on a t-score ≤ -1.0 and > -2.5. 
These t-scores are derived from areal bone mineral density (aBMD) obtained via DXA, but 
aBMD only accounts for 60-70% of bone strength (Calder, Inglis, & MacIntyre, 2010). Risk of 
fracture is now commonly determined by fall risk and many other factors, including aBMD at the 
femoral neck (t-score), age, sex, previous fragility fracture, and corticosteroid use (Scientific 
Advisory Council of Osteoporosis Canada [SACOC], 2010). 
In addition to bone mineral density, bone strength is also determined by bone quality 
characteristics including macro (size and shape) and micro-architecture (trabecular and cortical 
bone properties) (Konstantinidis et al., 2012). These structural properties (i.e. micro and macro-
architecture) of bone are demonstrated via three dimensional measures. Three dimensional 
measures also allow for the determination of true bone mineral density, considered volumetric 
density, rather than areal (aBMD) (Ashe et al., 2006; Calder et al., 2010; Rüegsegger et al., 
1976). From this point on, for the purpose of this thesis, volumetric density will be referred to 
simply as density, while areal density will be referred to as aBMD.  
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 2.3.2. Why is osteoporosis important? Osteoporosis and related fractures are a serious 
and global public health problem affecting the aging population (de Kam et al., 2009; Nikander 
et al., 2010). Fractures of the hip, spine, and wrist are most common and are associated with 
increased mortality and morbidity, height loss and kyphosis, overall loss of independence in 
activities of daily living, and a reduced quality of life (Bolton et al., 2012; de Kam et al., 2009). 
Hip and spine fractures specifically are of clinical relevance because of the related morbidity and 
mortality (Kohrt, Villalon, & Barry, 2013).Osteopenia and osteoporosis in women increases 
fracture risk by 1.8 and 4.0 fold, compared to those with normal aBMD (Siris et al., 2001; 
Wayne et al., 2007). In men and women older than 60, osteoporosis is associated with 80% of 
fractures (Garriguet, 2011).The quest to reduce bone fragility could follow many paths, including 
maximizing peak bone mass in childhood and adolescence, minimizing age-related density loss, 
and preventing falls and consequential fractures (Nordström, Tervo, & Högström, 2011).  Total 
body peak bone mass is reached by the chronological age of 18.8 years in females and 20.5 years 
in males (Baxter-Jones, Faulkner, Forwood, Mirwald, & Bailey, 2011); but as previously 
discussed, bone mass and bone strength are not one and the same. 
Bone strength indices at the peripheral sites (i.e. forearm, lower leg) may identify non-
vertebral fracture risk similar to aBMD of the femoral neck (i.e. hip) (Sheu et al., 2011). Thus, 
osteoporosis as diagnosed by aBMD is a poor indicator of fracture risk at the individual level 
(Sheu et al., 2011); density can provide more insight into fracture risk by estimating indices of 
bone strength (Kontulainen et al., 2008). Increasing or maintaining bone strength via exercise, in 
those who may be vulnerable to osteoporosis, is the primary focus of this thesis for successful 
aging, as exercise may increase bone strength as well as enhance muscle strength, balance, 
coordination, and neuromuscular function all translating to reduced fracture risk  (Hamilton, 
Swan, & Jamal, 2010; Nordström et al., 2011).  
 2.3.3. How is bone strength regulated? Bone is a living tissue and the most common 
cell in bone, the osteocyte, senses and responds to loads and related strains associated straings 
from muscle contractions, leading to adaptations in bone shape, size, and strength via regulation 
of osteoblasts and osteoclasts under control of the ‘bone mechanostat’  (Burr, 1997; Frost, 1987; 
Ferretti, Cointry, Capozza, & Frost, 2003). Osteoblasts are exclusive bone formation cells and 
osteoclasts exclusive bone resorption cells in the body (Weitzmann & Pacifici, 2005). The 
complementary processes of bone formation and resorption regulates bone homeostasis 
 13 
 
 
 
 
(Konstantinidis et al., 2012). This homeostasis is proposed to be regulated by feedback of the 
‘bone mechanostat’ (Ferretti et al., 2003). In other words, the ‘bone mechanostat’ is a 
biomechanical feedback system that modulates bone modeling (via osteoblasts) and bone 
remodeling (via osteoclasts) to maintain bone strength to maintain the strains within the set 
points (Ferretti et al., 2003).  
 2.3.4. How are bone properties & strength measured? DXA is recognized as a valid 
and reliable measure of areal bone density (aBMD; Kohrt et al., 2013). Bone strength is 
measured by mechanical tests, but can be estimated by imaging bone properties and mass 
distribution. pQCT is recognized as a valid and reliable estimate of bone strength (Ashe et al., 
2006). Independently, both the DXA and pQCT provide information regarding bone health and 
fracture risk at different skeletal sites. However, a better overall understanding of bone density 
(areal and volumetric) and strength in regards to bone health and fracture risk can be assessed 
when DXA and pQCT are used in combination (Jarvinen, Kannus, & Sievänen et al., 1999). 
Osteoporosis diagnosis is based on aBMD derived t-scores, while pQCT measures bone structure 
and density of total, trabecular, and cortical bone. The latter pQCT measures can be used to 
calculate estimations of bone strength, which is not possible with DXA-derived aBMD. 
However, hip structural analysis (HSA) of a DXA scan at the femoral neck can give estimates of 
bone strength, but only at the hip. Further, a better overall understanding of muscle mass and 
density in regards to muscle health can be assessed. These instruments, along with muscle 
ultrasound, are described in further detail in the following sections. 
2.4. Methodology 
2.4.1. Muscle ultrasound. Muscle ultrasound employs high-frequency ultrasonic waves 
that distinguishes muscle from other tissues, such as skin, subcutaneous fat, bone, and blood 
vessels (Pillen, 2010). In comparison to the gold standard of magnetic resonance imaging (MRI), 
ultrasound is a valid and reliable measure of muscle tissue in older adults (Reeves, Maganaris, & 
Narici, 2004). Muscle ultrasound is non-invasive, real-time, and convenient, thus justifying the 
technique as a tool to measure changes in muscle in response to training (Pillen, 2010; Reeves et 
al., 2004).  
 2.4.2. Dual energy x-ray absorptiometry (DXA). DXA measures aBMD “by 
quantifying the attenuation of radiation by the skeleton during a rectilinear total body scan” 
(Brodowicz, Mansfield, McClung, & Althoff, 1994). DXA is widely available and is known to 
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be a precise (1-4%) measure of adipose, muscular, and bone components in older adults (Vellas 
et al., 2013). The instrument was recognized previously to be highly reproducible, although 
current reviews suggest high variability between instruments and testing sites (Brodowicz et al., 
1994; Vellas et al., 2013). Thus, the need to measure the same sites with the same instrument and 
technician over time is recognized to maintain validity and reliability.  
  Osteoporosis is defined as “bone density 2.5 standard deviation units below the young 
adult mean” and osteopenia as “bone mineral density 1.0 standard deviation unit below the 
young adult mean” (WHO, 1994).  Thus, osteopenia and osteoporosis is diagnosed based on t-
scores obtained from two-dimensional aBMD obtained via dual-energy x-ray absorptiometry 
(DXA). The number of standard deviations below the young adult (same sex) mean is called the 
t-score; the number of standard deviations below the mean of a similarly aged individual is 
called the z-score. Beyond predicting and diagnosing osteoporosis, the t-score at the femoral 
neck is used for determining fracture risk (SACOC, 2010). The hip, spine, and forearm are 
considered the most relevant sites measured by DXA in the Americas (WHO, 2004).  
 The standard single plane frontal image of the hip provides bone area, content, and areal 
density for the proximal femur, which includes the total hip, femoral neck, trochanter, 
intertrochanter, and Ward’s region. While most are unfamiliar with Ward’s region, this site has 
potential for clinical relevance (Figure 2.0). Ward’s region is identified as the intersection of 
three trabecular bundles at the femoral neck (Bonnick, 2010). Although now known as Ward’s 
region (rather than Ward’s triangle), it is not a specific anatomical region, but rather the region 
with the lowest calculated aBMD (Bonnick, 2010). Thus, Ward’s region is clinically relevant 
because it is potentially the weakest. While the information from the standard analysis proves 
useful, insight can be gained via further analysis.  
 Hip Structural Analysis (HSA) of DXA scans denotes a method of which a strength 
estimate is based on a single plane frontal image of the structural geometry of the hip (Beck, 
Ruff, Warden, Scott, & Rao, 1990).  The HSA program allows not only assessment of aBMD but 
also bone geometry such as subperiosteal width, cross-sectional area, and cross-sectional 
moment of inertia of the narrow neck, intertrochanter, and femoral shaft regions. Areal density 
reflects only a regional average which “may not reflect whether bone is appropriately placed to 
resist mechanical stresses leading to fracture” (Beck et al., 1990). Beck and colleagues (1990)  
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Figure 2.0. Diagram of the proximal femur dual energy x ray absorptiometry analysis, showing 
the global region of interest and subregions analysed. Reprinted from “Muscular development 
and physical activity as major determinants of femoral bone mass acquisition during growth” by 
G. Vincent-Rodriguez, I. Ara, J. Perez-Gomez, C. Dorado, J. A. L. Calbet, 2005, British Journal 
of Sports Medicine, 39, p. 612. 
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compared measured breaking strength of cadaver femurs from predominantly white elderly 
subjects to HSA predicted failure and found predicted strength in tension (r = 0.89, %SSE = 
21.3%) to have the best correlation, followed by predicted shear strength ( r = 0.83, %SSE = 
25.6%), and predicted compression strength (r = 0.66, %SEE = 34.6%). These results were based 
on Lunar DP3, with improvements in HSA performance being acknowledged if hip images were 
to be acquired via the older model Hologic QDR-1000 system (Beck et al., 1990). HSA derived 
predicted strength may detect changes in bone that aBMD from DXA simply cannot.  Baseline 
data of postmenopausal women in the cross-sectional Women’s Health Initiative study was 
analyzed to determine if differences in bone were found between women with high lean body 
mass fraction and activity levels, compared to those with lower levels (Beck, et al., 2010). 
Physical activity level is more accurately represented using lean body mass fraction and has a 
positive effect on femur aBMD and geometry when body size and other confounding factors are 
considered. Further, the expected increases in both bone mineral content (BMC) and region area 
in long bones in  response to physical activity led to ambigous effects on aBMD, as aBMD is 
equivalant to BMC per region area (Beck et al., 2010). Thus, the positive effects of physical 
activity on bone are more clearly represented by section modulus, a geometric index of bending 
strength obtained by HSA, as compared to aBMD (Beck et al., 2010).  
 2.4.3. Peripheral quantitative computed tomography (pQCT). DXA is a commonly 
used clinical tool because aBMD is used to diagnose osteoporosis. However, fracture risk may be 
lower when bone density is normal, but is no means negligible (WHO, 2004). DXA may be 
considered “the best single predictor of fracture risk”, yet only accounts for 60% of bone strength 
variance (Weinstein, 2000). Further, the accuracy of aBMD as derived by DXA “is contaminated 
by sizable, unavoidable, inextricable, independent soft tissue contributions” (Bolton, 2007). Only 
true indicators of bone and muscle strength can distinguish the different conditions contributing 
to bone diseases (i.e. primary, disuse, secondary) (Ferretti et al., 2003). Further, it has been 
suggested that DXA is only appropriate for diagnosing osteopenia, as osteoporosis requires 
assessment of bone strength (Ferretti et al., 2003).  
Bone strength based on bone microarchitecture via three dimensional measures can be 
estimated using the medical imaging tool pQCT (Sievanen et al., 1998). pQCT assesses bone 
morphometric properties (structure, geometry) in three dimension, enabling assessment of 
volumetric density (Ashe et al., 2006; Calder et al., 2010; Rüegsegger et al., 1976). 
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Morphometric properties can be used to estimate bone strength indices that can predict bone 
strength (i.e. fracture load) in compression, bending, or torsion and may provide a more reliable, 
accurate, and precise indicator of bone fragility than aBMD from DXA (Calder et al., 2010; 
Ferretti et al., 2003). Whereas aBMD provides overall areal density, structural properties provide 
information regarding distribution of mass (Ashe et al., 2006; Calder et al., 2010). Different 
fracture loads exert forces on the bone differently, meaning distributions of density may predict 
what type of fracture an individual is most susceptible too.   
pQCT is able to validly and reliably distinguish between trabecular and cortical bone 
(Ashe et al., 2006; Polidoulis, Beyene, & Cheung et al., 2012; Rinaldi, Wisniewski, Setty, & 
LeBoff, 2011; Szabo et al., 2011). In a systematic review by Hamilton et al. (2010) it is noted 
that most studies assessing effects of exercise on bone reported differences in cortical density 
and area, as well as bone strength. However, due to its higher turnover rate, trabecular bone may 
be most useful for early detection of bone changes, which is of importance in shorter duration 
studies (i.e. < 1 year) (Ashe et al., 2013; Polidoulis et al., 2012). A current systematic review and 
meta-analysis (Polidoulis et al., 2012) confirms what was previously stated: “Trabecular bone 
has large area-to-volume ratio,  is metabolically active tissue, and exhibits large inter-individual 
variability in density, and can therefore show marked changes in various skeletal disorders and 
considerable responses to various treatments” (Sievanen et al., 1998).  As the effects of exercise 
on bone are modest the differences in bone strength are expected to be small but clinically 
significant (Hamilton et al., 2010; Polidoulis et al., 2012). Karinkanta et al. (2007) found 
differences in bone strength indices of 2 mm3 (i.e. ≤ 1%) at the distal radius after resistance 
training for 12 months in women aged 70-78 years. A systematic review found similarly small 
(~0.9%) differences in bone strength indices at the distal tibia and tibial shaft of exercise training 
in older women via meta-analysis (Polidoulis et al., 2012).  Randomized control trials 
determining bone density changes via DXA in conjunction with bone strength indices changes 
via pQCT in response to resistance training are lacking and could provide  further insight. 
2.5. Modification 
Many factors are involved in aging, including the natural aging process (primary), 
lifestyle behaviors and chronic disease (secondary), and genetics (ACSM, 2009). Although aging 
cannot be stopped entirely, it could be modified via many strategies, including physical activity 
and/or exercise, nutrition, and pharmacology (ACSM, 2009; Ramage-Morin et al., 2010). 
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Specifically, strategies targeting pathophysiological inflammation could modify the chronic 
diseases of interest, sarcopenia and osteoporosis, and reduce the associated disability (Corsonello 
et al., 2010).   
 2.5.1. Physical activity versus exercise training. Continued or implemented physical 
activity as an older adult represents the best non-pharmacological approach to promote 
successful aging (ACSM, 2009; Cheung & Giangregorio, 2012; Corsonello et al., 2010; Gomez-
Cabello, Ara, Gonzalez-Aguero, Casajus, & Vincente-Rodriguez, 2012; Hamilton et al., 2010; 
Nikander et al., 2010; Nordström et al., 2011). Exercise training, although closely related to 
physical activity and physical fitness, connotes ‘intentional’ physical activity for the purpose of 
improving health and wellness (ACSM, 2011). Exercise regimens include: i) cardiorespiratory 
and resistance exercise training to maintain/improve health and physical fitness, ii) flexibility 
exercise to maintain/improve joint range of motion, and iii) neuromotor exercise to 
maintain/improve physical function and reduce risk of falls in older adults (ACSM, 2011).  
All exercise regimens are associated with health benefits and improved physical function 
in men and women, but specific exercise training may contribute to thwart inflammation 
components (Corsonello et al., 2010). Repeated bouts of exercise thwart inflammation by 
reducing the concentration of pro-inflammatory biomarkers via adaptive responses of the skeletal 
muscle and blood cells (Corsonello et al., 2010; Nicklas & Brinkley, 2009). Specifically, blood 
cells adapt by decreasing production of pro-inflammatory cytokines, and skeletal muscles adapt 
by reducing IL-6, TNFα, and ROS (Nicklas & Brinkley, 2009). Recent intervention studies in 
older adults engaging in exercise training confirm significant, or trending towards significant, 
reductions of inflammatory biomarkers, such as CRP, IL-6 and TNFα (Corsonello et al., 2010; 
Nicklas & Brinkley, 2009).  
 2.5.1.1. Resistance training. Resistance training is recognized as the most ideal stimulus 
for the modification of muscle and bone mass during the aging process (Cheung & Giangregorio, 
2012; Gomez-Cabello et al., 2012; Greig et al., 2009; Nikander et al., 2010). To improve muscle 
and bone strength in apparently healthy older adults the recommendation for resistance exercise 
training is performing 2-4 sets of 10-15 repetitions with 40-50% of 1-RM, while allowing 2-3 
minutes of rest between sets, of exercises that work every major muscle group of the body 2-3 
days per week, while allowing at least 48 hours between sessions (ACSM, 2011). Prior 
guidelines in Canada recommended 30-60 minutes of moderate activity most days of the week, 
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including strength using “a weight that will challenge your muscles” (Paterson, Jones, & Rice, 
2007). In a more recent review it was concluded that most studies suggest resistance exercise 
training 2-3 days per week with moderate to heavy (> 60% 1-RM) weight (Paterson et al., 2007). 
Further, unlike other forms of exercise, resistance training-induced adaptations in older adults are 
persistent (similar to that of younger adults), and remain even 12 weeks after cessation of the 
program, with results maintained above baseline for another 19 weeks after the initial 12 
(ACSM, 2009).  There is a direct relationship between muscle and bone adaptations to resistance 
training, further demonstrating the link between the two (ACSM, 2009). 
2.5.1.1.1. Resistance training and muscle. It is suggested that only muscle overload via 
resistance training may modify decreasing muscle mass and muscle strength with aging (Singh, 
2004). Muscle is responsive to progressive resistance training potentially via activation of the 
mammalian target of rapamycin (mTOR) muscle protein synthetic pathway (Candow et al., 
2012) and by increases in “muscle protein synthesis, satellite cell activity and content, anabolic 
hormone production, mitochondrial quality and function, and a decrease in catabolic cytokine 
activity” (Candow et al., 2011). Muscle accretion from resistance exercise then occurs via the 
pituitary gland: GnHR → GH → liver →  IGF-1 → Rac-alpha serine/threonine-protein 
kinase/protein kinase B (Akt/PKB) → mTOR → ribosomal protein S6 kinase (p70S6K) → 
increased translation→ muscle protein synthesis → muscle hypertrophy (Candow et al., 2012; 
Shing, Hunter, & Stevenson, 2009).  
Aging may alter the mechanism and time course of muscle response to resistance 
training, but the adaptive response is well preserved and results are persistent (ACSM, 2009). 
Regardless, even with a delayed time course of response, older adults can eliminate the deficits 
in strength of the lower body via neural adaptations within a short time period (i.e. 12 weeks); 
longer durations (i.e. 22 weeks) are required to increase muscle mass to levels of young non-
resistance trained individuals (Candow et al., 2011). The beneficial effects of long-term 
resistance training on muscle may be from protection against inflammation via decreases in 
skeletal muscle TNF-α messenger ribonucleic acid (mRNA) expression (Ogawa et al., 2010). 
Further beneficial effects of resistance training in relation to ‘mitochondrial free radical theory of 
aging’ (i.e. oxidative stress) may be from protection against oxidative stress via decreased 
production of ROS and increased activity of antioxidant enzymes and complex IV in the electron 
transport chain (thought to improve oxidant status) (Johnston et al., 2008).    
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2.5.1.1.2. Resistance training and bone. As previously discussed, bone adaptations of 
shape, size, and strength are in response to mechanical loading, and similar to muscle, bone 
remains responsive to mechanical loading with aging, but to a lesser degree than muscle (Kohrt 
et al., 2013).  Previous paradigms and theories suggest that older adults may lack the ability to 
genereate enough force via resistance training to stimulate bone formation required to achieve 
large gains in bone strength (Ashe et al., 2013; Frost, 1999; Nordström et al., 2011). It is 
confirmed that the effects of exercise on bone in older adults may be modest, but are clinically 
relevant (Ashe et al., 2013; Bolton et al., 2012; Hamilton et al., 2010; Nordström et al., 2011; 
Polidoulis et al., 2012).  
Resistance training stimulates modest (~1-2%)  increases in aBMD at the lumbar spine 
and femoral neck for older men and women and density at the distal tibia and tibial shaft in 
postmenopausal women (Cheung & Giangregorio, 2012; Kohrt et al., 2013; Kukuljan et al., 
2011; Polidoulis et al., 2012; Stolzenberg et al., 2013). These small increases at the femoral neck 
and lumbar spine seem more imperative because the increases correlate not only with a reduction 
of hip and spine fractures, but also with a reduction in 20-year fracture risk at any other site by 
~10% (Kelley, Kelley, & Kohrt, 2012). Improvements in density are more likely in the spine, 
versus femoral neck, possibly because of the higher proportion of cancellous bone at the spine 
(i.e. higher turnover rate than cortical bone found at the femoral neck) and/or because the 
femoral neck experiences loading during daily activities and thus exercise interventions may not 
generate a markedly higher strain than usual (Kohrt et al., 2013). Regardless, sustaining or 
increasing bone strength at any site would be sufficient to modify the development of 
osteoporosis, facilitate successful aging, and reduce fracture risk (Ashe et al., 2013; Bolton et al., 
2012; Cheung & Giangregorio, 2012; Hamilton et al., 2010; Kelley et al., 2012; Polidoulis et al., 
2012; Singh, 2004). Thus, exercise is a cost efficient modification strategy to increase bone and 
muscle strength, as well as contributing to successful aging by reducing fracture risk and 
functional deficits, and  improving quality of life (Bolton et al., 2012; Gomez-Cabello et al., 
2012; Hamilton et al., 2010; Polidoulis et al., 2012).  
Due to the promising evidence of exercise training on bone represented in previous 
literature, further research is needed. Specifically, there is a lack of literature representing the 
effects of a longer term, progressive resistance training program on muscle mass and strength 
and bone density and strength in the clinically relevant older adult population. Further, studies 
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with novel combination of a well known modification strategy (i.e. resistance training) with 
nutritional (i.e. bovine colostrum) and pharmaceutical (i.e. ibuprofen) strategies are fewer yet. 
2.5.2. Nutrition versus pharmacology. Kelley et al. (2012) suggest lifestyle changes 
such as adequate amounts of calcium/vitamin D and exercise prior to pharmacological 
approaches. Adequate intake (AI) recommendations for calcium (AI = 1,200mg/day for men and 
women ≥51y) and Vitamin D (AI = 10µg/day for men and women 51-70y; 15µg/day for men 
and women >70y) are based on amounts believed to cover the needs of all healthy individuals in 
the group (Otten, Pitzi Hellwig, Meyers, 2006). Calcium is essential for bone health and vitamin 
D improves the absorption of calcium, but vitamin D may also have direct effects on muscle 
health (Candow et al., 2012; Garriguet, 2011). Older adults are often deficient in vitamin D due 
to less sunshine exposure as well as decreased ability of the body to synthesize, absorb, activate, 
and express what little is available (Otten et al., 2006); this deficiency is related to decreased 
muscle size and strength and increased risk of recurrent falls and fractures (Candow et al., 2012). 
Thus, calcium and vitamin D supplementation is a proven nutritional supplementation for bone 
and muscle health. However, before turning to therapeutic agents, other nutritional strategies 
should be attempted.  
Therapeutic agents, such as hormone replacement therapy, selective estrogen-receptor 
modulators, and bisphosphonates, are known to stimulate responses similar to or greater than 
exercise (Kohrt et al., 2013). It can be assumed these effects would be greater than nutritional 
strategies alone as well. However, clinicians need to be selective in choosing the best line of 
defense for specific patient needs as combinations of therapeutic agents is not recommended 
(Body et al., 2010). Further, even with treatment via therapeutic agents further modification 
strategies are needed (Body et al., 2010). Moving forward, the novel combination of exercise 
supplemented with nutritional (i.e. bovine colostrum) and easily accessible, over-the-counter 
pharmaceutical (i.e. ibuprofen) supplementation targeting inflammation is an obvious 
exploratory path to modify sarcopenic muscle loss and bone fragility.   
2.5.2.1 Bovine colostrum. Bovine colostrum is by definition the first milk secreted by 
cows immediately following parturition (Larson, Heary, & Devery, 1980). Besides being a good 
source of carbohydrates, fat, and protein, bovine colostrum contains various bioactive 
components such as lactoferrin and Igs, as well as various growth factors including: i) epidermal 
growth factor, ii) TGF (a and b), iii) basic fibroblast growth factor, iv) platelet derived growth 
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factor, and v) IGF-1 (Klagsbrun & Neumann, 1979; Larson et al., 1980). IGF-1 is important for 
muscle, bone, and brain development, and is therefore the main growth factor of interest (Ceda et 
al., 2005; Degens, 2010; Ohlsson et al., 2011; Visser et al., 2002). The bioactive components of 
colostrum are known to stimulate DNA synthesis, protein synthesis, bone development, and 
cellular growth in neonatal and newborn animals (Burrin et al., 1997; Du et al., 2011; Hou, Xue, 
& Lin, 2012; Lee et al., 2008; Nakajima et al., 2011; Vidal, van den Broek, Lorget, & Donnet-
Hughes, 2004). It is not known if this anabolic effect applies to humans (Shing, Hunter, & 
Stevenson, 2009). The adult gut, unlike the neonatal gut, is relatively impermeable to large 
molecules (Burrin et al., 1997). It is theorized that strong trophic effects of the bovine colostrum 
“interact[ed] with the lumen of the intestine and initiate[d] a hormonal signal that indirectly 
stimulates…” various physiological effects (Brinkworth, Buckley, Slavotinek, & Kurmis, 2004). 
However, the mechanism of action of bovine colostrum supplementation on physiological and 
human immune parameters remains unknown and warrants further research (Burrin et al., 1997; 
Davison & Diment, 2010).  
 2.5.2.1.1 Mechanism. The adult gut, unlike the neonatal gut, is relatively impermeable to 
large molecules (Burrin et al., 1997). Previously it was theorized that strong trophic effects of the 
bovine colostrum “interact[ed] with the lumen of the intestine and initiate[d] a hormonal signal 
that indirectly stimulates…” various physiological effects (Brinkworth et al., 2004; Burrin et al., 
1997). Shing et al. (2009) outline the possible ‘kinetics’: macromolecules transport to mucosal 
surfaces via transcytosis mediated by Fc-receptor and then are able to withstand digestion in the 
stomach allowing them to the intestines where bovine colostrum aids in absorption of the active 
components. After successful digestion and absorption occurs, the exact mechanism of action 
remains unknown, but potential pathways via the central nervous system include the pituitary, 
hypothalamus, and autonomic nervous systems (i.e. sympathetic or parasympathetic activity) 
(Shing et al., 2009).  
 2.5.2.1.1.1 Insulin-like growth factor 1 (IGF-1). IGF-1 is the most abundant and well-
characterized growth factor in bovine colostrum and is homologous to human IGF-1 (Francis, 
Upton, Ballard, & McNeil, 1988; Marcotty, Frankenne, van Beeumen, Maghuin-Rogister, & 
Hennen, 1991). The protein synthesis that occurs from bovine colostrum supplementation is 
known to be largely due to the nutrients of the milk and likely a non-nutritive component, 
although the non-nutritive component may not necessarily be IGF-1 (Burrin et al., 1997). IGF-1 
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is the major mediator of growth hormone (GH), and thus has previously been the growth factor 
of interest, as increases in plasma IGF-1 may take part in mediating muscle strength and 
maintaining skeletal muscle mass and function (Buckley et al., 2003; Borst, et al., 2001). IGF-1 
is also important for development of bone tissue and reduction in IGF-1 in older adults is 
associated with lower bone mass (Ohlsson et al., 2011).  
Results from previous studies measuring serum levels of IGF-1 have been conflicting.  
Some have shown that levels of plasma IGF-1 increased after 2 weeks of supplementation with 
bovine colostrum and training in male and female athletes (Mero et al., 2002), while others have 
shown levels of plasma IGF-1 did not increase after supplementation and training (Buckley, 
Abbott, Brinkworth, & Whyte, 2002; Coombes, Conacher, Austen, & Marshall, 2002; Kuipers, 
van Breda, Verlaan, & Smeets, 2002). It was therefore concluded that “…although it appears that 
the physiological (Mero et al., 1997, 2002; Antonio et al., 2001; Brinkworth et al., 2002) and/or 
performance enhancing (Buckley et al., 2002; Coombes, et al., 2002; Hofman et al., 2002) 
effects of colostrum most likely result from the effect of some non-nutrient component, no study 
to date has been able to identify the specific non-nutrient component(s) responsible…..IGF-1 is 
unlikely to mediate the effects of bovine colostrum” (Buckley et al., 2003). 
 2.5.2.1.1.2. Bioactive components. Previously Igs were of interest due to possible 
stimulation of beneficial immune system effects (Davison & Diment, 2010). Strenuous exercise 
affects the immune system and leaves athletes vulnerable to infections, thus previous interest in 
bovine colostrum for sport performance was for the prevention of infections following strenuous 
exercise, specifically upper respiratory tract infections (URTI) (Carol, Witkamp, Wichers, & 
Mensink, 2011). Many components of the immune system response is impaired after bouts of 
strenuous exercise (i.e. physical stress) with typical responses including: i) increased leukocytes 
(including neutrophils, lymphocytes, atypical lymphocytes, and neutrophil:lymphocyte ratio), ii) 
increased substances that influence leukocytes function (i.e. inflammatory cytokines), iii) 
decreased natural killer cells, iv) depressed phagocytic activity of natural killer cells (i.e. 
oxidative burst and granulation), and v) decreased salivary immunoglobulin A (s-IgA; marker of 
mucosal immunity) (Carol et al., 2011; Davison & Diment, 2010). In previous studies athletes 
have used bovine colostrum as a nutritional supplement during training to enhance immune 
function, although no effects on either saliva or plasma immunoglobulin levels were found 
(Brinkworth & Buckley, 2003; Crooks, Cross, Wall, & Ali, 2010).  However, bovine colostrum 
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has been shown to increase anti-inflammatory cytokines (Shing, Peake, Suzuki, Jenkins, & 
Coombes, 2007). It is suggested that respiratory symptoms may actually result from 
inflammation rather than suppressed immune function (Bachert, van Kempen, Höpken, 
Holtappels, & Wagenmann, 2001). Thus, it is possible these beneficial effects of bovine 
colostrum during exercise training may be from decreased inflammation.   
 2.5.2.1.2 Bovine colostrum and muscle and bone. Previously Antonio et al. (2001) 
reported increases in bone free lean body mass in younger participants supplemented with 20 g/d 
of colostrum during 8 weeks of participants’ own unsupervised resistance training program. 
Whole body DXA scans were performed on all participants, but bone mineral content or aBMD 
were not reported. Previously Brinkworth et al. (2004) showed a trend (p=0.06) toward a greater 
increase in bone cross-sectional area in the trained upper arm of younger participants 
supplemented with 60 g/d of colostrum compared to whey protein for eight weeks. Participants 
on colostrum demonstrated a 2.4% increase in bone cross-sectional area whereas participants on 
whey demonstrated an equivalent percent decrease in bone cross-sectional area; these results 
neared statistical significance. As previously discussed, changes in bone with resistance training 
are often small but clinically significant, meaning the 2.4% increase seen in Brinkworth et al. 
(2004) may be clinically significant despite not achieving statistical significance. Further, it 
could be speculated that bone mineral content and aBMD were not reported in Antonio et al. 
(2001) due to lack of significance, or lack of interest in bone parameters. Evidence pertaining to 
the effect of bovine colostrum on bone in humans is lacking. 
 2.5.2.1.2.1 Bone density. A number of studies using animal models have also suggested a 
positive effect of bovine colostrum on bone. Supplementation with components of bovine 
colostrum (i.e. osteopontin, lactoferrin, epidural growth factor, and IGF-2) increased mineral 
density, micro-architectural properties, and mechanical strength of bones of ovariectomized rats 
(a model for postmenopausal osteoporosis) and reduced markers of bone resorption and 
increased markers of bone formation in serum (Du et al., 2011; Hou et al., 2012). The studies by 
Du et al. (2011) and Hou et al. (2012) used two control groups, ovariectomized rats with no 
supplement (true control) and ‘sham’ ovariectomized rats (i.e. fat near ovaries removed, but 
ovaries left intact) with no supplement (positive controls). Du and colleagues (2011) 
supplemented ovariectomized rats with 0mg/day (control; OVXC), 2mg/day (OVX2), 10mg/day 
(OVX10), or 50mg/day (OVX50) of bovine colostrum acid proteins (BCAP) for 12 weeks while 
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Hou and colleagues (2012) supplemented ovariectomized rats with 10mg/kg/day, 100mg/kg/day, 
1.0g/kg/day, or 2.0g/kg/day of lactoferrin for 6 months. Increases in density parameters including 
weight/length ratio (indicator of bone density), bone mineral content, and aBMD of the proximal, 
middle, and distal regions of the femur were shown, with a noteworthy stronger effect at the 
distal femur (Du et al., 2011). This was verified more recently when increases in aBMD of the 
femur and lumbar vertebrae was shown (Hou et al., 2012). The studies by Du et al. (2011) and 
Hou et al. (2012) demonstrated a significant dose-dependent increase in density. Lower dosages 
of either supplement were not sufficient enough to overcome the effects of the ovariectomy on 
density, but higher dosages were effective for restoring bone density (Du et al., 2011; Hou et al., 
2012). Previously a dose-dependent relationship between femur aBMD and dosage of growth-
protein colostrum (GP-C, 0.05, 0.5, or 5.0% of total diet) was shown in juvenile male rats (Lee et 
al., 2008), indicating the effects of bovine colostrum components on bone density transcend age 
and sex.   
 2.5.2.1.2.2 Bone micro-architecture and strength. A dose-dependent relationship between 
bovine colostrum supplementation and bone micro-architectural properties has also been shown 
in rats. Micro-architectural properties including trabecular number, thickness, and area in both 
femur and lumbar vertebrae were significantly higher and trabecular separation was significantly 
lower in bovine colostrum supplemented rats (Du et al., 2011; Hou et al., 2012).  Further, Du et 
al. (2011) showed failure load, strain, stress, and stiffness of the femur was significantly higher 
in the OVX50 (i.e. ovariectomized rats supplemented with 50mg/day bovine colostrum) group, 
leading authors to conclude that biomechanical properties were improved and bone strength 
enhanced, but this was only demonstrated in the OVX50 group compared to OVXC (i.e. not 
supplemented). Thus, smaller doses (2 or 10mg/day) of bovine colostrum supplementation were 
not effective, but higher doses (50mg/day) were, hence the dose-dependent relationship. Bone 
resorption was noted to appear severe via visual inspection when comparing OVXC to OVX50, 
although actual markers of bone resorption were not measured (Du et al., 2011).  
 2.5.2.1.2.3 Bone metabolism. Hou et al. (2012) measured markers of bone resorption (i.e. 
Ntx and β-CrossLaps [β-CTx]) and formation (i.e. osteocalcin and bone alkaline phosphatase 
[BALP]) and showed serum levels of bone resorption markers were lower and bone formation 
markers were higher, but only for higher dosage groups (i.e. 1.0g/kg/day and 2.0g/kg/day). These 
findings partially confirm the higher levels of osteocalcin (other markers not measured) 
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previously found in juvenile male rats (Lee et al., 2008). Bovine colostrum or proteins derived 
from colostrum (i.e. lactoferrin, GP-C) increase the proliferation of osteoblasts (i.e. cells 
involved in bone formation) and the release of growth factors from osteoblasts derived from rats 
(Lee et al., 2008; Nakajima et al., 2011), and bovine colostrum reduces activity of osteoclasts 
(i.e. cells involved in bone resorption) derived from rabbits (Vidal et al., 2004). Taken together, 
bovine colostrum, in whole or in part, shows a dose dependent beneficial effect on bone 
metabolism which may lead to increases in bone density, properties, and strength in animals. 
Due to the promising evidence represented in animal studies and lack of evidence representing 
humans, research studying the effect of bovine colostrum supplementation on bone in humans is 
needed.  
 2.5.2.1.3 Bovine colostrum interactions with exercise. In addition to improving immune 
function, athletes have used bovine colostrum as a nutritional supplement during training to 
improve exercise performance (Buckley et al., 2003; Hofman, Smeets, Verlaan, v.d. Lugt, & 
Verstappen, 2002) and increase muscle hypertrophy (Antonio et al., 2001). Exercise training 
with bovine colostrum supplementation increased lean tissue mass in young adults, but had no 
effect on strength (Antonio et al., 2001). Exercise training with bovine colostrum 
supplementation increased vertical jump and cycle power in young adults, but had no effect on 
strength (Buckley et al., 2003).  Speculations to explain lack of influence on strength increase 
include: i) participants were previously trained and thus it would be more difficult to improve 
muscular strength (Antonio et al., 2001; Buckley et al., 2003), and ii) high dosages (> 20g/d) 
may be necessary to improve strength (Antonio et al., 2001).  Thus, the effects of bovine 
colostrum on strength in young adults remain unclear (Shing et al., 2009).  There is currently no 
known literature that examines exercise training with bovine colostrum supplementation in older 
adults.  
 2.5.2.2 Ibuprofen. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that 
originates from the extracts of salicylate-containing plants, willow trees specifically, known for 
its anti-inflammatory properties (Pountos et al., 2012). Thus, ibuprofen may be successful at 
preventing sarcopenic muscle loss and bone fragility that occur with inflammation and aging, 
specifically when administered after mechanical loading (i.e. exercise training) (Candow et al., 
2013; Carbone et al., 2003; Greig et al, 2009; Kohrt et al., 2010; Kohrt et al., 2013; Trappe et al., 
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2011). Due to the questionable safety profile and mixed results from previous studies, more 
research is needed, specifically randomized controlled trial. 
Ibuprofen exerts a relative and reversible inhibitory effect on the non-selective enzyme 
COX via blockage of the pathway, as depicted in Figure 1.0 and previously identified in the 
literature (Greig et al., 2009). This mechanism is modified to maintain muscle and bone 
homeostasis, showing that PGE2 can stimulate either muscle protein synthesis or breakdown and 
bone formation or resorption, of which maintains muscle and bone homeostasis, respectively 
(Greig et al., 2009; Konstantinidis et al., 2012). Therefore, ibuprofen may exert beneficial effects 
on both bone and muscle. Gastrointestinal adverse events are also of concern because PGE2 
exerts a protective effect via: i) reducing acid secretion, ii) stimulating mucus production, and iii) 
vasodilating blood vessels of the gastric mucosa (Pountos et al., 2012; Whelton, 1999). However, 
multiple doses (>1200mg/day for >10days) of ibuprofen compared to placebo demonstrated 
equivalent adverse event frequency for gastrointestinal issues (Kellstein, Waksman, Furey, 
Binstok, & Cooper, 1999). Further, despite being referred to as ‘non-selective’ due to inhibition 
of both isoforms of COX, ibuprofen is known to inhibit COX-2 (where the anti-inflammatory 
effects come from) to a greater degree than COX-1 and thus has less gastrointestinal toxicity 
than an NSAID that selectively inhibits COX-1 (i.e. indomethacin) (McCarthy, Whitney, Hitt, & 
Al-Majid, 2004). 
2.5.2.2.1 Ibuprofen and muscle. Although the majority of studies focus on bone health in 
animals or humans, there is promising evidence from animal studies regarding beneficial effects 
of ibuprofen on muscle health (Greig et al., 2009). Ibuprofen supplementation in rats inoculated 
with tumor cells to stimulate cancer cachexia (muscle wasting that follows the same mechanism 
as muscle loss from aging) reduced gastrocnemius muscle mass loss, likely associated with 
increased soluble muscle protein content (McCarthy et al., 2004). Ibuprofen supplementation in 
older rats restored muscle protein anabolism normally altered by aging and the associated low 
grade inflammation, significantly decreasing muscle mass loss in the lower limb compared to 
older rats on placebo (Rieu et al., 2009).Taken together, ibuprofen may prevent age associated 
muscle loss, especially in the lower limb, by maintaining or increasing muscle protein sythesis. 
Due to the promising evidence represented in animal studies and lack of evidence representing 
humans, research studying the effect of ibuprofen supplementation on muscle in humans is 
needed. While there is lack of evidence in humans regarding ibuprofen alone, promising 
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evidence regarding ibuprofen and exercise in humans is discussed further (refer to section 
2.5.3.3.).  
 2.5.2.2.2 Ibuprofen and aBMD. NSAID use has no clear contraindication to bone 
pathology, as results from previous studies have been mixed, demonstrating adverse, neutral, or 
even beneficial effects of NSAID use on aBMD (Kohrt et al., 2013; Konstantinidis et al., 2012). 
Two epidemiological studies found modest increases in aBMD and bone properties following 
NSAID use (Bauer et al., 1996; Carbone et al., 2003). Of note, Carbone et al. (2003) is among 
the few studies in humans to report bone properties following NSAID use. It appears these 
increases in aBMD and bone properties may be due to attenuation of inflammatory cytokines that 
therefore inhibit bone resorption and permit the activation of bone formation (Kohrt et al., 2013; 
Konstantinidis et al., 2012).  This was confirmed by no significant increases in bone formation 
markers after NSAID use, but rather a significant decrease in bone resorption markers 
(Konstantinidis et al., 2012). The Canadian Multicentre Osteoporosis Study (CaMos) showed 
that postmenopausal women not on estrogen replacement therapy using COX-2 inhibitors on a 
daily basis (i.e. rofecoxib or celecoxib) showed higher aBMD of the total hip than non-users; this 
effect was exaggerated in those also taking aspirin on a daily basis (Richards et al., 2006). The 
Rancho Bernardo Study showed that women using NSAIDs such as ibuprofen had higher aBMD 
of all clinically relevant sites, with lumbar spine and forearm being significant, compared to 
nonusers (Morton, Barrett-Connor, & Schneider, 1998). Due to the promising evidence 
representing bone density measures and lack of evidence representing bone strength measures in 
humans, further research studying the effect of ibuprofen supplementation on bone density as 
well as bone structure and strength in humans is needed, specifically in postmenopausal women.  
 2.5.2.2.3 Ibuprofen interactions with exercise. Animal studies have shown the inhibition 
of the COX pathway via NSAID use diminished the beneficial response of bone formation to 
mechanical loading (Cheng et al., 1997; Chow, Fox, Lean, & Chambers, 1998; Li, Burr, & 
Turner, 2002). Indomethacin (i.e. NSAID) supplementation during or post-loading of ulna 
explants in 5 week old rats abrogated indicators of osteoblast recruitment and matrix production 
by osteoblasts (i.e. [3H]thymidine and [3H]proline incorporation, respectively) found during 
loading alone (Cheng et al., 1997). It is not clear if the results reported are representing 
supplementation during or post-loading, or a combination of both. Indomethacin 
supplementation before loading of the 8th caudal vertebrae in 13 week old female rats suppresses 
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the early response gene (i.e. c-fos) that detects induction of RNA synthesis in osteocytes found 
during loading alone (Chow et al., 1998). It was concluded the partial suppression of c-fos was 
due to inhibition of PG production via indomethacin (Chow et al., 1998). Indomethacin and  NS-
398 (a selective inhibitor of COX-2) supplementation 3 hours before tibia bending and axial ulna 
loading in adult female rats significantly decreased loading-induced bone formation and 
mineralizing surface of both the endocortical surface of the tibia and the periosteal surface of the 
ulna (Li et al., 2002). Further, the suppression of the endocortical tibia surface was less when 
supplementation of NS-398 was done 30 minutes before loading, as compared to 3 hours before, 
and the suppressed effect was diminished when supplementation was done 30 minutes after 
loading (Li et al., 2002). Recent work demonstrated ibuprofen supplementation during prolonged 
high-repetition high-force upper extremity work in 12 week old female rats preserved trabecular 
bone microarchitecture and density of the distal radial and ulnar epiphyses and metaphyses (Jain 
et al., 2014). The ibuprofen was administered via drinking water provided ad libitum, thus it can 
be assumed that supplementation occurred before, during, and after loading. Regardless, it was 
theorized that the preservation of trabecular bone volume and density could be due to prevention 
of bone resorption, as suggested by reduced osteoclast activity and bone inflammatory cytokines 
(Jain et al., 2014).  
 Collectively, animal studies suggest the detrimental effect (related to PGE2) may be 
reduced or diminished based on time of administration of ibuprofen (Kohrt et al., 2010; 2013). It 
is suggested that prostaglandin release at the time of or shortly after loading (i.e. during exercise) 
is the signal for mechanically induced bone formation.  COX-2 expression does not occur until 
30-90 minutes after the load is applied.  Thus prostaglandin synthesis by mechanically induced 
COX-2 expression after exercise may not be important for triggering new bone formation (Li et 
al., 2002). When ibuprofen is administered in humans following exercise training, the 
mechanism by which PGE2 acts is altered. After an exercise session, ibuprofen suppresses 
protein catabolism to a greater degree than protein anabolism, resulting in muscle accretion and 
protein retention (Trappe et al., 2011). This effect occurs via inhibition of COX-2 and PGE2 after 
the mechanically induced bone formation has already occurred (Candow et al., 2013; Kohrt et 
al., 2010; Trappe et al., 2011). Thus, administration of ibuprofen after resistance training will 
allow for the beneficial effects of mechanical loading occurring during training and the 
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detrimental effects of altered inflammation after resistance training in older individuals to be 
blunted.  
 Maximum daily dosages of ibuprofen (1,200mg/day) have been shown to increase 
quadriceps muscle volume and strength in older adults (men and women, 64 years) during 12 
weeks of structured exercise (Trappe et al., 2011). Lower dosages (400mg; maximum 
recommended single dosage) immediately following exercise training exercise did not improve 
muscle mass or volume when compared to placebo in premenopausal women or older adults 
training for 9 months (Kohrt, et al., 2010; Jankowski et al., 2015), young adults training for 6 
weeks (Krentz, Quest, Farthing, Quest, & Chilibeck, 2008), or postmenopausal women training 
for 9 weeks (Candow et al., 2013). Previous studies have therefore shown that 400mg of 
ibuprofen is not effective for increasing lean tissue mass or muscle strength in younger 
individuals or for older adults over relatively shorter (9 weeks) or longer (9 months) training 
periods. However, Kohrt et al. (2010) showed in a per-protocol analysis that 400mg of ibuprofen 
immediately following exercise training significantly increased bone mineral density of the total 
hip, femoral neck, troachanter, and femoral shaft, as compared to ibuprofen before exercise or 
placebo in young women. These results were not supported in a follow-up to the proof-of-
concept study in older adults by Kohrt et al. (2010). Rather, the most recent data by this group 
suggests that ibuprofen before or after exercise, as compared to placebo, may result in a more 
deletrious effect on hip sites (total hip, trochanter, subtrochanter) in both men and women; 
however, these results were not statistically significant and the study was underpowered to 
determine sex differences (Jankowski et al., 2015). The study by Jankowski et al. (2015) was 
limited by a drug dispensing error and lack of exercise control group; thus, while this recent 
work provides important insights, further research is warranted. There is currently no known 
literature that examines the independent and combined effects of longer term (i.e. 9 months) 
exercise training with ibuprofen supplementation in older women. NSAID use is widespread, and 
the benefits of exercise for the prevention and treatment of sarcopenia and osteoporosis is well-
known, making further research in this area of high clinical significance (Kohrt et al., 2013). 
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3.0. Objectives & Hypotheses 
3.1. Bovine Colostrum Study 
 3.1.1. Purpose & Hypothesis. The purpose of this study was to determine the effect of 
bovine colostrum supplementation during an 8 week resistance training program on 
inflammatory status, serum IGF-1 levels, lean tissue mass, strength, and bone turnover in men 
and women 50y and older. It was hypothesized that bovine colostrum supplementation during 
resistance training will prevent inflammation, increase IGF-1 levels, lean tissue mass, and 
strength,  and reduce bone turnover. From this study one manuscript was produced and published 
in the International Journal of Sport Nutrition and Exercise Metabolism. Please refer to section 
4.0. for the accepted author manuscript version of this manuscript. 
3.2. Ibuprofen Study 
 3.2.1. Research Question 1 - Purpose & Hypothesis. The purpose of this sub-study was 
to determine the effects of low-dose (i.e. 400mg) ibuprofen supplementation after exercise 
training over a 9 month period on DXA–derived aBMD at the lumbar spine, femoral neck, and 
total body, geometry of proximal femur, and total body lean tissue and fat mass, as well as 
predicted 1-repetition maximum muscle strength testing (1-RM; biceps curl, hack squat) in 
women 60y and older. It was hypothesized that ibuprofen supplementation following exercise 
training over a 9 month period will result in improvements in aBMD of the lumbar spine, hip, 
and total body, strength of the proximal femur, body composition, and muscular strength. 
Further, these effects will be greater when ibuprofen is consumed following resistance training 
exercise, as compared to sham exercise (i.e. flexibility training). 
3.2.2. Research Question 2 - Purpose & Hypothesis. The purpose of this sub-study was 
to determine the effects of low-dose (i.e. 400mg) ibuprofen supplementation after exercise 
training over a 9 month period on pQCT-derived bone properties and estimated strength of the 
distal radius and tibia, and muscle and bone properties and estimated strength at the forearm and 
lower leg in women 60y and older. It is hypothesized that ibuprofen supplementation following 
exercise training over a 9 month period will improve muscle and bone size, density, and 
estimated strength. Further, these effects will be greater when ibuprofen is consumed following 
resistance training exercise, as compared to sham exercise (i.e. flexibility training). 
From these sub-studies two manuscripts were prepared for submission to Osteoporosis 
International and the Journal of Bone and Mineral Research (JBMR), respectively. Please refer 
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to section 5 for the version of the manuscript for research question 1 approved by co-authors for 
submission to Osteoporosis International. Please refer to section 6.0. for the version of the 
manuscript for research question 2 approved by supervisors for submission to JBMR.  
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4.0. The Effect of Bovine Colostrum Supplementation in 
Older Adults during Resistance Training 
4.1. Introduction 
Skeletal muscle is lost after approximately the age of 50y, potentially leading to 
sarcopenia and loss of muscle strength and function (IWGS, 2011; Roubenoff, 2003).  Muscle 
loss may be related to a decrease in anabolic hormones and/or increased catabolism driven by 
inflammation (Roubenoff, 2003; Visser et al., 2002). Older muscle is more sensitive to damage 
via less effective anti-oxidant systems leading to an altered response of satellite cells in 
regeneration of damaged muscle (Degens, 2010; Thalacker-Mercer et al., 2010).  This response 
is linked to differential expression of skeletal muscle specific genes, with up-regulation of 
transcripts related to stress, inflammation, and protein degradation, and down-regulation of some 
transcripts related to protein synthesis in old versus young muscle (Degens, 2010; Thalacker-
Mercer et al., 2010). Chronic low-grade systematic inflammation is the main factor contributing 
to the attenuated hypertrophic response of older muscle to strength training (Degens, 2010) and 
plays an important role in the development of disability (Visser et al., 2002). Increased 
inflammation associated with aging diminishes the efficacy of insulin-like growth factor-1 (IGF-
1), an anabolic hormone responsible for muscle hypertrophy and regeneration (Degens, 2010) 
and therefore inflammation is associated with lower muscle mass and strength in older adults 
(Visser et al., 2002). Insulin-like growth factor-1 is also important for development of bone 
tissue and reduction in IGF-1 in older adults is associated with lower bone mass (Ohlsson et al., 
2011). 
Bovine colostrum is, by definition, the first milk secreted by cows immediately following 
parturition (Larson et al., 1980). Bovine colostrum contains essential amino acids and peptide 
components including whey and casein, and many bioactive components such as lactoferrin, 
immunoglobulins, and various growth factors (Klagsbrun & Neumann, 1979; Korhonen, 1977; 
Larson et al., 1980). Insulin-like growth factor-1 (IGF-1) is the most abundant and well-
characterized growth factor in bovine colostrum and is homologous to human IGF-1 (Francis et 
al., 1988; Marcotty et al., 1991). Bioactive components of colostrum are known to stimulate 
DNA synthesis, protein synthesis, and cellular growth in neonatal and newborn animals (Burrin 
et al., 1997; Francis et al., 1988) but it is unclear whether this anabolic effect applies to adult 
humans.  
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Bovine colostrum increases anti-inflammatory cytokines (Shing et al., 2007). Athletes 
have used bovine colostrum as a nutritional supplement during training to reduce upper 
respiratory tract infection, although no effects on either saliva or plasma immunoglobulin levels 
were found (Brinkworth & Buckley, 2003; Crooks et al., 2010); however, respiratory tract 
symptoms, often experienced during periods of heavy training, may actually result from 
inflammation rather than suppressed immune function (Bachert et al., 2001). Exercise training 
with bovine colostrum supplementation is also beneficial for improving exercise performance 
(Buckley et al., 2003; Hofman et al., 2002) and increasing lean tissue mass (Antonio et al., 2001), 
but the effects on strength remain unclear (Shing et al., 2009). It is possible beneficial effects of 
bovine colostrum during exercise training may be from decreased inflammation.   
The purpose of this study was to determine the effect of bovine colostrum 
supplementation during a resistance training program on inflammatory status, serum IGF-1 
levels, lean tissue mass, strength, and bone turnover in men and women 50y and older. It was 
hypothesized that bovine colostrum supplementation during resistance training would prevent 
inflammation, increase IGF-1 levels, lean tissue mass, and strength,  and reduce bone turnover.  
4.2. Methods 
 4.2.1. Participants. Forty participants (15 males 59.1 ± 5.4 y; 25 females, 59.0 ± 6.7 y) 
were recruited via an advertisement in a local newspaper. The sample size was based on studies 
of young individuals where change in lean tissue mass with bovine colostrum supplementation 
was 1.5-2 kg compared to 0-1.2 kg with whey protein with a standard deviation for this change 
of 0.5 to 1.0 kg (Antonio et al., 2001; Kerksick et al., 2007), an alpha of 0.05 and power of 0.8. 
This sample size calculation indicated 10 participants per group (i.e. 20 in total) were required. 
The sample size was doubled because older individuals have greater variability in their 
physiological measurements (i.e. muscle mass and strength) compared to younger individuals 
(Candow & Chilibeck, 2005). The study was approved by The University of Saskatchewan’s 
Research Ethics Board and participants gave informed consent for the study. Participants 
completed the Physical Activity Readiness Questionnaire (Thomas, Reading, & Shephard, 1992) 
prior to baseline testing to ensure there were no contra-indications to exercise participation.  
 4.2.2. Intervention. After completion of baseline testing (described below) participants 
were randomly assigned, by use of a computerized random number generator, to either bovine 
colostrum (N = 12 females, 7 males) treatment or the control group (whey protein; N = 13 
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females, 8 males). The study was double blinded: researchers, participants, and all individuals 
conducting outcome assessments were unaware of group assignments. Both groups were 
provided a 4 kg container and consumed 3 doses of 20g per day (60g/day total) colostrum or 
whey protein complex (containing about 38g of protein per 60g of complex) measured with a 
scoop provided. This dose was chosen because it is effective in young individuals for increasing 
lean tissue mass (Antonio et al., 2001; Kerksick et al., 2007). The bovine colostrum used in this 
study was a heat-treated spray-dried >25% IgG commercially available product (trade-named 
Eterna GoldTM manufactured and marketed by the Saskatoon Colostrum Co. Ltd., Saskatoon, 
Canada).  The product is derived from first day post-partum excess colostrum collected from 
Canadian dairy cows and is licensed by Health Canada as a natural health product for immune 
system and athletic support (Natural Health Product Number 80035324; full details on the 
product can be viewed at: http://www.saskatooncolostrum.com/english/Article/Details/4779_ 
Eterna-Gold-Colostrum-For-People.html). Whey protein was used as the placebo because it 
matches bovine colostrum for protein content but does not have substantial effects on muscle 
size and strength or bone resorption in older adults (Candow et al., 2006). The whey placebo was 
purchased commercially from Cereal By Products Co., Mt. Prospect, Illinois and was selected to 
match to the colostrum in overall nutritional composition (Table 4.0). The composition of the 
bovine colostrum and whey protein supplements was verified by an independent laboratory 
(SunWest Food Laboratory Ltd., Saskatoon SK, Canada). On exercise days participants were 
instructed to take one dose within 30 minutes before and another dose within 30 minutes after 
their exercise session with a third dose at their discretion; on non-exercise days all doses were 
taken at the participant’s discretion. Participants mixed supplement with liquid of choice (e.g. 
water, juice, or milk) in a provided blender.  
All participants were assigned a full body resistance program of 12 machine-based 
exercises. Participants were required to attend an orientation session to be familiarized with the 
machines and exercises prior to starting their program. Following orientation, participants were 
instructed to complete three sets of 8-12 repetitions (working to fatigue) for each exercise, under 
supervision on three separate days, again for familiarization with the exercises and to reduce any 
“learning” effects prior to strength testing. Participants were then tested for 1-RM strength. The 
exercise intervention was conducted three non-consecutive days per week and included three sets 
of 8-12 repetitions on Lever machines (Pulse Fitness Systems; Winnipeg, Manitoba, Canada) 
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(with exception of abdominal crunches) for the following exercises: bench press, iso-lateral lat 
pulldown, shoulder press, biceps curl, triceps extension, leg press, leg flexion and extension, 
back extension, and hip adduction and abduction. All sets were performed to fatigue and 
resistance was progressively increased once a participant could complete 12 repetitions with 
good form. All exercise sessions were supervised by Canadian Society for Exercise Physiology-
Certified Exercise Physiologists to ensure proper form and resistance; this ensured compliance to 
each prescribed exercise and the appropriate sets and repetitions. In addition to tracking 
workouts and recording supplement compliance in logs, participants were required to sign an 
attendance sheet at each visit. Adverse events during the study were recorded on adverse event 
forms. Following the intervention participants were asked which supplement they thought they 
were receiving (to test if blinding was effective) and asked to return remaining supplement to be 
weighed as confirmation of supplement compliance.  
 4.2.3. Outcome measures. All variables were assessed at baseline and after the eight-
week intervention. Variables assessed included muscle thickness of the elbow flexors and knee 
extensors by ultrasound, IGF-1, and C-reactive protein (CRP; as a marker of inflammation) from 
blood samples, urinary cross-linked N-telopeptides of Type 1 collagen (i.e. Ntx; bone 
resorption), body composition by dual energy X-ray absorptiometry (DXA), and strength by 
determination of 1-repitition maximum (1-RM) on bench press and leg press. Strength testing 
was always done last so as not to influence muscle thickness or body composition testing 
because of muscle swelling. Measurement techniques are described in detail below. 
 4.2.3.1. Body composition. Body composition was assessed with DXA in array mode 
(QDR Discovery Wi, Hologic, Inc., Bedford, Md.) using QDR software for Windows XP (QDR 
Discovery). Lean tissue mass, fat mass, and bone mineral content were assessed from whole-
body scans. The coefficients of variation for these measurements are 0.5%, 3%, and 0.5% 
respectively (Chilibeck et al., 2013).  
 4.2.3.2. Strength. Strength (1-RM) was assessed during the bench press and leg press 
exercises, which were chosen as representative exercises for upper- and lower-body strength. We 
have previously described these assessments elsewhere (Chrusch et al., 2001). The coefficients 
of variation for these measurements are 3.0% and 3.6% for leg press and bench press, 
respectively (Chrusch et al., 2001). 
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 4.2.3.3. Muscle thickness. Ultrasound was used to assess muscle thickness of the elbow 
flexors and knee extensors of the dominant limb prior to 1-RM testing. We have described these 
methods in detail elsewhere (Farthing & Chilibeck, 2003; Candow & Chilibeck, 2005). The 
coefficients of variation (CVs) for muscle thickness measurements are 2.5% for elbow flexors 
and 2.1% for knee extensors (Candow & Chilibeck, 2005). 
 4.2.3.4. Serum assessment. Blood samples were drawn from an anticubital vein, 
centrifuged and plasma harvested and separated into aliquots, which were frozen at -80 degrees 
C. Samples were thawed and analyzed for: i) IGF-1 using ELISA (Enzo Life Sciences) (intra-
assay CV = 3.6%) and ii) CRP as a marker of inflammation using ELISA (ALPCO Diagnostics) 
(intra-assay CV = 3.8%). Samples from all time points for each individual were analyzed in the 
same assay to eliminate between-assay variability. 
 4.2.3.5. Bone resorption. Participants were instructed to collect 24-hour urine samples as 
previously described (Pinkoski et al., 2006). Baseline urine collection was completed prior to 
starting the study and post-intervention urine collection was completed in the 3 days after the 
exercise intervention. Participants continued consuming the supplement during these 3 days. 
Alcohol and intense exercise was prohibited during the 24 hours of collection and the 24 hours 
prior. Returned urine containers were measured for urine volume, and aliquots were removed 
and frozen at -80 degrees C prior to being thawed and analyzed in duplicate within the same 
assay by ELISA (Osteomark NTx test, Ostex International, Inc., Seattle, WA) (intra-assay CV = 
6.7%) for bone resorption via Ntx. The concentration of Ntx in urine samples [expressed as bone 
collagen equivalents (BCE)] was corrected for urinary creatinine and multiplied by 24-h urine 
volume to produce a value for daily Ntx excretion relative to daily creatinine excretion. 
Creatinine was assessed by a commercially available colorimetric kit (Cayman Chemical Co., 
Ann Arbor, MI) (intra-assay CV = 6.0%). The concentration was multiplied by 24-hr urine 
volume to determine the amount excreted over 24 hr.  
 4.2.3.6. Diet and physical activity monitoring. Participants completed the Godin Leisure-
Time Exercise Questionnaire (Godin & Shephard, 1985) during baseline testing and at the end of 
the intervention, and were asked to include only physical activities outside of the intervention. 
Participants were told at the start of the study not to change their diets substantially during the 
study. Participants were given two 3-day food logs; one to be completed prior to starting the 
supplement and one during the last week of the intervention to ensure diets remained consistent 
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throughout the intervention. Food logs were entered and analyzed via United States Department 
of Agriculture Center for Nutrition Policy and Promotion (USDA, Alexandria, VA) online food 
tracker SuperTracker.  
 4.2.4. Data analysis. An independent t-test was used to assess baseline characteristics 
and to compare compliance between groups. Repeated-measures ANOVA with within-factor 
defined as time and between-factors defined as gender and group was used to assess all 
dependent variables. The following assumptions were tested and met: i) independence of 
observations, ii) normality, and iii) sphericity. All analyses were done using IBM SPSS 
(Statistics version 20, Chicago). To ensure statistical results for the leg press strength 
measurement were not due to differences between baseline means, we also ran an analysis of 
covariance for this variable, testing for differences between groups at 8 weeks, using baseline 
strength as a covariate. Analysis was done on an intent-to-treat basis. Results are expressed as 
means and standard deviations. Significance was accepted when p≤0.05. 
4.3. Results 
Baseline characteristics were not significantly different between groups. Participants in 
the colostrum group were on average 78.6±17.6 kg, 171±7 cm, and 61.8 ±4.8 y as compared to 
participants in the whey group who were on average 74.0±19.2 kg, 169±9 cm, and 57.5 ± 6.3 y. 
 4.3.1. Compliance and blinding. One female participant from the whey group withdrew 
due to personal reasons and was lost to follow-up. Two participants from the whey group 
discontinued use of supplement due to gastrointestinal reflux the investigators classified as 
“definitely” related to the supplement, but continued with the exercise training. Exercise and 
supplement compliance was not significantly different between groups. Participants in the 
colostrum group were 86 ± 20% compliant to the exercise and 97 ± 12% compliant to the 
supplement compared to participants in the whey group who were 84 ± 21% compliant to the 
exercise and 88 ± 23% compliant to the supplement. Thirty-seven percent of the participants in 
the colostrum group and 25% of participants in the whey protein group correctly guessed their 
group assignment. 
 4.3.2. Gender differences. As expected, there were several gender-based effects. Males 
had greater leg press and bench press strength, IGF-1 levels, bone mineral content, lean tissue 
mass, elbow flexors and knee extensors muscle thickness, and kcal, protein, and carbohydrate 
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intake compared to females (p<0.05). Males had lower percent body fat compared to females 
(p<0.01). 
 4.3.3. Body composition. Over time, there was a significant increase in lean tissue mass 
(p<0.001) and bone mineral content (p=0.012) and a significant decrease in percent fat (p<0.01) 
with no differences between groups (Table 4.1). There were no significant changes in fat mass 
(Table 4.1).  
 4.3.4. Strength. There was a significant group by time interaction for leg press strength, 
with strength increasing more in the colostrum group than the whey protein group (p = 0.026; 
Figure 4.0). Baseline and post-intervention strength measures for the colostrum group were 121 
± 40 and 145 ± 53 kg, and for the whey protein group were 143 ± 51 kg and 151 ± 58 kg. An 
analysis of covariance with baseline leg press strength as the covariate indicated that adjusted 
means at the end of the intervention were significantly greater in the colostrum compared to the 
whey protein group (165 ± 5 kg vs. 149 ± 5 kg; p=0.045). There were no differences for changes 
in bench press strength between groups (Figure 4.1). There was a significant time main effect for 
bench press strength (p < 0.001) with the colostrum group increasing from 57 ± 31 to 69 ± 35 kg 
and the whey protein group increasing from 63 ± 37 to  79 ± 46 kg. There was a gender by time 
interaction for leg press and bench press strength, (p < 0.05), with males increasing more than 
females (data not shown). 
 4.3.5. Muscle size. Muscle thickness of the knee extensors and elbow flexors increased 
over time (p<0.001) with no difference between groups (Table 4.1).  
 4.3.6. Serum & urine measurements. There was a group by time interaction for urinary 
Ntx, with the colostrum group decreasing more than the whey protein group (p = 0.024; Table 
4.1).  There were no differences between groups over time, nor were there any time main effects 
for levels of CRP and IGF-1 (Table 4.1). 
 4.3.7. Questionnaires. There were no significant differences over time or between 
groups for leisure time physical activity (Table 4.1). 
 4.3.8. Nutrition. Both groups decreased dietary protein intake (excluding the nutritional 
supplement) over time (p = 0.047) (Table 4.2). There were no differences between groups over 
time for any nutritional variables (Table 4.2). 
 4.3.9. Adverse events. Five participants reported adverse events related to 
gastrointestinal problems.  Two participants consuming colostrum reported adverse events 
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classified as ‘mild’ in severity included bloating, nausea, diarrhea, and unsettled stomach. The 
researchers classified the adverse events as either ‘probable’ or ‘possible’. The two participants 
continued taking the colostrum supplement for the remainder of the study; however one reduced 
the dosage. The other three adverse events were also related to gastrointestinal problems in 
participants consuming whey. Two of these three adverse events were classified as ‘moderate’ in 
severity (gastro esophageal reflux). These adverse events were considered “definitely” related to 
the supplement based on cessation of symptoms upon stopping the supplement and reappearance 
of the adverse event upon re-introduction. Both participants discontinued the supplement. The 
other participant’s adverse event was ‘mild’ in severity (nausea), and considered ‘possibly’ 
related to the supplement. This participant continued taking the supplement.  
4.4. Discussion 
The present study is the first to examine the effects of bovine colostrum supplementation 
during a resistance training program in older adults. Colostrum supplementation promoted 
greater increases in leg press strength than did whey protein. Colostrum supplementation also 
reduced bone resorption compared to whey protein. Both colostrum and whey protein 
supplemented groups significantly increased bench press strength, muscle size, lean tissue mass, 
and bone mineral content over time. Males had greater baseline values for most outcome 
measures, which was to be expected and is supported by previous studies (Chilibeck, Stride, 
Farthing, & Burke, 2004). Despite this, male and female participants responded equally to the 
supplementation (i.e. there were no supplement group x gender x time interactions). 
The increase in leg press strength associated with colostrum supplementation is important 
because older adults lose strength in the lower body to a greater extent than in the upper body 
(Candow & Chilibeck, 2005; IWGS, 2011). The group supplemented with colostrum increased 
leg press strength by about 21% whereas the group supplemented with whey protein had a non-
significant increase in leg press strength of about 5%. The increase in the colostrum group might 
be clinically significant because a 20% decline in leg press strength with aging is associated with 
increased functional limitations (Brill et al., 2000).  The mechanism for the greater increase in 
leg press strength in the colostrum group is unclear because the groups did not differ in changes 
in lean tissue mass or knee extensor muscle thickness. A possible explanation as to the lack of 
increase in leg press strength in the whey group is they had slightly (but not statistically) higher 
baseline strength and therefore may have been closer to their physiological ceiling and had less 
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room for improvement. The greater increase in leg press strength in the colostrum group could be 
due to statistical error (i.e. type I error with multiple statistical tests). Both groups increased 
equally in bench press strength. Males increased leg press and bench press strength more than 
females; this is supported by previous studies (Chilibeck et al., 2004). Further research is needed 
to determine if there is a true increase in strength due to colostrum supplementation or whether 
other factors such as an increase in muscle quality may be responsible for the apparent increase 
in strength.  
The participants receiving bovine colostrum had a greater decrease in bone resorption 
(assessed by urinary Ntx) compared to participants consuming whey protein. This suggests 
bovine colostrum might have benefits for bone health. Previously Brinkworth et al. (2004) 
showed a trend (p=0.06) toward a greater increase in bone cross-sectional area in the trained 
upper arm of participants supplemented with colostrum compared to whey protein for eight 
weeks. A number of studies using animal models have also suggested a positive effect of bovine 
colostrum on bone. Supplementation with proteins extracted from bovine colostrum (i.e. 
osteopontin, lactoferrin, epidural growth factor, and IGF-2) increased mineral density, micro-
architectural properties, and mechanical strength of bones from ovariectomized rats (a model for 
postmenopausal osteoporosis), and reduced markers of bone resorption and increased markers of 
bone formation in serum (Du et al., 2011; Hou et al., 2012). Bovine colostrum or proteins 
derived from colostrum (i.e. lactoferrin) increase the proliferation of osteoblasts (i.e. cells 
involved in bone formation) and the release of growth factors from osteoblasts derived from rats 
(Lee et al., 2008; Nakajima et al., 2011), and bovine colostrum reduces activity of osteoclasts 
(i.e. cells involved in bone resorption) derived from rabbits (Vidal et al., 2004).  
Bovine colostrum contains substantial amounts of IGF-1 (Marcotty et al., 1991). IGF-1 is 
the major mediator of growth hormone (GH) and is linked to muscle hypertrophy (Allen & 
Boxhorn, 1989). Participants in this study had no increase in serum IGF-1 levels with colostrum 
supplementation. While Mero et al. (2002) showed that levels of plasma IGF-1 increased after 2 
weeks of bovine colostrum supplementation and training in male and female athletes, most other 
studies have shown levels of plasma IGF-1 did not increase after bovine colostrum 
supplementation and training (Buckley et al., 2003; Buckley et al., 2002;  Shing et al., 2009). It is 
theorized that the increase in IGF-1 in the Mero et al. (2002) study may have been transient due 
to the short supplementation period, whereas studies that have longer supplementation periods 
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may allow enough time for the body to facilitate a negative feedback and return the plasma 
concentrations to normal (Buckley et al., 2003). It should also be noted that Mero et al. (2002) 
used carbohydrate as a control; whereas other studies used protein as a control. This may also 
account for differences in IGF-1 responses between studies. 
We found no significant differences between colostrum and whey protein groups for 
changes in systemic inflammation (i.e. C-reactive protein). Similarly Crooks et al. (2010) found 
no significant differences in C-reactive protein after 10 weeks of daily 50g supplementation of 
either colostrum or skim-milk powder during intense swim training (both in water and on-land).     
The decrease in protein intake over time for both groups is likely due to participants 
compensating for the additional protein provided by the supplement by reducing protein 
consumption elsewhere in their diet. As the food logs analyzed did not include the supplement, 
the post values for protein consumption do not include the 38 grams of protein provided by the 
colostrum or the whey.  
4.5. Conclusion 
Bovine colostrum may have benefits over whey protein for increasing lower body 
strength and reducing bone resorption in older adults but had no effect beyond those seen with 
whey supplementation and resistance training on measurements of upper body strength, IGF-1, 
inflammation, or body composition. Our finding that short-term colostrum supplementation 
decreased bone resorption compared to whey protein suggests that the long-term effects of 
bovine colostrum on clinically relevant measures of bone health (i.e. hip or lumbar spine bone 
mineral density) should be investigated. 
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Table 4.0. Colostrum versus whey nutritional breakdown. 
         Colostrum  Whey 
Crude Protein (%) 
 
62.4 
 
64.6 
      Crude Fat (%) 
 
13.9 
 
14.7 
      Carbohydrates (g/100g) 13.5 
 
12.5 
      Calories/100g 
 
429 
 
441 
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Table 4.1. Body composition, muscle thickness, serum, urine, and leisure time activity results. 
                                                      Colostrum                                              Whey 
 Baseline Post Baseline Post 
BMC (kg)* 2.44 ± 0.39 2.47 ± 0.40 2.41 ± 0.59 2.42 ± 0.61 
Fat mass (kg) 27.5 ± 13.0 27.4 ± 13.1 25.0 ± 9.3 24.8 ± 9.0 
Lean tissue mass (kg)* 47.8 ± 9.4 48.5 ± 9.0 46.3 ± 12.7 46.8 ± 12.8 
Total mass (kg) 77.7 ± 18.0 78.4 ± 17.5 73.7 ± 19.3 74.1 ± 19.1 
Fat (%)* 34.1 ± 10.5 33.7 ± 10.6 33.7 ± 7.9 33.3 ± 7.8 
Biceps (cm)* 2.64 ± 0.75 2.91 ± 0.76 2.54 ± 0.59 2.81 ± 0.65 
Quadriceps (cm)* 2.73 ± 0.53 2.95 ± 0.65 2.57 ± 0.47 2.78 ± 0.53 
CRP (mg/l) 2.3 ± 2.6 2.4 ± 3.2 2.1 ± 2.9 2.5 ± 3.5 
IGF-1 (ng/ml) 155.3 ± 35.4 156.1 ± 36.1 162.3 ± 44.1 159.0 ± 42.0 
Ntx (nmol BCE/mmol 
Crn) 1085 ± 585 770 ± 359** 1074 ± 614 1172 ± 762 
LTEQ 29 ± 30 29 ± 25 33 ± 22 29 ± 21 
____________________________________________________________________________ 
Data are means ± standard deviation; BMC = bone mineral content; CRP = C-reactive protein; 
IGF-1 = Insulin-like growth factor-1, Ntx = cross-linked n-telopeptides of type I collagen; BCE 
= bone collagen equivalents; Crn= creatinine. 
*Time main effect (p<0.05). 
**The change in the colostrum group was greater than the whey protein group (p<0.05). 
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Table 4.2. Nutrition. 
                                                   Colostrum                                              Whey 
 Baseline Post Baseline Post 
Calories (g/day) 2001 ± 472 1886 ± 292 1726 ± 506 1673 ± 522 
Fat (g/day) 68 ± 20 67 ± 18 62 ± 24 58 ± 32 
Carbohydrates 
(g/day) 256 ± 68 234 ± 44 215 ± 53 212 ± 59 
Protein (g/day) 
without supplement*  85 ± 20 81 ± 23 73 ± 22 63 ± 21 
Protein (g/day) with 
supplement  119 ± 23  98 ± 31 
Protein (g/kg) 
without supplement 1.16 ± 0.44 1.08 ± 0.38 0.91 ± 0.39 0.79 ± 0.36 
Protein (g/kg) with 
supplement  1.59 ± 0.47  1.34 ± 0.36 
 
Data are means ±standard deviations. 
*Time main effect (p<0.05). 
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Figure 4.0. 1-Repetition maximum for leg press. 
*Significant difference versus whey protein (p<0.05); Data are change in leg press strength ± 
standard deviations. 
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Figure 4.1. 1-Repetition maximum for bench press. 
*Time main effect (p<0.01); Data are change in bench press strength ± standard deviations. 
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5.0. Effects of Low-dose Ibuprofen Supplementation and Resistance Training on Bone and 
Muscle in Postmenopausal Women: A Randomized Controlled Trial 
5.1. Introduction 
Inflammation is considered a main pathophysiological contributor to sarcopenia (i.e., loss 
of muscle mass and muscle function) (IWGS, 2011) and osteoporosis (i.e., loss of bone mass and 
bone strength) (ACSM, 2009). Sarcopenia and osteoporosis are associated with frailty and 
functional impairment, resulting in the decreased capacity to perform daily living activities, 
ultimately impacting on quality of life and increasing mortality (De Martinis et al., 2006; IWGS, 
2011). Resistance training is an effective intervention for increasing muscle and bone mass; 
however, aging individuals experience an attenuated response to resistance training which 
contributes to aging anabolic resistance and sarcopenia (Breen & Philips, 2011). Furthermore, 
the increase in areal bone mineral density (aBMD) at clinically relevant sites such as the lumbar 
spine and femoral neck with resistance training are modest (~1-2%) but nonetheless beneficial 
(Gomez-Cabello et al., 2012; Kohrt et al., 2013). Therefore, a longer-term (i.e. > 6 months) 
resistance training program combined with additional interventions may be required to produce 
significant muscle and/or bone benefits in aging adults. 
 Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) known for its anti-
inflammatory properties via reductions of prostanoids derived from reactions catalyzed by the 
cyclooxygenase (COX-1 and COX-2) enzymes (Rainsford, 2009). Ibuprofen supplementation 
attenuates the loss of muscle mass in animal models of aging (McCarthy et al., 2004; Rieu et al., 
2009). Epidemiological studies in humans demonstrate associations between regular NSAID use 
and moderate (~2 - 6%) increases in aBMD at clinically relevant sites (Bauer et al., 1996; 
Carbone et al., 2003; Morton et al., 1998; Richards et al., 2006). A systematic review suggests 
that the beneficial effects of NSAIDs on bone health may be due to the attenuation of 
inflammatory cytokines inhibiting bone resorption (Konstantinidis et al., 2012). Collectively, 
ibuprofen may reduce inflammation associated muscle and bone loss in aging humans.  
 Evidence of the combined effects of exercise and ibuprofen supplementation is limited. 
When ibuprofen is administered following exercise training, the inhibition of prostaglandins 
(PGE2) may have beneficial effects on muscle and bone health via prevention of protein 
catabolism, resulting in muscle accretion and protein retention in older adults (Trappe et al., 
2011); and inhibition of the altered inflammatory response of COX-2 and prostaglandin E2 
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(PGE2) after the mechanically induced bone formation has already occurred (Kohrt et al., 2010; 
2013). A high dose of ibuprofen (1,200 mg daily) is effective for increasing muscle size and 
strength in older adults over a short resistance training period (12 weeks) (Trappe et al., 2011). A 
lower dose of ibuprofen (400 mg) administered only after resistance training (3-5 days/week) 
over a shorter training period was not effective in increasing lean tissue mass or muscle strength 
in younger individuals or older women (Candow et al., 2013; Krentz et al., 2008); however, it 
was effective for increasing the aBMD of clinically relevant sites in premenopausal women 
during a longer training period (9 months) (Kohrt et al., 2010). While ibuprofen given after 
resistance training appears beneficial for bone in premenopausal women, this was not evident in 
a recent study of postmenopausal women over a similar training period (Jankowski et al., 2015). 
Research over longer training periods in older women remains scarce, with the only notable 
study lacking an exercise control group, thus not allowing for the determination of the interaction 
between resistance training and ibuprofen (Jankowski et al., 2015). 
 Additional anti-inflammatory interventions combined with resistance training are needed 
to determine if there are clinically relevant improvements in aging muscle and bone. The purpose 
of our study was to investigate the effects of a long term (9 months) intervention of combined 
ibuprofen (400 mg) and exercise training on muscle and bone in postmenopausal women (60y or 
greater). We hypothesized a combined effect of progressive resistance training and ibuprofen 
supplementation leading to improved lean tissue mass and bone properties.  
5.2. Participants and Methods 
 5.2.1. Study Design. A double-blind (for ibuprofen), factorial randomized controlled trial 
design was employed to compare the independent and combined effects of ibuprofen 
supplementation and exercise training. Participants were randomized 1:1:1:1 to one of four 
groups after being cleared for inclusion. Randomization was completed using a computer-
generated allocation schedule with a block size of four by one of the investigators who was not 
involved in the measurement of outcome variables or the analysis. The four unique groups were: 
i) resistance training combined with ibuprofen supplementation (ExIbu); ii) resistance training 
combined with placebo supplementation (Ex); iii) flexibility training (exercise placebo) 
combined with ibuprofen supplementation (Ibu); and iv) flexibility training combined with 
placebo supplementation (Control). Ibuprofen dosage was 400 mg after exercise training only 
(maximum 3 times per week) for 9 months. This dose was chosen because it is safe and effective 
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for increasing aBMD (hip region) when taken after resistance training in premenopausal women 
(Kohrt et al., 2010). Further, this dosage was well-tolerated in a 9 week pilot study of 
postmenopausal women completed by our research group (Candow et al., 2013). Ibuprofen and 
placebo (methylcellulose) were administered in a double-blind fashion in the form of capsules 
that were identical in taste, color, and appearance. The supplement was pre-packaged into 
containers that were sequentially numbered according to the randomization schedule, of which 
the allocation sequence was concealed from the research assistants enrolling and assessing the 
participants. After completion of the baseline testing, participants were provided containers with 
the supplement (i.e. ibuprofen or placebo), calcium and vitamin D (600 mg/d and 400 IU/d, 
respectively), and an exercise/supplement tracking log. Participants in the stretching group took 
their supplement at home while participants in the resistance training group took their 
supplement as provided directly by a research assistant after each resistance training session as 
post-exercise ibuprofen has a beneficial effect on aBMD (Kohrt et al., 2010). Calcium and 
Vitamin D was taken daily at home by all participants. Although participants could not be 
blinded to the exercise assignment, they were blinded to the hypothesis that the resistance 
training would be superior to flexibility training. All the researchers involved in the outcome 
assessment and analysis were blinded to the group assignment. The personnel supervising the 
training program were blinded to the supplement (i.e. ibuprofen or placebo). Statistical analysis 
was blinded through the coding of the groups. The study was approved by the Biomedical 
Research Ethics Board of the University of Saskatchewan. Reporting of this study adhered to the 
Consolidated Standards of Reporting Trials (CONSORT) guidelines for randomized clinical 
trials. This trial was registered with clinicaltrials.gov (NCT01886196). 
 5.2.2. Participants. Postmenopausal women 60 years or older were recruited via 
advertisements in local newspapers and posters from January 2013 to September 2013. All 164 
potential participants that responded to the advertisements were assessed for study eligibility by 
modification of the Mediterranean Osteoporosis Study Questionnaire (MEDOS) (Dequeker et al., 
1991). Participants were further evaluated for 10-year risk of fracture based on age and femoral 
neck aBMD t-score (i.e. Canadian Association of Radiologists and Osteoporosis Canada 
[CAROC]) and excluded if they were classified as “high” risk for fracture (SACOC, 2010). The 
CAROC method classifies individuals as being at “low”, “moderate”, or “high risk” for fracture, 
where fragility fracture or systemic corticosteroid use (i.e. a prednisone equivalent dosage of 
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≥7.5 mg/day for at least three cumulative months during the preceding year) moves the 
individual up one risk category (SACOC, 2010). Grounds for further exclusion included usage of 
medication or presentation of disease that is known to affect bone mineral metabolism. Thus, 
participants with Crohn’s Disease or Cushing Disease, currently taking systemic corticosteroids, 
or having taken bisphosphonates, hormone replacement therapy, selective estrogen receptor 
modulators, parathyroid hormone, or calcitonin within the past 12 months were excluded. 
Participants were also excluded if they were currently taking medication or had presentation of 
disease that is known to interfere with ibuprofen. Thus, participants with severe osteoarthritis or 
severe heartburn, ulcers, or gastritis requiring acid reducers (e.g. H2 blockers or proton pump 
inhibitors), currently taking NSAID (e.g. prophylactic acetylsalicylic acid) or blood thinners due 
to past episodes of deep vein thrombosis or pulmonary embolism were excluded. Participants 
were instructed not to ingest any type of NSAID for the duration of the study. Finally, 
participants were excluded if they were active smokers or were currently taking part in a 
moderate to vigorous resistance-training program more than once per week.  
 After applying the exclusion criteria, 144 women were eligible and 90 decided to 
participate in the study (see Figure 5.0 for flow diagram of participants). Participants were 
randomized into 4 groups, as described in the study design (Figure 5.0). The sample size was 
based on a previous intervention of young individuals (n = 54) with beneficial aBMD response to 
NSAID supplementation after exercise (Kohrt et al., 2010) and increased because older 
individuals have greater variability in their physiological measurements (Candow & Chilibeck, 
2005).  
 Participants signed informed consents and completed the Physical Activity Readiness 
Questionnaire (PAR-Q) (Thomas et al., 1992) prior to baseline testing to ensure there was no 
contra-indication to exercise participation. Those with a positive response to the PAR-Q and 
those over the age of 69 y were required to have their physician complete the Physical Activity 
Readiness Medical Examination (PARmedX) prior to participation. All participants completed 
the intervention by July 2014. 
 5.2.3. Interventions. Ibuprofen and placebo obtained from the Saskatoon Medical Arts 
Pharmacy (Saskatoon, SK) were administered orally in identical capsules at a dose of 400 mg 
immediately following exercise training (resistance and flexibility training) 3 days per week 
maximum. The contents of the ibuprofen (96% ibuprofen) were verified through independent 
 52 
 
 
 
 
laboratory testing (Eagle Analytical Services, Houston, TX). The placebo capsule contained 
methylcellulose that was indistinguishable in appearance from the ibuprofen. All participants 
received a supplement of 600 mg of calcium and 10 μg (400 I.U.) of vitamin D per day in the 
form of a pill or chew (Jamieson Laboratories, Toronto, ON) to assist in meeting the 
Osteoporosis Society of Canada recommendations of 1200 mg per day for calcium and 20 μg 
(800 I.U.) per day for vitamin D (SACOC, 2010).  
 The exercise intervention consisted of resistance training performed 3 days per week on 
non-consecutive days. Prior to their first exercise session, participants attended an orientation 
session in our research gymnasium to be familiarized with the exercises and machines. 
Orientation and all resistance training exercise sessions were completed under the supervision of 
a Canadian Society for Exercise Physiology-Certified Exercise Physiologist research assistant 
(www.csep.ca). The resistance training exercise intervention required 2 sets of 8-12 repetitions 
of 12 exercises designed to train all major muscle groups. Exercises were performed on Lever 
machines (Pulse Fitness Systems; Winnipeg, Manitoba, Canada) or with free weights. Exercises 
performed on machines included: hack squat, hip flexion, extension, adduction, and abduction, 
and dorsiflexion. Exercises performed with dumbbells included: biceps curl, forearm curl, 
supinated wrist curl, pronated wrist curl, front and side step ups, single leg lunge, and plantar 
flexion. In addition, participants performed a medicine ball toss and catch against a wall. 
Participants were encouraged to work to muscle fatigue and monitored to ensure that resistance 
was increased once two full sets of 12 repetitions could be performed with good form. 
Participants were required to sign in for every exercise session and provided with resistance 
training logs to track sets, loads, and repetitions (i.e. overall volume) and supplement tracking 
logs to track dosages of supplement and calcium and vitamin D consumption.  
 The exercise placebo consisted of a home-based flexibility program performed 3 days per 
week on non-consecutive days. Flexibility participants completed an orientation at our research 
gymnasium and were provided with a print version of the home-based program. The exercise 
placebo intervention required 2 sets held for 20-30 seconds of flexibility (i.e. stretching) 
exercises targeting all major muscle groups. The exercise placebo groups were contacted 
monthly to assess compliance to the program and monitor adverse events. Flexibility participants 
were advised not to perform any resistance training exercise for the duration of the intervention.   
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Compliance to the exercise intervention was assessed by attendance at the supervised 
exercise sessions (Ex and ExIbu) and tracking logs for the home-based flexibility program (Ibu 
and Control). Adverse events for all groups during the intervention were recorded on an adverse 
event form. Compliance to the supplement and calcium and vitamin D for all groups was 
assessed via tracking logs and amount of left-over supplement. In addition, prior to being 
‘unblinded’, to assess the effectiveness of the blinding, participants were questioned regarding 
what supplement they thought they were consuming. The duration of the intervention was 9 
months.  
 5.2.4. Outcomes. All outcome measurements were completed at baseline and 9 months 
(Kohrt et al., 2010). Primary outcomes were the aBMD of the proximal femur and lumbar spine. 
Secondary outcomes were: cross-sectional area (CSA), subperiosteal width (SPW), and section 
modulus (Z) of the narrow part of the femoral neck, the intertrochanter region, and the shaft of 
the proximal part of the femur; total body aBMD, lean tissue and fat mass; biceps curl and hack 
squat muscular strength; and backwards tandem walking balance performance. Tertiary 
outcomes were adverse events. Dual energy x-ray absorptiometry (DXA) scans were performed 
prior to any physical testing to determine study eligibility. Following the DXA scan, participants 
completed balance testing, and then performed a standardized warm-up prior to any strength 
tests. The tests were performed in this particular order to prevent compromisation of balance 
testing due to muscle fatigue resulting from strength testing.  
 5.2.4.1. Dual energy x-ray absorptiometry (DXA). Areal bone mineral density and body 
composition were assessed via DXA in array mode (QDR Discovery Wi; Hologic, Inc., Bedford, 
MD, USA) using QDR software for Windows XP (QDR Discovery). Sites measured included 
lumbar spine (L1 - L4 vertebrae), proximal femur (total hip, femoral neck, trochanter, 
intertrochanter, and Ward’s region), and total body. The coefficients of variation for lumbar 
spine, proximal femur and total body aBMD in our laboratory are 0.7%, 1.0%, and 0.5%, 
respectively (Chilibeck et al., 2012). Hip Structural Analysis (HSA) was used for assessment of 
CSA, SPW, and Z of the narrow neck (NN), intertrochanter (IT) and femoral shaft (FS) regions 
(Beck et al., 1990). All DXA analyses were performed by blinded study radiologist. Bone CSA is 
representative of bone mineral mass within a cross-section in terms of the cortical equivalent 
surface area and indicative of bone compressive strength. SPW is measured as the outer diameter 
of the bone computed as the blur-corrected width of the mass profile. Section Modulus (Z) 
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provides an estimate of bone bending strength (Beck et al., 1990). The coefficients of variation 
for NN, IT, and FS regions, respectively, for our laboratory are as follows: CSA (2.6%, 2.2%, 
and 1.8%); SPW (5.3%, 1.8%, and 1.2%); and Z (3.5%, 3.4%, and 2.1%) (Chilibeck et al., 2013). 
Body composition, including fat free mass (i.e. lean mass), fat mass, and percent body fat, was 
also assessed via DXA scan. The coefficients of variation for lean mass and fat mass are 1.0% 
and 3.0%, respectively (Chilibeck et al., 2013). 
 5.2.4.2. Backward tandem walk. Dynamic balance was assessed, taking into account 
errors made, via a timed backward tandem (i.e. heel to toe) walk over a raised 6 m long board 
(Chilibeck et al., 2013). The time to cover the distance and number of errors (i.e. number of 
times stepping off the board) were averaged over two trials.  
 5.2.4.3. Submaximal prediction of 1-repetition maximum. Upper and lower body 
strength were assessed via the submaximal prediction of 1-repetition maximum (1RM). 
Participants were shown proper form and breathing prior to performing a muscle-specific warm-
up. For upper body warm-up, testers selected a load for biceps curl that the participant could 
easily perform 8 repetitions with proper form. For lower body warm-up, participants performed 8 
repetitions on the hack squat machine with no additional load added (i.e. weight of the machine 
as warm-up weight). Testers then selected an estimated load for the upper and lower body test 
that the participant could perform no more than 10 repetitions with proper form. If 10 repetitions 
were completed in the first attempt, a one-minute rest period was given, then the process was 
repeated with a heavier load for a second and/or third attempt. If 10 repetitions were not 
completed in the first attempt the test was terminated. 1RM was predicted by finding the 
corresponding percentage of load utilized for number of repetitions completed (e.g. 7 repetitions 
corresponds to 83%, thus if load utilized was 50 kg then predicted 1RM is 60 kg) (Baechle et al., 
2000). 
5.2.5. Descriptive Outcomes. 
 5.2.5.1. Questionnaires. Participants completed a food frequency questionnaire (FFQ) 
and leisure time exercise questionnaire (LTEQ) (Godin & Shephard, 1985). The validated FFQ 
was used to assess the changes from baseline to post-intervention for total energy, macro-
nutrients, and dietary calcium and vitamin D intakes based on Canadian dietary reference intakes 
(Block 98#256318-2; Block Dietary Data Systems, Berkeley, CA, USA). The validated FFQ, 
along with directions and images showing sample portion sizes, was sent home with participants 
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to complete and was checked for completeness when returned prior to being sent for computer 
analysis (Nutrition Quest, Berkeley, CA, USA;  www.nutritionquest.com). The changes in LTEQ 
from baseline to post-intervention were also determined. In older adults the LTEQ has good 
reliability (test-retest correlation of 0.62-0.74) and has been shown to have a positive association 
with muscular strength and power (Candow & Chilibeck, 2005; Godin & Shephard, 1985).  
 5.2.5.2. Adverse events. Participants were asked to report any adverse events (AE) that 
occurred throughout the duration of the study. AE forms included a brief description of the 
event, onset and resolution (unless on-going) dates, rating for seriousness and severity, and 
relationship to study procedure.  
 5.2.6. Statistical Analysis. Data were analyzed on an intent-to-treat basis using IBM 
SPSS Statistics for Windows (Version 21.0; Armonk, NY: IBM Corp). Baseline characteristics 
of all variables were compared between groups using a Student’s t-test. Comparisons of 
intervention arms were analyzed via a three-factor analysis of variance, with between-group 
factors for drug (ibuprofen versus placebo) and exercise (resistance training versus flexibility 
training [exercise placebo]) and one within-subjects factor for time (baseline versus nine months 
post-intervention). Tetrad contrast hypothesis tests were used for the post-hoc analyses. All 
descriptive results were expressed as either means and standard deviations or mean absolute 
changes and 95% confidence intervals. We report partial eta-squared (ƞp²) as estimate of effect 
size. P-values < 0.05 were deemed statistically significant. 
5.3. Results 
The final analysis included 69 intent-to-treat participants with the remainder lost to 
follow-up (Figure 5.0). Baseline descriptives by intervention group are presented in Table 5.0. 
Reported compliance corresponds to both exercise and supplement as the supplement was only 
consumed after exercise, and appeared similar between groups (p >0.05): i) ExIbu: 89%, ii) Ex: 
84%, iii) Ibu: 88%, and iv) Control: 87%. At the end of the study, the percent able to correctly 
identify the supplement they were blindly receiving was: i) ExIbu (n = 17): 47%, ii) Ex (n = 19): 
63%, iii) Ibu (n = 15): 47%, and iv) Control (n = 14): 79%. The remainder either never began 
supplementation, guessed incorrectly, or were unable to guess. Compliance to calcium and 
vitamin D supplementation was similar (p >0.05) between groups: i) ExIbu: 83%, ii) Ex: 72%, 
iii) Ibu: 76%, and iv) Control: 84%. The number of participants analysed per outcome varied. 
For hip geometric properties, one (n = 1) scan could not be analysed for IT variables due to 
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improper positioning. One (n = 1) intent-to-treat participant did not return for a DXA scan, but 
completed other post-testing outcomes. For the balance tests, some participants (n = 5) could not 
safely complete the backward tandem walk. For the exercise tests, some participants could not 
complete the biceps curl 1RM (n = 6) or hack squat 1RM (n = 15) due to injury or refusal. 
Incomplete questionnaire data for LTEQ (n = 7) and FFQ (n = 8) were due to refusal to complete 
or return questionnaires.   
 5.3.1. Bone Properties. Group × time interactions were not significant for the aBMD of 
the lumbar spine, femoral neck, or total body (Table 5.1; Figure 5.1), or hip geometric properties 
(Table 5.2). For sub-regions of the hip scans, an exercise × supplement × time interaction was 
significant for aBMD of the Ward’s area (p = 0.015; ƞp2 = 0.088). When comparing change 
scores between groups, only the change score for the stretching with ibuprofen group was 
different from the stretching with placebo group (p = 0.017). The stretching with placebo (i.e. 
control) group decreased Ward’s region aBMD (Figure 5.2). 
 5.3.2. Body Composition. Group × time interactions were not significant for lean tissue 
mass; however, the exercise × time interaction was significant for fat mass (p = 0.033; ƞp2 = 
0.069) and percent body fat (p = 0.019; ƞp2 = 0.083). Resistance training decreased fat mass and 
percent body fat compared to stretching (Table 5.3).  
 5.3.3. Strength and Balance. The exercise × time interaction was significant for biceps 
curl strength and hack squat strength (p <0.001). Resistance training increased biceps curl (ƞp2 = 
0.313) and hack squat (ƞp2 = 0.456) strength compared to stretching (Table 5.3). Group × time 
interactions were not significant for balance (Table 5.3).  
 5.3.4. Diet and Activity. The exercise × time interaction was significant for total energy 
(p = 0.046; ƞp
2 = 0.068) and fat intake (p = 0.039; ƞp2 = 0.073). The stretching group decreased 
total energy intake via reduced fat intake compared to resistance training (Table 5.4). The 
exercise × time × supplement interaction was significant for dietary vitamin D intake (p = 0.024; 
ƞp
2 = 0.081) but changes did not differ between the groups in the post-hoc analysis (Table 5.4). 
Group × time interactions were not significant for remaining macronutrients, dietary calcium 
intake, or amount of leisure time exercise performed from baseline to post-intervention (Table 
5.4). The recommended dietary allowances of 0.8g/kg of protein were met by all groups. 
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 5.3.5. Adverse Events. Of the 90 women randomized, two serious adverse events (SAEs) 
were reported during the intervention; one in a participant assigned to ExIbu and one in a 
participant assigned to Control. Both SAEs were deemed as “not related” to the intervention; 
however, both discontinued the intervention. The SAE in the ExIbu participant was a transient 
ischemic attack (TIA). The SAE in the Control participant was a fractured pelvis due to a fall on 
ice. 
5.4. Discussion 
To our knowledge, this is the first study to examine the combined effects of longer term 
exercise training with ibuprofen supplementation on muscle and bone in postmenopausal women 
using a factorial design. Resistance training promoted greater increases in biceps curl and hack 
squat strength and decreases in body fat than stretching. Contrary to our hypothesis, augmenting 
resistance training with ibuprofen did not have an additive effect on bone properties or muscle 
mass.  Exercise training and/or ibuprofen supplementation had no effect on aBMD of the lumbar 
spine (L1 - L4 vertebrae), femoral neck, or total body. There was a 6% decrease in aBMD of 
Ward’s region in the Control group compared to a 3% increase in the Ibu group, implying that 
ibuprofen helped maintain bone density at this site. Ward’s region is clinically relevant as it is 
identified as the region at the femoral head with the lowest aBMD (i.e. potentially the weakest). 
Collectively, these findings suggest that ibuprofen may have some beneficial bone effects for 
postmenopausal women. 
 Our results add to the limited body of research investigating the effects of ibuprofen 
supplementation and resistance training on aging muscle and bone biology. One notable study 
(Kohrt et al., 2010) demonstrated that 400 mg of ibuprofen given after resistance training 
sessions over nine months improved hip aBMD (total, trochanter, femoral neck and shaft) in 
premenopausal women. However, recent research by this group demonstrated no significant 
effect on the aBMD in postmenopausal women regardless of whether supplementation occurred 
before or after resistance exercise training (Jankowski et al., 2015). The recent data presented by 
this group supports a trend for a deleterious effect of ibuprofen given after exercise (and before) 
in women, specifically at the hip (Jankowski et al., 2015). The authors recommended the 
cautious interpretations of their findings due to the lack of an exercise control group and drug 
dispensing error (Jankowski et al., 2015). Evident was the need for further studies in humans 
with greater sample size and follow-up time. 
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 Our finding of a small beneficial effect of ibuprofen on bone (Ward’s region) is 
supported by epidemiological studies that have found associations between regular NSAID use 
and improved bone density (Bauer et al., 1996; Carbone et al., 2003; Morton et al., 1998; 
Richards et al., 2006). Our study, however, showed no benefit when ibuprofen was consumed 
immediately after exercise sessions. An optimal intervention might be to alter the timing of the 
exercise bout and ibuprofen supplementation, perhaps taking ibuprofen at a time point during the 
day when one is not exercising (e.g. minimum eight hours before or after) or taking ibuprofen on 
non-exercise days. 
 Inhibition of prostaglandin synthesis by ibuprofen or other COX-inhibitors in animal 
studies has produced variable results on mechanically-loaded bone. The effect of ibuprofen may 
depend on the timing of administration with regards to the mechanical stimulus. Animal studies 
suggest that ibuprofen supplementation before or during, but not after, loading impairs the bone 
response and adaptation to mechanical loading (including inflammation mediated bone 
formation) (Chow et al., 1998; Li et al., 2002). Thus, while prostanoids are theorized to be 
required for mechanically induced bone formation to occur, the prostanoid-dependent 
mechanism responsible for bone formation functions during mechanical loading, not after (Chow 
et al., 1998; Li et al., 2002). Collectively, animal studies suggest prostaglandin synthesis 
mechanically induced by COX-2 expression after loading does not contribute to bone formation. 
Ingesting ibuprofen after resistance training would therefore allow the prostanoid-dependent 
mechanism during loading to stimulate bone formation while blunting the increased production 
of harmful prostaglandins following exercise that may contribute to chronic inflammation. Our 
results, however, do not support either a detrimental or beneficial effect of ibuprofen 
supplementation after exercise loading of bone.  
 Ibuprofen and exercise were neither additive nor effective for increasing lean tissue mass. 
These findings are in support of prior studies showing no significant benefit to lean tissue mass 
when supplementing resistance training with 400 mg (versus placebo) of ibuprofen in 
premenopausal or postmenopausal women during resistance training programs (Kohrt et al., 
2010; Candow et al., 2013; Krentz et al., 2008); however, potential exists for a higher ibuprofen 
dose to increase muscle mass in older adults who are participating in a resistance training 
program. It was demonstrated that 1,200 mg of ibuprofen following resistance training increased 
lean tissue mass in older adults (Trappe et al., 2011). Perhaps the lack of improvement in lean 
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tissue mass in our study and others (Kohrt et al., 2010; Candow et al., 2013; Krentz et al., 2008) 
is due to a lower dose (i.e. 400 mg  versus 1,200 mg). The low-dose of ibuprofen used, while 
safe and effective for increasing hip aBMD in premenopausal women (Kohrt et al., 2010), may 
not have been sufficient enough to counteract the resistance-training induced inflammatory 
response and catabolism which occurs in postmenopausal women. While the inflammatory and 
catabolic effects of exercise may lead to greater muscle protein synthesis and are thus beneficial 
in younger adults, this may not be the case with aging adults. While it is well accepted that 
resistance training prevents sarcopenia, evidence from animal studies suggest ibuprofen may be 
of benefit as well (Greig et al., 2009). A daily dosage of 30 mg∙kg-1 prevented muscle wasting in 
old (i.e. 20 month old) rats; again, this would translate to a much higher dose than used in our 
study and others if implemented in humans (e.g. 2,220 mg for a 70 kg adult) (Rieu et al., 2009).  
 The effects of pro-inflammatory cytokines at the cellular and metabolic level should 
theoretically manifest as a measurable loss of muscle mass and strength and bone density and 
strength. There is dysregulation of inflammatory cytokines with age leading to over-production 
of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) 
(Degens, 2010). Precursors for these inflammatory cytokines include prostaglandins (i.e. PGE1 
and PGE2) which are synthesized through the cyclooxygenase pathway from arachidonic acid 
mediated by the enzymes cyclooxygenase-1 and 2 (COX-1; COX-2) (Degens, 2010; Lopez-Otin 
et al., 2013). In our study, inflammation may have been reduced at the cellular and metabolic 
level and simply did not manifest into measurable changes at the tissue level. One could include 
measurements of the cellular and metabolic level over a shorter duration if a longer duration 
study is not feasible. However, an optimal intervention might require a longer duration, perhaps 
over 2 years, to allow changes to manifest at the tissue level.  
 The 4-group design of our study allowed the assessment of the interaction between 
ibuprofen and exercise training. An additional strength of our study was the high compliance in 
all intervention arms. However, our study had a number of limitations. Our study was most likely 
underpowered to detect statistically significant differences between groups for primary variables. 
To detect ≥1% difference in aBMD of clinically relevant sites with 90% power each group 
would require approximately 40 per-protocol participants (2 sided, p≤0.05); thus, to account for 
~20% attrition, a sample size of 200 is required (Jankowski et al., 2015). Future research efforts 
should employ a similar study design with four recommended alterations: i) increase to a daily 
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dosage of 400 mg of ibuprofen, ii) alter the timing of the ibuprofen supplementation, so that 
supplementation does not occur within close proximity to the exercise, iii) lengthen the duration 
of the intervention, and iv) increase sample size to 200.  
5.5. Conclusion 
Ibuprofen supplementation immediately after resistance training did not have an additive 
effect on bone or muscle mass. However, our findings suggested that ibuprofen as administered 
by itself may have some benefit at Ward’s region of the proximal femur. The timing and the dose 
of the ibuprofen may be important. 
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Table 5.0. Baseline data by intervention group.  
 
 
All values are means (SD); SD= standard deviation. 
Abbreviations: aBMD = areal bone mineral density; CSA = cross-sectional area; SPW = 
subperiosteal width; Z =section modulus; 1RM = 1-repitition maximum; LTEQ = leisure time 
exercise questionnaire.
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Table 5.1.  Mean absolute changes (95% CI) from baseline to 9 months for areal bone mineral density within groups.  
 
All values are mean absolute changes (95% CI) in g/cm2; CI = confidence interval. 
Exercise and ibuprofen main effects, and their interaction are presented in last two columns.  
aIbu different from Control groups (post hoc; p = 0.017).  
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Table 5.2.  Mean absolute changes (95% CI) from baseline to 9 months for hip structural analysis within groups; CI = confidence 
interval. 
 
 Exercise and ibuprofen main effects, and their interaction are presented in last two columns.  
Abbreviations: CSA = cross-sectional area; SPW = subperiosteal width; Z = section modulus; Intertroch = intertrochanter. 
 
 
 
 
 
 
 
 
 
 
 
 
Exercise Supplement Interaction
Change 95% CI Change 95% CI Change 95% CI Change 95% CI p-value p-value p-value
Narrow neck CSA (cm2) 0.06 (-0.15, 0.08) -0.02 (-0.13, 0.05) -0.13 (-0.20, 0.02) 0.00 (-0.12, 0.01) 0.432 0.790 0.708
Narrow neck SPW (cm) -0.01 (-0.13, 0.05) 0.12 (0.01, 0.19) 0.05 (-0.13, 0.16) 0.00 (-0.04, 0.13) 0.977 0.076 0.250
Narrow neck Z (cm3) 0.02 (-0.08, 0.09) 0.34 (-0.11, 0.07) -0.06 (-0.13, 0.06) 0.00 (-0.08, 0.05) 0.708 0.911 0.630
Intertroch CSA (cm2) 0.34 (-0.08, 0.18) -0.50 (-0.13, 0.28) 3.68 (-0.23, 0.12) 0.00 (-0.31, 0.77) 0.868 0.257 0.331
Intertroch SPW (cm) 0.37 (-0.09, 0.14) -0.54 (-0.02, 0.24) 3.00 (-0.22, 0.18) 0.00 (-0.21, 0.65) 0.770 0.146 0.490
Intertroch Z (cm3) 0.75 (-0.08, 0.29) -0.71 (-0.15 0.45) 3.00 (-0.25, 0.23) 0.00 (-0.24, 0.64) 0.842 0.370 0.569
Shaft CSA (cm2) 0.08 (-0.02, 0.14) -0.08 (-0.09, 0.07) 2.51 (-0.12, 0.07) 0.00 (-0.20 0.53) 0.609 0.439 0.118
Shaft SPW (cm) -0.20 (-0.07, 0.03) -0.16 (-0.07, 0.01) 0.38 (-0.08, 0.02) 0.00 (-0.07, 0.10) 0.526 0.548 0.339
Shaft Z (cm3) 0.00 (-0.03, 0.07) -0.19 (-0.08, 0.04) 2.15 (-0.14, 0.02) 0.00 (-0.17, 0.46) 0.572 0.258 0.083
ExIbu (n = 18) Ex (n = 19) Ibu (n = 17) Control (n = 15)
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Table 5.3. Mean absolute changes (95% CI) from baseline to 9 months for body composition, balance, and strength; CI = confidence 
interval. 
 
Exercise and ibuprofen main effects, and their interaction are presented in last two columns.  
Dynamic balance is average of two attempts. 
*p-value for the main effect; Resistance training improved compared to stretching groups. 
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Table 5.4.  Mean absolute changes (95% CI) from baseline to 9 months for descriptive outcome variables; CI = confidence interval. 
 
aValues only include nutrients from dietary intake and do not include the supplements given during the study. 
Exercise and ibuprofen main effects, and their interaction are presented in last two columns.  
*P-value for the main effect; Stretching group decreased total energy and fat intake compared to resistance training group. 
 
 
 
 
 
 
 
Exercise Supplement Interaction
Change 95% CI Change 95% CI Change 95% CI Change 95% CI p-value* p-value p-value
Total Energy Intake (kcal/d) 192 (-315, 77) -212 (-133, 276) -444 (-502, 267) 0 (-394, 18) 0.047 0.165 0.596
Total Protein Intake (g/d) 6 (-14, 4) -5 (-10, 8) -9 (-19, 9) 0 (-16, 3) 0.209 0.329 0.862
Total Fat Intake (g/d) 35 (-16, 12) -16 (-5, 20) -29 (-22, 13) 0 (-19, 2) 0.039 0.253 0.654
Total Carbohydrate Intake (g/d) -38 (-40, -4) -12 (-23, 21) -48 (-52, 28) 0 (-52, 1) 0.143 0.289 0.377
Calcium Intake (mg/d)a -30 (-186, 19) -130 (-146, 97) -192 (-349, 134) 0 (-226, -63) 0.073 0.391 0.959
Vitamin D (μg/d)a -70 (-33, 60) -7 (-88, -7) 69 (-120, 37) 0 (-63, 55) 0.583 0.949 0.024
Leisure Physical Activity Score -9 (-12, 9) -5 (-6, 7) 22 (-7, 12) 0 (-6, 25) 0.211 0.362 0.591
(arbitrary units)
ExIbu (n = 18) Ex (n = 19) Ibu (n = 17) Control (n = 15)
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Figure 5.0. CONSORT Flow diagram. Participant flow throughout duration of study.
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Figure 5.1. Mean %-difference from baseline to post-testing of areal bone mineral density 
(aBMD) of the femoral neck, lumbar spine, and total body. Error bars = standard deviation.  
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Figure 5.2. Percent (%) difference from baseline to post-testing of areal bone mineral density 
(aBMD) of the trochanteric, intertrochanter, total hip, and Ward’s region. Error bars = standard 
deviation. 
*Significant exercise × supplement × time interaction with significant difference between Ibu 
and Control groups (post hoc; p = 0.017).  
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6.0. Effects of Low-dose Ibuprofen Supplementation and Resistance Training on pQCT-
derived Bone and Muscle Properties in Postmenopausal Women: A Randomized 
Controlled Trial 
6.1. Introduction 
Chronic inflammation may be a contributing factor to the loss of bone and muscle mass 
and strength with aging (ACSM, 2009; Corsonello et al., 2010; Franceschi, 2007; IWGS, 2011). 
Resistance training is a proven strategy for decreasing inflammation and increasing bone and 
muscle accretion (Calle & Fernandez, 2010). Anti-inflammatory therapies, such as non-steroidal 
anti-inflammatory drugs (NSAIDs), are theorized to have beneficial effects on aging bone and 
muscle (Greig et al., 2009; Kohrt et al., 2013; Trappe et al., 2011). Therefore, the combination of 
resistance training and ibuprofen, a popular NSAID, may be an effective lifestyle intervention to 
improve musculoskeletal health when aging.  
Epidemiological and experimental evidence of the combined therapy of resistance 
training with ibuprofen on bone and muscle properties is limited. One epidemiological study has 
demonstrated associations between regular NSAID use and 13% - 34% greater cortical and 
trabecular density at the lumbar spine; areal bone mineral density (aBMD) of the total body and 
at the hip were just 4 - 5% greater (Carbone et al., 2003). Randomized controlled trials in 
humans (while limited in number) have shown benefits for aBMD, at clinically relevant sites, in 
premenopausal women who supplemented resistance training with low-dose ibuprofen (400 mg, 
3 days/week, 9 months) (Kohrt et al., 2013; 2010); however, recent research by the same group 
demonstrated no benefits for aBMD in postmenopausal women after a similar intervention 
(Jankowski et al., 2015). Further, no benefits for fat-free mass in pre or postmenopausal women 
were evident (Jankowski et al., 2015; Kohrt et al., 2010), unlike studies in animals (Rieu et al., 
2009) or older participants on higher doses of ibuprofen (i.e. 1200 mg/d; Trappe et al., 2011). 
The only notable study in postmenopausal women over a longer training period limited measures 
to DXA-derived body composition (aBMD, fat-free mass) and lacked an exercise control group; 
therefore, this study was not able to determine architectural changes in bone and muscle quality, 
and was unable to assess independent and combined effects of resistance training and ibuprofen 
(Jankowski et al., 2015). 
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None of the studies have yet investigated independent and combined musculoskeletal 
effects of resistance training and ibuprofen or assessed effects on bone structure and strength.   
The latter is important as literature suggests that possible changes in bone structure and strength 
can be overlooked if measurements rely on DXA-derived aBMD measurements only (Adami et 
al., 1999; Jarvinen et al., 1999; Polidoulis et al., 2012). Measuring bone structure and volumetric 
density via peripheral quantitative computed tomography (pQCT) enables assessment of possible 
redistribution of bone mineral and an estimation of the intervention effect on bone strength 
(Adami et al., 1999; Jarvinen et al., 1999; Hamilton et al., 2010; Martyn-St James & Carroll, 
2006; Wolff, van Croonenborg, Kemper, Kostense, & Twisk, 1999). 
 The purpose of this study was to investigate the effects of long term (9 months) low-dose 
ibuprofen (400 mg) and exercise training on properties of bone and muscle in postmenopausal 
women. It was hypothesized that the combined effects of progressive resistance training and 
ibuprofen supplementation would be additive for improving bone properties, estimated bone 
strength, muscle cross-sectional area and density compared to placebo exercise (flexibility) and 
supplement. 
6.2. Participants and Methods 
6.2.1. Study Design. To compare the independent and combined effects of ibuprofen 
supplementation and exercise training, a blinded (for ibuprofen), factorial randomized control 
trial was employed. Participants were randomized on a 1:1:1:1 basis to one of four groups after 
exclusion criteria were applied. Randomization was completed using a computer-generated 
allocation schedule with a block size of four by one of the investigators who was not involved in 
the measurement of outcome variables or the analysis. The four groups were resistance training 
combined with ibuprofen supplementation (ExIbu), resistance training combined with placebo 
supplementation (Ex), flexibility training (i.e. stretching, placebo-exercise) combined with 
ibuprofen supplementation (Ibu), and flexibility training combined with placebo supplementation 
(Control). An ibuprofen dosage of 400 mg was administered immediately after exercise training 
only (maximum 3 times per week) for 9 months. Higher dosages (≥ 1,200 mg/d) over a longer 
duration (≥ 6 months) increases risk of adverse effects (Rainsford, 2009). We have previously 
found that 400 mg of ibuprofen was well tolerated (no adverse effects) in a 9 week pilot study in 
postmenopausal women (Candow et al., 2013). Placebo (methylcellulose) capsules were 
identical in taste, color, and appearance and administered similarly. The supplement was pre-
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packaged into sequentially numbered containers according to the randomization schedule. The 
allocation sequence was concealed from the study personnel enrolling and assessing the 
participants. All participants were provided supplements of calcium and vitamin D (600 mg/d 
and 400 IU/d, respectively), the corresponding exercise training program, and an 
exercise/supplement tracking log. Participants in the resistance training group were provided 
with the supplement directly by blinded study personnel after performing exercise at our research 
facility, while participants in the flexibility group consumed their supplement after performing 
exercise (stretching) at home. Participants were not blinded to the exercise assignment; however 
they were blinded to the hypothesis that resistance training would be superior to flexibility 
training. The study personnel supervising the resistance training program were blinded to the 
supplement (i.e. ibuprofen or placebo). All study personnel involved in the outcome assessment 
and analysis were blinded to the group assignment, including the study statistician via coding of 
the groups. The study was approved by the Biomedical Research Ethics Board of the University 
of Saskatchewan. Reporting of this study adhered to the Consolidated Standards of Reporting 
Trials (CONSORT) guidelines for randomized clinical trials. This trial was registered with 
clinicaltrials.gov (NCT01886196).  
6.2.2. Participants. Postmenopausal women aged 60 years or greater were recruited from 
January 2013 to September 2013 via advertisements in local newspapers and posters. A total of 
164 potential participants responded to the advertisements (Figure 1). Participants were assessed 
for eligibility using a modified version of the Mediterranean Osteoporosis Study Questionnaire 
(Dequeker et al., 1999). Participants were not eligible if they had a high risk of fracture 
(according to a 10-year risk of fracture classification based on age and femoral neck aBMD t-
score (i.e. Canadian Association of Radiologists and Osteoporosis Canada [CAROC])), as well 
as previous use of systemic corticosteroids or fragility fracture after the age of 40 years 
(SACOC, 2010). Thus, potential participants presenting with osteoporosis in the hip were 
excluded. Grounds for further exclusion included usage of medication or presentation of disease 
that were known to affect bone mineral metabolism or having contra-indications with ibuprofen. 
Thus, participants currently taking systemic corticosteroids, or having taken bisphosphonates, 
hormone replacement therapy, selective estrogen receptor modulators, parathyroid hormone, or 
calcitonin within the past 12 months or presenting with Crohn’s Disease or Cushing Disease 
were excluded. Further, participants currently taking NSAIDs (e.g. prophylactic acetylsalicylic 
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acid) or blood thinners due to past episodes of deep vein thrombosis or a pulmonary embolism or 
presenting with severe osteoarthritis or severe heartburn, ulcers, or gastritis requiring acid 
reducers (e.g. H2 blockers or proton pump inhibitors) were also excluded. Finally, participants 
were not eligible if they were active smokers or currently (within past 6 months) performing a 
strength training regimen.   
After applying the exclusion criteria, 144 women were eligible to take part in the study, 
of which 90 agreed to participate (Figure 1). A sample size goal of 100 was estimated based on a 
previous study, which had 54 participants, demonstrating an adaptive response of femoral neck 
aBMD via NSAID supplementation after exercise in younger adults (Kohrt et al., 2010) and 
increased based on greater aBMD variability in older adults (Candow & Chilibeck, 2005). The 
participants signed informed consents and completed the Physical Activity Readiness 
Questionnaire (PAR-Q) and Physical Activity Readiness Medical Examination (PARmedX) 
(Thomas et al., 1992) prior to baseline testing to ensure there was no contra-indication to 
exercise participation.  
6.2.3. Interventions. Ibuprofen (Saskatoon Medical Arts Pharmacy, Saskatoon, SK) and 
placebo capsules were ingested immediately following exercise training (3 days per week for 9 
months). Contents of the ibuprofen (96% ibuprofen) were verified by testing in an independent 
laboratory (Eagle Analytical Services, Houston, TX). The placebo capsule was composed of an 
inert product (i.e. methylcellulose) that was indistinguishable (i.e. taste, appearance) from the 
ibuprofen. All participants received a supplement of 600 mg of calcium and 10 μg (400 I.U.) of 
vitamin D per day in the form of a pill or chew (Jamieson Laboratories, Toronto, ON) to help 
ensure they met the Osteoporosis Society of Canada recommendations of 1200 mg per day for 
calcium and 20 μg (800 I.U.) per day for vitamin D (SACOC, 2010).  
Whole-body exercise training was performed 3 days per week, on non-consecutive days, 
to reduce the risk of injury and minimize fatigue. Exercise orientations and all resistance training 
exercise sessions were completed at our research facility under the direct supervision of study 
personnel (Certified Exercise Physiologists certified by the Canadian Society for Exercise 
Physiology; www.csep.ca). Flexibility training was performed at home. The resistance training 
program consisted of 2 sets of 8-12 repetitions (to fatigue) for 12 exercises designed to provide 
direct training stimulus to the entire body. Machine exercises (Lever, Pulse Fitness Systems; 
Winnipeg, Manitoba, Canada) included hack squat, hip flexion, extension, adduction, and 
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abduction, and dorsiflexion. Dumbbell exercises included biceps curl, forearm curl, supinated 
wrist curl, pronated wrist curl, front and side step ups, single leg lunge, and plantar flexion. 
Participants also performed a medicine ball toss and catch against a wall. The exercise training 
placebo consisted of a home-based flexibility program of 2 sets held for 20-30 seconds (to mild 
discomfort) designed to improve flexibility of major muscle groups. Stretches included the 
sternocleidomastoid, trapezius, anterior and posterior deltoid, pectoralis, rhomboids, latissimus 
dorsi, quadratus lumborum, iliopsoas, gluteals (maximus, medius, minimus), piriformis, 
quadriceps (rectus femoris, vastus lateralis, vastus intermedius, vastus medialis), hamstrings 
(semitendinosus, semimembranosus, biceps femoris), gastrocnemius, and soleus muscle 
(Anderson, 2010). Flexibility participants were advised not to perform any resistance training 
exercise for the duration of the intervention. Participants tracked exercise, supplement dosages, 
and calcium and Vitamin D consumption. Study personnel tracked communication with all 
participants and attendance to the research gym (resistance training groups). Communication 
with the resistance training group occurred during sessions at the research gym and with the 
flexibility training group during monthly phone calls made by study personnel. Compliance was 
assessed via tracking logs and the amount of leftover supplement. Outcome measurements were 
performed prior to (i.e. baseline) and following the 9 month intervention (i.e. post-testing).  
6.2.4. Outcomes. Primary pQCT-derived outcome measures were total and trabecular 
bone area, content, and density and bone strength index at the distal radius. Secondary pQCT-
derived outcome measures include total and trabecular bone area, content, and density and bone 
strength index at the distal tibia and total area, cortical bone area, content, and density, and bone 
strength indices at the radius and tibia shaft. Tertiary pQCT-derived outcome measures included 
muscle cross-sectional area and density of the forearm and lower leg. Anthropometrics were 
taken prior to pQCT measurements.  
6.2.4.1. Anthropometrics. Height was measured using a wall-mounted stadiometer 
(Holtain Limited, Britain) to the nearest 0.1 cm. The non-dominant radius and tibia lengths were 
measured with an anthropometric sliding caliper (segmometer; Rosscraft Innovations, Canada) 
three times, with the median value recorded. For the radius, the proximal lateral radial head and 
the most distal point of the styloid process were palpated and the distance measured while the 
participant stood (Eston et al., 2009). For the tibia, the superior margin of the medial epicondyle 
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and the base of the medial malleolus were palpated and the distance measured while the 
participant sat in a cross-legged position (Eston et al., 2009). 
6.2.4.2. Peripheral quantitative computed tomography (pQCT).  Bone and muscle 
properties and estimated bone strength of the non-dominant forearm and lower leg were assessed 
via pQCT (Stratec Medizintechnik GmbH, Pforzheim, Germany). Participants were positioned 
with the forearm and lower leg centered in the gantry while attempting to maintain the comfort 
level of the participant (Duckham et al., 2013; Frank et al., 2012). A scout view was performed 
and a reference line was placed at the medial tip of the distal endplate for both the radius and 
tibia. Cross-sectional slices were then obtained at the distal (4% of radius and tibia length) and 
shaft (65% of radius and 66% tibia lengths, respectively) sites with scanning parameters set at 
2.4 mm slice thickness, 0.4 mm pixel size, and 20 mm/s scanning speed (Duckham et al., 2013; 
Frank et al., 2012). We used manufacturer software (Stratec, version 6, Pforzheim, Germany) 
and our standard protocols to analyze bone and muscle outcomes (Duckham et al., 2013; Frank-
Wilson et al., 2015). Outcomes for the distal sites included total area (ToA; mm2), content (ToC; 
mg/mm), and density (ToD; mg/cm3); trabecular area (TrA; mm2), content (TrC; mg/mm), and 
density (TrD; mg/cm3); and bone strength index against compressions (BSIc; mg2/mm4). BSIc 
was calculated as the product of ToA and squared ToD (BSIc = ToA × ToD2; mm4) 
(Kontulainen et al., 2008). At the distal sites, ToA and ToD were defined using Contour Mode 1 
(outer threshold of 169 mg/cm3) while TrA, TrC and TrD were defined using Peel Mode 1 
(threshold of 480 mg/cm3). Outcomes for the shaft sites included total area (ToA; mm2); cortical 
area (CoA; mm2), content (CoC; mg/mm), and density (CoD; mg/cm3); stress-strain index during 
torsion (SSIp; mm3); and muscle cross-sectional area (MuA; mm2), and density (MuD; mg/cm3). 
At the shaft sites, ToA was defined using Contour Mode 1 (outer threshold of 280 mg/cm3) while 
CoA, CoC, and CoD were defined using Separation Mode 4 (threshold of 480 mg/cm3) 
(Duckham et al., 2013); MuA and MuD were defined using threshold of 40 mg/cm3 (Frank-
Wilson et al., 2015). Precision errors (CV%rms) for the bone and muscle parameters in 
postmenopausal women measured in our laboratory range between 0.7-6.1%, with the largest 
error observed in the distal radius BSIc (Duckham et al., 2013; Frank-Wilson et al., 2015). 
6.2.5. Descriptive Outcomes. Participants completed a food frequency questionnaire 
(FFQ; Block 98#256318-2, Block Dietary Data Systems, Berkeley, CA, USA) and leisure time 
exercise questionnaire (LTEQ) (Godin & Shephard, 1985) to assess the changes from baseline to 
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intervention completion for total energy, macronutrients, and dietary calcium and Vitamin D 
levels, and exercise not associated with the intervention. Participants were further asked to report 
any adverse events that occurred throughout the duration of the study; these were recorded on 
adverse event forms. 
6.2.6. Statistical Analysis. Data were analyzed on an intent-to-treat basis using IBM 
SPSS Statistics for Windows (Version 21.0; Armonk, NY: IBM Corp). Baseline descriptives for 
all variables between groups were compared using Student’s t-tests. Variables were analyzed via 
a three-factor analysis of variance (ANOVA), with time as a within-group factor (baseline versus 
nine months post-intervention) and drug (ibuprofen versus placebo) and exercise (resistance 
training versus flexibility [placebo]) as between-group factors. Tetrad contrast hypothesis tests 
were used for the post-hoc analyses. We report partial eta-squared (ƞp²) as estimate of effect size. 
All descriptive results were expressed as either means and standard deviations or mean absolute 
changes and 95% confidence intervals. P-values ≤ 0.05 were deemed statistically significant.    
6.3. Results 
Baseline data for the intervention groups are presented in Table 6.0. There were no 
significant differences between groups for any variables at baseline. Of the 90 participants 
randomized, 69 were included in the final analysis, 21 (77%) were lost to follow-up (Figure 6.0). 
Compliance to the interventions was similar (p > 0.05) between groups: ExIbu 89%, Ex 84%, 
Ibu 88%, and Control 87%. Reported compliance corresponds to both exercise and supplement 
as the supplement was only consumed after exercise. Of the participants that adhered to the 
ibuprofen/placebo intervention, the percent able to correctly identify the supplement were: ExIbu 
(n = 17) 47%, Ex (n = 19) 63%, Ibu (n = 15) 47%, and Control (n = 14) 79%. Compliance to 
calcium and vitamin D supplementation was similar between groups (p > 0.05): ExIbu 83%, Ex 
72%, Ibu 76%, and Control 84%. Finally, the number of participants analysed per outcome 
varied as follows. Two radius shaft scans were excluded from the analysis from two intent-to-
treat participants due to significant movement artefacts. Two tibia scans (distal and shaft) were 
excluded from one intent-to-treat participant due to improper placement of the reference line. 
Five intent-to-treat participants were unable to complete scanning of the lower leg due to a large 
leg girth and the limiting size of the gantry.  
6.3.1. Bone Properties and Strength. A significant exercise × supplement × time 
interaction for total bone content at the distal radius was evident (p = 0.009; ƞp² = 0.082) (Table 
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6.1; Figure 6.1). ExIbu decreased the average total bone content in comparison to the Ex (p = 
0.032) and Ibu (p = 0.050) group (Table 6.1; Figure 6.1). There was a significant exercise × 
supplement × time interaction for total area at the radial shaft (p = 0.048; ƞp² = 0.062) (Table 
6.1). Post-hoc analyses failed to find significance when comparing changes between groups. 
There was a significant exercise × supplement × time interaction for cortical density at the radial 
shaft (p = 0.038; ƞp² = 0.067) (Table 6.1). When comparing changes between groups, Ibu 
maintained the average cortical density at the radial shaft compared to a decrease for Control (p 
= 0.050) (Table 6.1). No significant interactions were apparent for the other remaining variables 
at the distal radius and tibia or at the radial and tibial shaft (Table 6.1). 
6.3.2. Muscle Properties. Interactions for muscle properties at the forearm were not 
significant. There was a significant exercise × time interaction for lower leg muscle density (p = 
0.015; ƞp² = 0.099) (Table 6.2). Resistance training preserved the average lower leg muscle 
density more so than flexibility training.  
6.3.3. Diet and Activity. There was a significant exercise × supplement × time 
interaction for average dietary vitamin D intake (p = 0.024; ƞp² = 0.081). Post-hoc analyses failed 
to find significance when comparing average changes between groups. Interactions for the 
average dietary calcium intake were not significant. Further, there was a significant exercise × 
time interaction for the average total energy (p = 0.047; ƞp² = 0.068) and fat intake (p = 0.039; 
ƞp² = 0.073). The stretching group decreased average total energy intake via reduced average fat 
intake compared to the resistance training group. Baseline to post-intervention averages for 
remaining macronutrients (carbohydrates, protein) and activity outcomes were not different 
between groups. All groups met the recommended dietary allowances of 0.8g/kg of protein. 
6.3.4. Adverse Events. Throughout the duration of the intervention, there were two 
serious adverse events (SAEs) reported, which included a transient ischemic attack (ExIbu) and a 
fractured pelvis from a fall on ice (Control). Although both SAEs were deemed “not related” to 
the intervention, both participants discontinued the study. 
6.4. Discussion 
To our knowledge, this is the first study to examine the efficacy and interactions of 
resistance training with ibuprofen supplementation on pQCT-derived bone properties, estimated 
bone strength and muscle properties in postmenopausal women. Results showed that the 
combination of resistance training and ibuprofen had a negative effect on distal radius content; 
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however, ibuprofen alone maintained cortical density and resistance training preserved muscle 
density compared to stretching alone. Resistance training and ibuprofen therefore independently 
maintained bone or muscle in postmenopausal women.  
 Our results add to the limited evidence on the effects of resistance training combined with 
ibuprofen supplementation on bone in postmenopausal women. Two previous studies performed 
by the same research group (Kohrt et al., 2010; Jankowski et al., 2015) demonstrated conflicting 
results in premenopausal compared to postmenopausal women. Resistance training supplemented 
with 400 mg of ibuprofen (immediately after exercise, 3 days/week) improved aBMD of the hip 
in premenopausal women over 9 months of training, but not in postmenopausal women (Kohrt et 
al., 2010; Jankowski et al., 2015). In these studies, menopausal status may have been a 
contributing factor as the cessation of estrogen likely influence bone and muscle biology 
(Horstman et al., 2012). We provide evidence that the independent benefits and deleterious 
interactions manifest to a greater extent in measures of bone properties (versus areal bone 
density) at clinically relevant sites (i.e. wrist), other than the hip in postmenopausal women. 
Collectively, these findings justify the need for further clinical studies.   
 Our findings are in contrast to studies involving premenopausal women and rodents. 
Research in premenopausal women suggests a beneficial effect when ibuprofen is consumed 
immediately after loading (Kohrt et al., 2010). Production of pro-inflammatory prostanoids, 
derived from reactions catalyzed by the cyclooxygenase (COX-1 and-2) enzymes, is inhibited by 
NSAIDs (Rainsford, 2009). Animal studies suggest that the loading-induced osteogenic response 
and consequential bone formation process is not suppressed when COX-2 inhibitors are 
consumed immediately after loading vs. before loading in mature rats (Chow et al., 1998; Li et 
al., 2002). Literature to date (human or animal) has yet to suggest a deleterious effect. As such, 
one has to be cautious when applying results from younger adults and animals to older adults. 
For example, the osteogenic response in older adults may be delayed (compared to younger 
adults), so that consuming ibuprofen post-exercise may prevent both the osteogenic and 
inflammatory response which could influence bone and muscle biology.   
 A decline in total bone content at the distal radius after resistance training with ibuprofen 
supplementation may lead to bone fragility at the wrist. Total bone content provides a surrogate 
measure for bone’s resistance to axial compressive forces (Kontulainen et al., 2008) and 
discriminates between fractured and non-fractured women (Schneider et al., 2001). Both 
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resistance training and ibuprofen alone maintained total content at the distal radius over the 9-
month intervention. Further investigation with a longer duration, and altered timing of ibuprofen 
supplementation, is warranted to assess the potential for resistance training or ibuprofen to 
increase bone content and other properties at the fracture-prone distal radius.  
Resistance training preserved lower leg muscle density (-3.5%) to a greater extent than 
stretching (-5.5%). This finding may have clinical relevance related to fall and fracture 
prevention. Our group demonstrated lower calf muscle density in postmenopausal women with 
recent wrist fracture compared to non-fractured peers (Crockett et al., 2015) and lower muscle 
density of the lower leg in women who were fallers versus non-fallers (Frank et al., 2015). Also, 
thigh muscle density has shown to predict hip fracture risk in older men and women (Lang et al., 
2010). Current study adds to this evidence by indicating efficacy of resistance training to 
preserve muscle density in the lower leg. Maintained muscle density in postmenopausal women 
may help reduce the risk of falls and related injuries, including fractures.  
 Our study had several strengths. The four group design of our study allowed assessment 
of both additive effects and possible interactions between ibuprofen and exercise training. 
Further, pQCT can provide peripheral bone strength index which may predict clinically relevant 
wrist fracture and serves as early indicator of future hip fracture risk (Sheu et al., 2011). 
However, limitations in our study need to be addressed. While able to indicate hip fracture risk, 
pQCT cannot directly assess the clinically relevant hip (or spine). The lower dosage of ibuprofen 
utilized (400 mg, 3 days per week) may not have been great enough to elicit independent or 
additive improvements in muscle, as previously demonstrated in older adults and old rats, 
respectively (Rieu et al., 2009; Trappe et al., 2011). Our findings should be interpreted with 
caution, as some observed changes did not exceed the reported least significant changes (LSC) 
estimated for postmenopausal women within one year (Duckham et al., 2013). While the 
differences observed in lower leg muscle density were greater than reported LSC (5.3%) in 
postmenopausal women, differences in distal radius total content and radial shaft cortical density 
changes were not (LSC: 7.3% and 5.3%, respectively) (Duckham et al., 2013; Frank-Wilson et 
al., 2015). Our study was most likely underpowered to detect small differences in bone changes 
within the nine months of training. Theoretically, however, if observed changes continued to 
manifest in a similar direction and magnitude for an additional 3 months they may have 
exceeded LSC and/or differences between groups may have become statistically significant. Our 
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findings support the recommendation for a minimum of 2 years for exercise interventions 
assessing bone structure and strength adaptation (Nikander et al., 2010).  
In summary, our results indicated a deleterious interaction between resistance training 
and ibuprofen (-1.5%) on bone mass at the distal radius in comparison to resistance training 
(0.6%) or ibuprofen (0.5%) alone. Ibuprofen alone also maintained cortical density (1.1%) when 
compared to the control group (-1.8%) at the radial shaft. Collectively, these results suggested 
that resistance training or ibuprofen provides independent benefits for maintaining bone 
properties at the forearm, but contrary to our original hypothesis, when ibuprofen is consumed 
immediately after resistance training, these benefits are negated, rather than enhanced. 
Resistance training and/or ibuprofen supplementation had no effect on bone properties or 
strength at the tibia. While further interventions of this nature in postmenopausal women and 
older men are warranted, the study design could be adjusted to accommodate cumulating 
evidence. Based on our findings, future study design could include increasing to daily dosages of 
ibuprofen, provide the ibuprofen supplementation several hours beyond the resistance training, 
increase duration of the intervention to two years, increase the sample size and include men in 
the study sample.   
6.5. Conclusion 
Ibuprofen supplementation immediately following resistance training sessions did not 
have an additive effect on bone and muscle properties or estimated bone strength. Our findings 
suggests that ibuprofen consumed immediately after resistance training had a deleterious effect 
on bone mineral mass at the distal radius while  resistance training or ibuprofen  supplementation 
alone prevented bone loss. 
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Table 6.0. Baseline data by intervention group. 
 
All values are means (SD).  
Abbreviations: ToA = Total area; ToC = Total content; ToD = Total density; TrA = Trabecular 
area; TrC = Trabecular content; TrD = Trabecular density; BSIc = Bone strength index against 
compression; CoA = Cortical area; CoC = Cortical content; CoD = Cortical density; SSIp = 
Strength strain index against torsion.
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Table 6.1. Mean absolute changes (95% CI) from baseline to 9 months for bone properties and strength within groups; CI = 
confidence interval. 
 
Exercise Supplement Interaction
Change 95% CI Change 95% CI Change 95% CI Change 95% CI p-value p-value p-value
Distal Radius
  ToA (mm2) -2.33 (-13.08, 8.42) -0.17 (-17.84, 17.50) 4.95 (-15.66, 25.56) 2.41 (-8.87, 13.70) 0.512 0.980 0.755
  ToC (mg/mm) -1.53 (-3.00, -0.06)ab 0.61 (-0.66, 1.88)a 0.51 (-1.51, 2.52)b -1.28 (-2.59, 0.03) 0.921 0.809 0.009
  ToD (mg/cm3) -0.94 (-10.22, 8.33) 2.31 (-10.12, 14.73) -1.40 (-11.55, 8.75) -4.87 (-13.19, 3.44) 0.444 0.982 0.500
  TrA (mm2) -1.21 (-15.21, 12.79) -0.61 (-21.96, 20.75) 5.57 (-20.40, 31.54) 3.88 (-10.66, 18.43) 0.549 0.954 0.903
  TrC (mg/mm) -1.11 (-4.23, 2.01) 0.75 (-3.02, 4.53) 0.84 (-4.83, 6.51) 0.23 (-2.64, 3.10) 0.706 0.741 0.514
  TrD (mg/cm3) -1.97 (-5.69, 1.75) 2.66 (-2.16, 7.48) -1.21 (-5.99, 3.57) -2.12 (-3.64, -0.60) 0.304 0.342 0.159
  BSIc (mg2/mm4) -0.49 (-1.56, 0.58) 0.23 (-0.91, 1.37) -0.14 (-1.13, 0.84) -0.88 (-1.95, 0.19) 0.732 0.733 0.829
Radial Shaft
  ToA (mm2) 2.51 (-0.25, 5.27) -0.25 (-3.93, 3.44) -0.61 (-4.58, 3.36) 1.71 (-0.96, 4.38) 0.466 0.839 0.048
  CoA (mm2) 1.33 (-1.19, 3.85) 0.36 (-1.39, 2.12) -1.04 (-4.13, 2.05) 1.14 (-0.38, 2.66) 0.275 0.358 0.070
  CoC (mg/mm) -0.05 (-1.35, 1.25) 0.21 (-0.93, 1.35) -0.36 (-2.34, 1.61) -0.22 (-1.60, 1.16) 0.365 0.508 0.789
  CoD (mg/cm3) -16.84 (-42.90, 9.21) -2.59 (-29.17, 23.99) 9.16 (-9.88, 28.21)c -19.79 (-33.04, -6.53)c 0.595 0.423 0.038
  SSIp (mm3) 1.84 (-11.14, 14.81) -1.04 (-11.90, 9.82) 5.87 (-3.37, 15.12) -2.80 (-12.28, 6.67) 0.796 0.483 0.401
Distal Tibia
  ToA (mm2) 6.23 (-11.23, 23.69) 9.64 (-2.46, 21.75) 4.47 (-17.79, 26.72) 8.89 (-15.56, 33.35) 0.861 0.675 0.948
  ToC (mg/mm) -0.33 (-3.09, 2.43) 1.91 (-0.07, 3.89) 0.31 (-4.73, 5.36) 4.47 (-5.16, 14.10) 0.577 0.159 0.630
  ToD (mg/cm3) -1.76 (-4.08, 0.57) -0.60 (-3.03, 1.83) -0.81 (-3.74, 2.12) -5.60 (-12.83, 1.62) 0.299 0.35 0.119
  TrA (mm2) 8.85 (-11.58, 29.29) 12.76 (-3.47, 29.00) 12.58 (-14.83, 39.98) 12.61 (-15.53, 40.74) 0.890 0.656 0.928
  TrC (mg/mm) 1.57 (-3.40, 6.54) 4.27 (0.30, 8.24) 1.15 (-4.89, 7.20) 3.79 (-4.29, 11.86) 0.846 0.339 0.992
  TrD (mg/cm3) -0.36 (-1.76, 1.05) 1.12 (-0.31, 2.54) -0.33 (-1.46, 0.80) 0.48 (-2.34, 3.30) 0.725 0.188 0.701
  BSIc (mg2/mm4) -0.50 (-1.23, 0.23) 0.33 (-0.56, 1.21) -0.23 (-1.17, 0.70) -2.89 (-8.46, 2.68) 0.942 0.545 0.787
Tibial Shaft
  ToA (mm2) -1.39 (-10.05, 7.27) 0.66 (-6.17, 7.48) -6.55 (-13.23, 0.13) 1.17 (-7.06, 9.40) 0.548 0.179 0.508
  CoA (mm2) -0.47 (-2.49, 1.55) -0.93 (-4.71, 2.84) 1.85 (-0.87, 4.56) 0.37 (-1.36, 2.09) 0.236 0.579 0.593
  CoC (mg/mm) -0.66 (-2.94, 1.61) -0.77 (-2.24, 0.69) 1.60 (-1.54, 4.74) -2.13 (-4.18, -0.09) 0.719 0.094 0.080
  CoD (mg/cm3) -0.57 (-6.92, 5.77) 0.91 (-9.78, 11.59) -1.56 (-7.86, 4.74) -7.89 (-14.35, -1.44) 0.257 0.484 0.373
  SSIp (mm3) -9.26 (-37.79, 19.27) -14.76 (-46.86, 17.35) -12.81 (-44.60, 18.97) -20.41 (-46.15, 5.32) 0.870 0.657 0.941
ExIbu (n = 18) Ex (n = 19) Ibu (n = 17) Control (n = 15)
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Exercise and ibuprofen main effects, and their interaction are presented in last two columns. 
Abbreviations: ToA = Total area; ToC = Total content; ToD = Total density; TrA = Trabecular area; TrC = Trabecular content; TrD = 
Trabecular density; BSIc = Bone strength index against compression; CoA = Cortical area; CoC = Cortical content; CoD = Cortical 
density; SSIp = Strength strain index against torsion. 
aExIbu different from Ex (post hoc; p = 0.032). 
bExIbu different from Ibu (post hoc; p = 0.050). 
cIbu different from Control (post hoc; p = 0.050). 
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Table 6.2. Mean absolute changes (95% CI) from baseline to 9 months for muscle properties within groups; CI = confidence interval. 
 
Exercise and ibuprofen main effects, and their interaction are presented in last two columns.  
Abbreviations: MuA = Muscle area; MuD = Muscle density. 
*p-value for the main effect; Resistance training preserved lower leg muscle density compared to stretching. 
Exercise Supplement Interaction
Change 95% CI Change 95% CI Change 95% CI Change 95% CI p-value* p-value p-value
Forearm Muscle
  MuA (mm2) 43.90 (-13.78, 101.57) 78.19 (31.57, 124.80) -4.97 (-62.97, 53.03) -2.56 (-54.16, 49.04) 0.706 0.402 0.973
  MuD (mg/cm3) -3.47 (-5.97, -0.96) -3.39 (-5.29, -1.49) -4.37 (-6.29, -2.45) -3.24 (-4.93, -1.55) 0.694 0.533 0.585
Lower Leg Muscle
  MuA (mm2) -116.00 (-271.32, 39.32) -22.01 (-174.86, 130.84) -93.45 (-360.57, 173.66) -88.78 (-333.23, 155.67) 0.868 0.834 0.874
  MuD (mg/cm3)a -2.52 (-3.88, -1.17) -2.51 (-4.20, -0.82) -4.16 (-5.69, -2.62) -3.80 (-5.17, -2.43) 0.015 0.570 0.959
ExIbu (n = 18) Ex (n = 19) Ibu (n = 17) Control (n = 15)
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Figure 6.0. CONSORT Flow diagram. Participant flow throughout duration of study. 
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Figure 6.1. Percent (%) difference from baseline to post-testing of total bone content (mg/mm) at the distal radius.  
*ExIbu different from Ex (post hoc; p = 0.032). 
*ExIbu different from Ibu (post hoc; p = 0.050). 
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7.0. Discussion 
The overall aim of this thesis was to investigate the efficacy of novel anti-inflammatory 
agents during resistance training to prevent muscle and bone loss in older adults. This was 
achieved by carrying out two randomized controlled trials. Both studies supplemented resistance 
training with novel anti-inflammatory agents, bovine colostrum or ibuprofen; these supplements 
both target the pro-inflammatory COX pathway, but via unique mechanisms. Older adults were 
recruited as the interactions between resistance training and supplements utilized are unknown in 
this population. Efficacy of the intervention was assessed at the tissue level via imaging 
equipment, DXA and/or pQCT. However, distinction in study design was determined by existing 
literature. The bovine colostrum study recruited older men and women to participate in an 8 
week intervention because sex differences and long-term safety of supplementation have yet to 
be identified. In contrast, the ibuprofen recruited older women to participate in a 9 month 
intervention because sex differences and long-term safety of supplementation have been 
identified.  
7.1. Summary 
The bovine colostrum study recruited men and women over 50 y to perform 8-weeks of 
resistance training supplemented by 60 g/d of either bovine colostrum or whey protein. The 
ibuprofen study recruited postmenopausal women over 60 y to perform 9-months of either 
resistance training or stretching (placebo exercise) supplemented by 400 mg of ibuprofen or 
placebo immediately after exercise (3 days/week). The overall hypothesis was that the 
combination of resistance training and novel supplementation (bovine colostrum or ibuprofen) 
would be additive for muscle and bone health in older adults. The additive benefits would be 
derived in different manners due to unique anti-inflammatory properties of the supplements 
utilized. Resistance training supplemented with bovine colostrum increased lower body strength 
compared to whey protein (placebo), while the same was not true of ibuprofen supplementation. 
The ibuprofen study demonstrated that resistance training alone increased upper and lower body 
strength and preserved lower leg muscle density compared to stretching. These findings are 
important because older adults lose lower body strength to a greater extent than upper body, and 
this loss is associated with decreased functional ability. Further, resistance training supplemented 
with bovine colostrum reduced bone resorption (beneficial for bone health) compared to whey 
protein (placebo), but the same was not true of ibuprofen. Contrary to our hypothesis, the 
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combination of resistance training with ibuprofen supplementation was deleterious rather than 
additive for bone properties, specifically for bone mass at the wrist region. However, ibuprofen 
alone improved areal bone mineral density of Ward’s region and maintained distal radius total 
bone content and radial shaft cortical density compared to placebo. The reduction in bone 
resorption at the cellular level may eventually manifest as maintenance of bone density and 
strength at the tissue level via bovine colostrum supplementation, similar to the effects of 
ibuprofen alone. Collectively, bovine colostrum or ibuprofen supplementation during resistance 
training shows promises to increase or maintain muscle and bone health. However, while bovine 
colostrum in close proximity to exercise appears beneficial, ibuprofen should not be consumed 
within close proximity to exercise.  
7.2. Strengths and Limitations 
The studies completed for this thesis are among the first known to determine the efficacy 
of either bovine colostrum or ibuprofen supplementation during exercise training in older adults. 
Efficacy was determined by utilizing randomized, double-blind, placebo-controlled, parallel 
group trials. Thus, while the major strength of both studies completed is due to study design, 
they are not without further strengths. To measure efficacy of interventions to improve muscle 
and bone health an emphasis was placed on assessing muscle and bone properties and strength, 
while neural adaptations were not assessed. Thus, while the major limitation of both studies 
completed is due to lack of assessing neural adaptations, they are not without further limitations. 
7.2.1. Strengths. While study design proved to be a major strength of both studies, the 
ibuprofen study utilized a four group design that further allowed determination of independent 
and additive benefits of resistance training and ibuprofen supplementation; this study is the first 
known to utilize this unique design. Further, the ibuprofen study is among the first known 
randomized controlled trials to determine the efficacy of resistance training to improve bone 
properties, specifically of the clinically relevant distal radius. In both studies participants and 
study personnel were blinded to supplement allocation, but could not be blinded to exercise 
allocation. The ibuprofen participants were, however, blinded to the hypothesis that resistance 
training was superior to stretching for muscle and bone health. To facilitate blinding of 
participants to supplement allocation, measures were taken to provide active supplement and 
placebo in forms that were identical in taste and appearance. Bovine colostrum and placebo 
(whey protein) was provided in powder form, while ibuprofen and placebo (methylcellulose) was 
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provided in pill form. Further, the use of whey protein as a macro-nutrient matched placebo for 
bovine colostrum allowed the determination of the efficacy of the additional bioactive 
ingredients (i.e. IGF-1, Ig) found in bovine colostrum; thus, any differences could not be 
attributed to the protein content of bovine colostrum, a known anabolic substance. Upon 
questioning of participants after intervention completion it was determined that the measures 
taken to blind participants to supplement were effective.  
7.2.2. Limitations. Bovine colostrum supplementation during resistance training 
increased leg press strength more so than whey protein. The additive increases in leg press 
strength could not be explained by increases in total body lean tissue mass nor muscle thickness 
of the quadriceps, as these variables were similar between groups. Similarly, resistance training 
alone was effective for increasing biceps curl and hack squat strength, but not total body lean 
tissue mass, as compared to stretching. Collectively, the gains in strength in both studies, 
whether via resistance training alone or with additive benefits from supplements, could not be 
attributed to changes in muscle mass. Candow et al. (2011) suggests 12 weeks is sufficient to 
eliminate deficits (between older and younger adults) of muscle strength in the lower body via 
neural adaptations. It is reasonable to consider that the improvements in strength demonstrated in 
both studies may be attributable to neural adaptations, which were not assessed, and thus serves 
as a major limitation.  
Further limitations could be the assessment of lean tissue mass for the total body. It could 
be speculated that the increases in leg press strength in the bovine colostrum study are due to 
increases in lean tissue mass of the gluteal muscles, as the seated leg press utilized for 1-RM 
testing may recruit gluteal muscles. Standard DXA analyses includes gluteal muscles in the 
trunk, thus it would be difficult to distinguish if changes in gluteal lean tissue mass occurred. 
This could also be the case with the increases in hack squat strength with resistance training 
alone seen in the ibuprofen study, as the hack squat, when performed properly, also largely 
engages the gluteal muscles. However, it is also feasible that the increases in leg press strength 
with bovine colostrum supplementation might be due to increases in muscle density rather than 
muscle mass, of which the former was not assessed. The ibuprofen study, which assessed muscle 
density, demonstrated that resistance training alone preserved muscle density of the lower leg.  
However, there were no differences in forearm muscle density to accompany increases in biceps 
curl strength in the ibuprofen study. The lack of response of forearm muscle properties to 
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resistance training alone may be due to limitation of strength measure utilized (biceps curl versus 
grip strength). However, increases in biceps curl strength without preservation of muscle density 
of the forearm are likely attributable to neural, further supporting this limitation (Candow et al., 
2011; Crockett et al., 2015; Lorbergs et al., 2011).  
The increases in the upper body strength measure utilized in the ibuprofen study (biceps 
curl) from resistance training alone were not accompanied by increases in muscle mass or 
density of the forearm. Thus, the mechanism leading to increases in total bone content of the 
distal radius with resistance training alone is unknown. Besides the consideration of neural 
adaptations, these findings may suggest that the bone response was stimulated by impact from 
the medicine ball toss-and-catch performed, rather than muscle forces on the bone from the 
biceps and wrist curls performed in the resistance training program. However, distinguishing 
between the two (muscle forces versus impact) would prove difficult and serves as a limitation.  
Finally, bovine colostrum supplementation during resistance training decreased bone 
resorption markers while whey protein supplementation increased bone resorption markers. 
While at the cellular level this suggests bovine colostrum has benefits for bone, bone mineral 
content did not improve. This is not surprising as the shorter duration of the study, while 
necessary for determining safety of high-dose consumption over longer periods,  was likely not 
long enough to measure tissue-level differences. Regardless, this study is the first known in 
humans to report markers of bone metabolism or DXA-derived bone variables. Animal studies 
utilizing ovariectomized rats (postmenopausal model) provide evidence of a dose dependent 
beneficial effect on bone metabolism which may lead to increases in bone density, properties, 
and strength (Du et al., 2011; Hou et al., 2012). Thus, by measuring markers of bone resorption 
(to account for shorter duration) this study is the first to suggest bovine colostrum 
supplementation has beneficial effect on bone metabolism in humans. However, a longer 
duration study including measures of bone properties and strength is required to confirm if the 
beneficial effects on bone metabolism (at the cellular level) will manifest at the tissue level in 
humans similar to animals.  
7.3. Future Directions 
The strength and limitations of the randomized controlled trials completed for this thesis 
provide important insight for future research. The four group design allowing determination of 
independent and combined effects should be utilized. To allow sufficient time for cellular level 
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changes to manifest at the tissue level, a study duration of 2 years is suggested. With the 
increased duration outcome variables should be assessed at three time points (i.e. baseline, 1yr, 
and post-intervention) and adverse events monitored carefully on a continuous basis by study 
physician. Inclusion of both DXA- and pQCT-derived muscle and bone variables would provide 
the greatest insight as to the changes occurring at the tissue level. Alterations of the dosage, and 
timing of supplementation, could also be manipulated. High-dose bovine colostrum 
supplementation (60 g/d) may not be feasible over a longer duration (> 8 weeks), thus the dosage 
could be reduced to be more manageable (e.g. 30 g/d). Low-dose ibuprofen supplementation 
(400 mg after exercise only, 3 d/wk) appeared to be insufficient, specifically for muscle strength 
and properties, thus the dosage could be increased to daily. However, ibuprofen should not be 
taken within close proximity to exercise. Finally, to detect ≥1% difference in aBMD of clinically 
relevant sites with 90% power each group would require approximately 40 per-protocol 
participants (2 sided, p≤0.05) (Jankowski et al., 2015). Thus, to account for attrition a sample 
size of 200 is required, which should include men and women. For this reason a multi-center 
study may be of benefit.  
7.4. Conclusions 
The findings of this thesis add to the evidence that resistance training stimulus can 
improve muscle and maintain bone health with age. Bovine colostrum improved the efficacy of 
resistance training to increase leg press strength and reduce bone resorption, while ibuprofen 
alone (i.e. independent of resistance training) improved bone density and properties of clinically 
relevant sites (Ward’s region, distal radius and radial shaft). Further, while bovine colostrum 
may be consumed immediately after exercise, ibuprofen should not be consumed within close 
proximity of exercise; the interaction negates rather than enhances the benefits of resistance 
training or ibuprofen alone. Collectively, this thesis contributes novel, relatively inexpensive, 
easily accessible, and implementable strategies to modify sarcopenia and osteoporosis.  From a 
patient perspective, this could reduce fracture risk and the devastating consequences. From a 
clinical perspective, this would greatly reduce the burden on the health care system from 
primarily preventable diseases. 
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Participant Information and Consent Form 
 
Title: The effect of bovine colostrum supplementation in older adults 
Principal Investigator: Philip D. Chilibeck, Ph.D., Professor, College of Kinesiology, 
University of Saskatchewan, phone: 966-1072 
Student Researcher: Whitney Duff, M.Sc., (doctoral student supervised by Philip Chilibeck), 
College of Kinesiology, University of Saskatchewan, phone: 966-1123 
Sponsors: Mitacs Accelerate Program and the Saskatoon Colostrum Co. Ltd. 
 Emergency Telephone Number: 230-3849 
 
Introduction 
You are invited to take part in this research study that involves combining strength training and 
nutritional supplementation with bovine colostrum. Bovine colostrum is the milk that is secreted 
by cows during the first day after calving. It is unique in that it is very high in protein and 
contains a number of nutrients that may improve immune function and one’s ability to train with 
greater intensity during a strength training program. The bovine colostrum supplement we are 
using for this study is commercially available. 
Your participation is voluntary. It is up to you to decide whether or not you wish to take part. If 
you decide to participate, you are still free to withdraw at any time and without giving any 
reasons for your decision. If you do not wish to participate, you will not affect your relationship 
with the researchers or the university. 
Please take time to read the following information carefully. You can ask the study staff to 
explain any information that you do not clearly understand. You may ask as many questions as 
you need. Please feel free to discuss this with your family, friends or family physician before you 
decide. 
Who is conducting the study? 
The study is being funded by the Saskatoon Colostrum Co. Ltd. with matching funds from 
Mitacs, which is a government funding organization that supports research that collaborates with 
industry. The sponsors of this study will reimburse the investigators and university for the cost of 
undertaking this study. 
Why is this study being done? 
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This study is being done because we want to determine the effect of colostrum supplementation 
during a strength training program for increasing muscle mass and strength in people who are 50 
years of age and older. After the age of 50 years, muscle mass and strength decrease, and this can 
lead to functional impairment. Bovine colostrum is high in protein and nutrients that may 
decrease inflammation and improve immune system function. Previous research done elsewhere 
indicated colostrum supplementation increases muscle mass in younger people on a strength 
training program. The purpose of this study is to determine whether colostrum supplementation 
has the same effects in older people. Bovine colostrum contains a growth factor (called insulin-
like growth factor-1 or IGF-1) that is important for the growth of muscles and also for 
maintaining cognitive abilities (i.e. mental function). A secondary purpose of our study will be to 
assess the effect of colostrum supplementation on cognitive function. We will also assess blood 
and urine markers of inflammation, and bone and muscle breakdown to see if colostrum 
supplementation can preserve muscle and bone. 
Who can participate in this study? 
You are eligible to participate in this study if you are male or female 50 years or older. We will 
determine whether exercise training is safe for you by having you fill out a brief questionnaire 
(the Physical Activity Readiness Questionnaire). If there is doubt about the safety of exercise 
participation for you based on this questionnaire, we will need to get permission from your 
family physician, with your approval, before you can participate in this study.  
What does the study involve? 
The study involves 8 weeks of strength training (one hour, 3 days per week) during which you 
will consume either bovine colostrum or whey protein supplement. Whey protein supplement is 
being used as a comparator because it has the same amount of protein as colostrum, but does not 
contain some of the ingredients purported to protect immune system function. 
If you agree to participate in the study you will be randomly assigned (i.e. by chance by a 
computer) to a group that receives 60 grams per day bovine colostrum supplement or 60 grams 
per day whey protein. You will have a 50% chance of being assigned to either group. Both 
supplements will be consumed in capsules 3 times per day. On training days (3 days per week), 
you will consume the supplement before and after your strength training session and then once 
with a meal. On non-training days you will consume the supplement 3 times per day with meals. 
The study is “double blind” which means that neither you nor the study personnel will know 
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what supplement you are receiving until the end of the study. In case of emergency however, we 
can find out which supplement you are on. 
The strength training program will involve training one hour per day, three days per week, for 8 
weeks in our research training facility (located at the Williams Building at the University of 
Saskatchewan). Training will be fully supervised and will involve 12 different exercises 
targeting all the major muscle groups.  
Before and after the 8 week training program we will do the following assessments on you: 
1) Lean tissue, fat, and bone mass will be assessed with dual energy X-ray absorptiometry by a 
nuclear medicine technologist in the RJD Williams Building (221 Cumberland Ave North, Room 
108). This involves lying on a table while you are scanned with an X-ray. This test takes about 
10 minutes. 
2) The size of the muscles at the front and back of your upper arms and legs will be assessed by 
ultrasound by a Kinesiology research assistant at the RJD Williams Building (221 Cumberland 
Ave. North, Room 108). This involves placing a gel on your skin and placing a probe over the 
gel. The probe emits sound waves that allow assessment of the thickness of your muscles. This 
will take about 20 minutes. 
3) Your strength will be determined by assessing the maximal amount of weight you can lift 
during a “bench press” exercise and a “leg press” exercise. The bench press involves lying on a 
bench and pushing a weight up from chest level. The leg press involves pushing a weight with 
your feet while extending your legs. You will initially be given a warm-up on an exercise bike, 
following by light stretching, and lifting light weights on the bench press and leg press. This 
strength testing will take about 25 minutes. This will be supervised by a Kinesiology research 
assistant at the RJD Williams Building (221 Cumberland Ave. N., Room 108). 
4) A certified phlebotomist (i.e. a person trained to collect blood samples) will collect about 15 
mL of blood from a vein in your forearm in Room 349 of the Physical Activity Complex, 87 
Campus Dr. This will be used to assess markers of inflammation and IGF-1 levels. This involves 
inserting a needle into your forearm. This takes about 10 minutes. 
5) We will give you a brief exam to test your cognitive function. This takes about 10 minutes. 
This involves a series of moderately challenging mental questions relating to language, recall, 
and calculations. 
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6) You will be required to collect urine in a container for 24 hours. We will supply you with this 
container and you will be required to return it to our lab. The procedure requires that you follow 
a meat-free diet for 3 days, with urine being collected on the third day. The reason you need to 
follow a meat-free diet is that we are measuring a marker of muscle protein breakdown in your 
urine samples and this marker increases if you eat meat. This will be done immediately before 
and immediately after the 8 weeks of training and supplementation. This is only required for the 
pre- and post-testing periods. 
7) You will be required to keep a record of all the foods and beverages that you consume over a 
3 day period. This will be done during the first week and last week of your training and 
supplementation. The purpose of this food and beverage diary is so that we can monitor the 
influence of any foods and beverages you consume on changes in your strength and muscle 
mass. 
8) You will fill out a leisure-time physical activity questionnaire. This questionnaire asks how 
many times per week you do activities that are rated as “mild”, “moderate”, or “strenuous” in 
intensity. This questionnaire will take about 5 minutes to complete. 
All testing (except the urine collection and food diaries) will be done during 2 study visits – one 
at baseline (i.e. before the training and supplementation program) and one after the 8-week 
training and supplementation program. We anticipate that each of these visits for measurements 
will last between 75 and 90 minutes. 
At each study visit, a research assistant will ask you whether you have had any problems with the 
supplement or the exercise program. 
There will be a total of 40 participants in this study at the University of Saskatchewan. 
What are the benefits of participating in this study? 
You may increase your muscle mass and strength by participating in this study. These benefits 
are not guaranteed. 
What are the possible risks and discomforts? 
Bovine colostrum or whey protein supplementation: In a previous study of younger individuals 
taking the same dose of colostrum and whey protein, 18% of participants reported mild gastro-
intestinal symptoms that included bloating, cramps, and diarrhea. 
The exercise may result in muscle pulls or strains, or muscle soreness. You will be given a 
proper warm-up prior to exercising and qualified exercise trainers will supervise training 
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sessions. Adequate rest (at least 48 hours) will be given between training and testing sessions to 
ensure that your muscle is recovered by the next training session. Training will initially be quite 
light and we will gradually increase the amount of training done per session over the first two 
weeks of training to allow your muscles to get used to the training and minimize muscle 
soreness. 
The ultrasound measurements may involve discomfort as the gel used might feel cold. 
There is a small amount of radiation exposure from the dual energy X-ray scans. This is equal to 
one tenth of the amount of radiation you would receive from taking a trans-Atlantic flight from 
North American to Europe, or less than 0.5% from what you would receive from a routine full-
mouth dental X-ray. 
Possible side effects from blood drawing include fainting, inflammation of the vein, pain, 
bruising or bleeding at the site of puncture. 
What are alternatives to the study? 
You do not have to participate in this study to receive a supervised exercise training program or 
the nutritional supplement. Supervised training programs are available at different gyms in the 
city and the nutritional supplements being evaluated in this study are available at health food 
stores. 
What happens if I decide to withdraw? 
Your participation in this research is voluntary. You may withdraw from this study at any time. 
You do not have to provide a reason. Your relationships with the researchers or the university 
will not be affected.  
If you choose to enter the study and then decide to withdraw at a later time, all data collected 
about you during your enrolment will be retained for analysis.  
What happens if something goes wrong? 
In the case of a medical emergency related to the study, you should seek immediate care and, as 
soon as possible, notify the principal investigator. Inform the medical staff you are participating 
in a clinical study. Necessary medical treatment will be made available at no cost to you. By 
signing this document, you do not waive any of your legal rights against the sponsor, 
investigators or anyone else. 
What happens after completion of the study? 
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We will inform you of the overall study results after we have analyzed all data (approximately 
March 2013). 
What will the study cost me? 
You will not be charged for the study supplements or any research-related procedures. You will 
not be paid for participating in this study. Reimbursement for study-related expenses (e.g. travel, 
parking, meals) is not available. 
Will my participation be kept confidential? 
In Saskatchewan, the Health Information Protection Act (HIPA) defines how the privacy of your 
personal health information must be maintained so that your privacy will be respected. Your 
name will not be attached to any information, nor mentioned in any study report, nor be made 
available to anyone except the research team.  It is the intention of the research team to publish 
results of this research in scientific journals and to present the findings at related conferences and 
workshops, but your identity will not be revealed. 
Who do I contact if I have questions about the study? 
If you have any questions or desire further information about this study before or during 
participation, you can contact Philip Chilibeck at 966-1072 or phil.chilibeck@usask.ca 
If you have any concerns about your rights as a research participant and/or your experiences 
while participating in this study, contact the Chair of the University of Saskatchewan Research 
Ethics Board, at 306-966-4053 (out of town calls 1-888-966-4053). The Research Ethics Board is 
a group of individuals (scientists, physicians, ethicists, lawyers and members of the community) 
that provide an independent review of human research studies. This study has been reviewed and 
approved on ethical grounds by the University of Saskatchewan Research Ethics Board.  
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CONSENT TO PARTICIPATE 
 
I have read (or someone has read to me) the information in this consent form. 
I understand the purpose and procedures and the possible risks and benefits of the study.  
I have been informed of the alternatives to the study.  
I was given sufficient time to think about it. 
I had the opportunity to ask questions and have received satisfactory answers. 
I am free to withdraw from this study at any time for any reason and the decision to stop taking 
part will not affect my future relationships at the university. 
I agree to follow the principal investigator's instructions and will tell the principal investigator at 
once if I feel I have had any unexpected or unusual symptoms. 
I have been informed there is no guarantee that this study will provide any benefits to me.  
I give permission for the use and disclosure of my de-identified personal health information 
collected for the research purposes described in this form. 
I understand that by signing this document I do not waive any of my legal rights. 
I will be given a signed and dated copy of this consent form. 
My family physician can be informed about my participation in this study, and, if required, 
consulted regarding my health and treatment. 
  Yes, you may contact my primary care physician  
  No, please do not contact my primary care physician 
  I do not have a primary care physician. 
 
 I agree to participate in this study: 
 
Printed name of participant:     ______________________                  
Signature  _______________________      Date___________________________  
Printed name of person obtaining consent: _____________________       
Signature  _________________________ Date___________________________                                                                                                         
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Participant Information and Consent Form 
 
Title: Ibuprofen supplementation after resistance training and its effects on bone in older 
women 
Principal Investigators: Philip D. Chilibeck, Ph.D., Professor, College of Kinesiology, 
University of Saskatchewan, phone: 966-1072; Darren Candow, Faculty of Kinesiology and 
Health Studies, University of Regina, phone: 306-585-4906 
Co-Investigators: Adam Baxter-Jones, Ph.D., Professor, College of Kinesiology, University of 
Saskatchewan, phone: 966-1078; Saija Kontulainen, Ph.D., Associate Professor, College of 
Kinesiology, University of Saskatchewan, phone: 966-1077; Gordon Zello, Ph.D., Professor, 
College of Pharmacy and Nutrition, University of Saskatchewan, phone: 966-5825; Michael 
Szafron, Ph.D., Assistant Professor, School of Public Health, University of Saskatchewan, 
phone: 966-5768, Regina Taylor-Gjevre, M.D., Associate Professor, College of Medicine, 
phone: 966-8280 , Bindu Nair, M.D., Associate Professor, College of Medicine, phone: 966-
8267. 
Student Researcher: Whitney Duff, M.Sc., (doctoral student supervised by Philip Chilibeck and 
Saija Kontulainen), College of Kinesiology, University of Saskatchewan, phone: 966-1123 
Sponsor: Canadian Institutes of Health Research 
 Emergency Telephone Number: 230-3849 
 
Introduction 
You are invited to take part in this research study that involves combining exercise training and 
supplementation with ibuprofen in women who are 60y or older.  
Your participation is voluntary. It is up to you to decide whether or not you wish to take part. If 
you decide to participate, you are still free to withdraw at any time and without giving any 
reasons for your decision. If you do not wish to participate, you will not affect your relationship 
with the researchers or the university. 
Please take time to read the following information carefully. You can ask the study staff to 
explain any information that you do not clearly understand. You may ask as many questions as 
you need. Please feel free to discuss this with your family, friends or family physician before you 
decide. 
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Who is conducting the study? 
The study is being funded by the Canadian Institutes of Health Research. The Canadian Institutes 
of Health Research will reimburse the investigators and university for the cost of undertaking 
this study. However, neither the institution nor any of the investigators or staff will receive any 
direct financial benefit from conducting this study. 
Why is this study being done? 
As we age, we lose muscle and bone mass. The loss of muscle and bone mass may be related to a 
decrease in physical activity. It may also be related to the increased inflammation that occurs in 
our bodies as we age. The objective of this study is to determine the effect of combining exercise 
training and an anti-inflammatory drug (ibuprofen) for improving bone mineral density, bone 
architecture and geometry (all of which determine bone strength), muscle mass, strength, and 
balance ability. 
Who can participate in this study? 
You are eligible to participate in this study if you are a female aged 60y or older. You cannot 
take part in the study if you have taken medications that affect bone mineral density within the 
past 12 months (for example, hormone replacement therapy, bisphosphonates, corticosteroids), 
or have diseases that might affect bone metabolism (for example Crohn’s Disease and Cushing 
Disease). Furthermore, you will be excluded if you suffer from severe osteoarthritis, if you are a 
smoker, and if you are currently participating in moderate-vigorous resistance-exercise training 
more than once per week. You will also be excluded if you are deemed to be at high fracture 
risk, based on your baseline bone mineral density measurement. You should not participate in the 
study if you are on blood thinners because of past episodes of deep vein thrombosis or 
pulmonary embolism. You also should not participate if you have suffered from severe 
heartburn, an ulcer or gastritis. We will determine whether exercise training is safe for you by 
having you fill out a brief questionnaire (the Physical Activity Readiness Questionnaire). If there 
is doubt about the safety of exercise participation for you based on this questionnaire, we will 
need to get permission from your family physician before you can participate in this study.  
What does the study involve? 
If you agree to participate in the study you will be randomized (i.e. assigned by chance, by a 
computer) into one of 4 groups: Group 1 will do resistance exercise three times per week and 
consume 400 mg of ibuprofen immediately after each exercise session; Group 2 will do 
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flexibility (i.e. stretching) exercise three times per week and consume 400 mg of ibuprofen 
immediately after each exercise session; Group 3 will do resistance exercise three times per week 
and consume a placebo immediately after each exercise session; Group 4 will do flexibility (i.e. 
stretching) exercise three times per week and consume a placebo immediately after each exercise 
session. A “placebo” is something that looks like the ibuprofen but has no active ingredients. It is 
necessary to use a placebo in this type of experiment to determine the effectiveness of the 
ibuprofen. You will not know whether you receive the ibuprofen or placebo and neither will the 
investigators (i.e. the study will be double blind). This can be determined, however, in case of 
emergency. You will have an equal chance of being assigned to one of the four groups.  
The exercise training and ibuprofen/placebo supplementation will be done three times per week 
for 9 months. If you are in the resistance training group you will do 4 different dumbbell 
exercises involving your forearms, exercise that involves throwing and catching a heavy ball (i.e. 
a “medicine” ball), stepping exercises, a “hack squat” exercise (an exercise done on a machine 
that involves lifting weights with your legs), single leg lunges while holding dumbbells, and four 
different hip exercises done on a machine. If you are in the flexibility training group you will be 
given a flexibility program that will involve stretching all the major muscle groups. The 
resistance training will be fully supervised at our gym facility in the Williams building. We will 
give you an orientation session for the flexibility program and then this program will be 
continued at home. It is expected that training sessions will take about an hour each. 
All women will receive 500 mg of calcium and 10 μg (400 I.U.) of vitamin D per day throughout 
the study. 
Measurements of bone, muscle size, strength, balance, physical activity levels and diet will be 
performed at baseline and at the end of the intervention (9 months). The following tests will be 
done: 
1) Bone mineral density of your hip and lumbar spine, and lean tissue mass of your whole body 
will be determined with dual energy X-ray absorptiometry. This requires you to lie on a padded 
table for about 10 minutes while an X-ray assesses your bone and lean tissue mass. 
2) Bone architecture and geometry at the forearm and lower leg will be determined by peripheral 
quantitative computed tomography (pQCT) and high-resolution pQCT. Both of these 
measurements require that you put your forearm or lower leg into a hole of a computed 
tomography machine. The regular pQCT assesses bone and muscle in the upper part of your 
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forearm and lower leg; whereas the high-resolution pQCT measures bone at the wrist area and 
distal part of the lower leg. These measurements take about 30 minutes each. 
3) Muscular strength will be determined by measuring the maximal amount of weight you can 
lift during a biceps curl and during the hack squat. This testing involves a warm-up of cycling 
and stretching and then attempts to lift progressively heavier weights. These tests will take about 
half an hour. 
4) Flexibility will be determined by having you do a trunk forward flexion test. This involves 
sitting on the floor with your legs outstretched. You will be required to reach as far as possible 
towards your toes with your hands. This test takes about 2 minutes. 
5) Balance will be determined by walking backwards toe-to-heel on a board that is 5 cm above 
the ground for 6 meters. This test will be repeated twice. We will measure the time it takes you 
to do this test and the number of times you step off the board. This test takes about 5 minutes. 
6) We will give you questionnaires about your diet and physical activity levels. These 
questionnaires take about half an hour to complete. 
We will try to do all the six measurements mentioned above in one lab session. The total time for 
these measurements will be about 2 hours. 
There will be a total of 100 participants in this study at the University of Saskatchewan. 
What are the benefits of participating in this study? 
You may increase your bone mineral density, flexibility, muscle mass and strength by 
participating in this study. These benefits are not guaranteed. 
What are the possible risks and discomforts? 
From previous clinical studies, the most common side effects of ibuprofen (i.e. 10-30% of 
people) include: 
Nausea  
Abdominal pain (stomach pain)  
Heartburn  
Dizziness  
Unexplained rash.  
 
Less common side effects (1-10%) include: 
Diarrhea  
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Vomiting  
Indigestion  
Constipation  
Stomach cramps  
Bloating  
Gas  
Headache  
Nervousness  
Ringing in the ears (tinnitus)  
Decreased appetite  
Swelling 
 
Rare side effect (<1%) include: 
Ulcer in the stomach or intestines (peptic ulcer)  
Hepatitis  
High liver enzymes  
Depression  
Insomnia  
Hair loss  
Hearing problems  
Problems with vision, such as blurred vision or changes in color vision  
High blood pressure (hypertension)  
Congestive heart failure  
Dry eyes and mouth  
Meningitis 
 
Ibuprofen may interfere with the effects of aspirin; therefore, you should not consume aspirin 
during the study. 
 
The exercise may result in muscle pulls or strains, or muscle soreness. You will be given a 
proper warm-up prior to exercising and qualified exercise trainers will supervise training 
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sessions. Adequate rest will be given between training and testing sessions to ensure that your 
muscle is recovered by the next training session. Training will initially be quite light and we will 
gradually increase the amount of training done per session over the first couple of weeks of 
training to allow your muscles to get used to the training and minimize muscle soreness. 
There is a small amount of radiation exposure from the dual energy X-ray scans and the 
peripheral quantitative computed tomography. This is equal to the amount of radiation you 
would receive during 4 weeks from natural sources and is about two thirds of the dose of 
radiation you would receive during a cross-county airplane flight. 
What are alternatives to the study? 
You do not have to participate in this study to receive a supervised exercise training program or 
the ibuprofen. Supervised training programs are available at different gyms in the city and the 
ibuprofen is available at any drug store. 
What happens if I decide to withdraw? 
Your participation in this research is voluntary. You may withdraw from this study at any time. 
You do not have to provide a reason. Your relationships with the researchers or the university 
will not be affected.  
If you choose to enter the study and then decide to withdraw at a later time, all data collected 
about you during your enrolment will be retained for analysis.  
What happens if something goes wrong? 
In the case of a medical emergency related to the study, you should seek immediate care and, as 
soon as possible, notify the principal investigator. Inform the medical staff you are participating 
in a clinical study. Necessary medical treatment will be made available at no cost to you. By 
signing this document, you do not waive any of your legal rights against the sponsor, 
investigators or anyone else. 
What happens after completion of the study? 
We will inform you of the overall study results after we have analyzed all data. 
What will the study cost me? 
You will not be charged for the ibuprofen, calcium and vitamin D supplements, or any research-
related procedures. You will not be paid for participating in this study. Reimbursement for study-
related expenses (e.g. travel, parking, meals) is not available. 
Will my participation be kept confidential? 
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In Saskatchewan, the Health Information Protection Act (HIPA) defines how the privacy of your 
personal health information must be maintained so that your privacy will be respected. Your 
name will not be attached to any information, nor mentioned in any study report, nor be made 
available to anyone except the research team.  It is the intention of the research team to publish 
results of this research in scientific journals and to present the findings at related conferences and 
workshops, but your identity will not be revealed. 
Who do I contact if I have questions about the study? 
If you have any questions or desire further information about this study before or during 
participation, you can contact Philip Chilibeck at 966-1072 or phil.chilibeck@usask.ca 
If you have any concerns about your rights as a research participant and/or your experiences 
while participating in this study, contact the Chair of the University of Saskatchewan Research 
Ethics Board, at 306-966-4053 (out of town calls 1-888-966-4053). The Research Ethics Board is 
a group of individuals (scientists, physicians, ethicists, lawyers and members of the community) 
that provide an independent review of human research studies. This study has been reviewed and 
approved on ethical grounds by the University of Saskatchewan Research Ethics Board.  
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CONSENT TO PARTICIPATE 
 
I have read (or someone has read to me) the information in this consent form. 
I understand the purpose and procedures and the possible risks and benefits of the study.  
I have been informed of the alternatives to the study.  
I was given sufficient time to think about it. 
I had the opportunity to ask questions and have received satisfactory answers. 
I am free to withdraw from this study at any time for any reason and the decision to stop taking 
part will not affect my future relationships at the university. 
I agree to follow the principal investigator's instructions and will tell the principal investigator at 
once if I feel I have had any unexpected or unusual symptoms. 
I have been informed there is no guarantee that this study will provide any benefits to me.  
I give permission for the use and disclosure of my de-identified personal health information 
collected for the research purposes described in this form. 
I understand that by signing this document I do not waive any of my legal rights. 
I will be given a signed and dated copy of this consent form. 
My family physician can be informed about my participation in this study, and, if required, 
consulted regarding my health and treatment. 
  Yes, you may contact my primary care physician  
  No, please do not contact my primary care physician 
  I do not have a primary care physician. 
 
 I agree to participate in this study: 
 
Printed name of participant:     ______________________                  
Signature  _______________________      Date___________________________  
Printed name of person obtaining consent: _____________________       
Signature  _________________________ Date___________________________                                                                                                         
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Appendix C. Copy of permission to use published manuscript. 
RE: permission to use/license 
Martha Gullo <marthag@hkusa.com> on behalf of Permissions Mailbox 
<permissions@hkusa.com> 
Wed 10/7/2015 2:54 PM 
 
To: Duff, Whitney <whitney.duff@usask.ca>;  
 
Dear Ms. Duff, 
 
You have Human Kinetics’ permission to include the accepted author manuscript version of 
your manuscript (i.e., the version of the manuscript that went through peer review and was 
accepted by a journal editor for publication – not the final published version) in your PhD    
dissertation. 
 
Please include an acknowledgment following this format: 
Accepted author manuscript version reprinted, by permission, from [Journal Title, year, 
volume (issue): x‐xx]. © Human Kinetics, Inc. 
 
If there’s anything else I can help you with, please don’t hesitate to ask. 
 
Best Regards, 
Martha 
    
   Martha Gullo 
   Senior Permissions Manager 
   Human Kinetics, Inc. 
   www.humankinetics.com 
   P: 217-351-5076 ext. 2223 
   F: 217-351-2674 
   E: marthag@hkusa.com 
